|
|
·|û¡GCliff10135274 µoªí®É¶¡:2014/10/15 ¤W¤È 01:05:51
|
¥»ª©°w¹ï¯E¹©°ò¥»±°Q½×Àù¯gªvÀø¡B§K¬ÌÀøªk¡BÁ{§É¸ê°T¡F¯E¹©¦U¶µ²£«~¬ãµo¶i«×°lÂÜ°Q½×¡FÄvª§¹ï¤â°ÊºA»P¦U¤è¶i«×°lÂÜ¡C¦P®É¯Ç¤Jª©¡uOBI-822¡BOBI-833¥H¥~ªº²£«~¡vªº¤º®e¡C·q½Ð¦U¦ì¤j¤j´N¥H¤WijÃDªº°ò¥»±Ä~Äò´£¨Ñ´¼¼z¡C ¥un¨¥¤§¦³ª«¡A¥ß½×¦³¾Ú¡A¦hªÅ¬ÒÅwªï¡C ¥»ºô»{¬°©¹«áY¹J¨ìÃþ¦üªºª¬ªp¡A¥i¥H¥Ñ¸Ó¶}ª©¤§¥D¤H¨Ó§P©w¡A ¨Ò¦p¦¹ª©´N¥ÑCliff¤j¤j¨Ó§P©wµo¨¥¤º®e¬O§_²Å¦X¸Óª©¤º®e¡A Y¥D¤H»{©w¤£²Å¡A¦A¥Ñ¥»ºô¤©¥H§R°£¡A¦p¦ó¡HBYª©¥D
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/7/1 ¤U¤È 09:57:50²Ä 320 ½g¦^À³
|
Cliff¤j ¨Ì·Ó²Ä¤@´Áªº¼Æ¾Ú¬Ý¨Ó¡A¤p§Ìªº¸ÑŪ¬O ±K¶°¬I¥´¦³§U©ó§ÜÅé¿@«×´£¤É¡A¤]´N¬O±N¨Ó 1.±K¶°ªº¬I¥´3-5¶g¡AY½T¹ê¯à»¤µo¥X§ÜÅ骺¯f¤H¡A´N«ùÄò°lÂܬI¥´ 2.±K¶°¬I¥´3-5¶g¡AYµL®ÄªÌ¡A´NµL»Ý¦A¬I¥´¤F 3.Y¯à´£¦·f°tÁÞ´¹¤ùÀË´ú¡A©Î³\´NµL»Ý¥Õ¥´¡A¥u¬O¥Ø«e¤£ª¾ÁÞ´¹¤ùµo®i¨ì«ç¼Ëªºµ{«× ¥H¤W¬°¤p§ÌÓ¤H¸ÑŪ»P²q´ú¡A§Æ±æ¦¹¦¸¸Ñª¼«á¡A³o¨Ç¼Æ¾Ú³£¯à²M·¡ªº§e²{ |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/7/1 ¤U¤È 09:20:11²Ä 319 ½g¦^À³
|
822¤@´Á¸ÕÅ礤¡AIgM»PIgG titer®øªøÅܤƹϡG¡]For Prostate Ca¡^ ¬Ý30£ggªº½u§Y¥i¡]¦]¬°¤@/¤G/¤T´Á³£¬O¥´30£gg¡^¡A¨CӹϪº¥ª¤W¤è¦³5Ӷ¦â´Â¤U¤p½bÀY¡Aªí¥Ü¬I¥´ªº¶g¼Æ¡A¤@´Á¥u¥´¤¾¯¡Aµ²ªG©â¦åÀËÅç¥X¨Óªº³Ì°ª§ÜÅé¿@«×³£¥X²{¦b5¦Ü13¶g¶¡¡A¥B¦b²Ä19¶g®É¡AÁöµM¥´¤F²Ä¤¾¯¡A«o§e²{³Ì§C§ÜÅé¿@«×¡C¡]±q1998¦~ÄáÅ@¸¢Àù¤Î«á¨Óªº¨ÅÀù¸ÕÅç¬Ò±o¨ìÃþ¦üµ²ªG¡^ IgM¡G ¡uhttp://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&p=PMC3&id=21925_pq0990752002.jpg ¡v IgG¡G ¡uhttp://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&p=PMC3&id=21925_pq0990752003.jpg ¡v ¨ì¤F¤G/¤T´Á®É¹êÅç³]p°µ¤FÅܧó¡G ¤@´Á¡]¨C¾¯§t¦³Globo H 30£gg¡^¡G ¬I¥´¶g¼Æ¡G 01/02/03/--/--/--/07/--/--/--/--/--/--/--/--/--/--/--/19 ¤G/¤T´Á¡]¨C¾¯¥ç§tGlobo H 30£gg¡^¡G ¬I¥´¶g¼Æ¡G 01/02/03/--/05/--/--/--/09/--/--/--/13/--/--/--/17/--/--/--/--/--/--/--/25/--/--/--/--/--/--/--/--/--/--/--/37¡F °lÂÜÀËÅç§ÜGH IgG and IgM/for ADCC/for CDC/for FACSªº¶g¼Æ¡G¡]FACS¥Î¨Ó½T»{²£¥Í¤F¦h¤Ö§ÜGH§ÜÅé¡A±Æ°£§ÜKLH©Î§ÜQS-21§ÜÅé¡^ --/--/03/--/05/--/--/--/09/--/--/--/13/--/--/--/17/--/--/--/--/--/--/--/25/--/--/--/--/--/--/--/33/--/--/--/37/--/--/--/41 ³Ñ¤UªºÅý°ª¤â̸ÑŪ¡C¡]¨S¦³¸Ñª¼¼Æ¾Ú¹ê¦b²q¤£¥X¤°»ò¡^ |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2015/7/1 ¤U¤È 06:18:39²Ä 318 ½g¦^À³
|
¤j®a¦n! £~£~¤jªº»¡ªk ©Î³\¥i°Ñ¦Ò 822¸ÕÅ窺©Û¶Ò¼Ð·Ç ¡§Subjects with metastatic breast cancer who have achieved stable disease (SD), partial response (PR), or complete response (CR) after at least 1 regimen of anticancer therapy (i.e. chemotherapy or target therapy, either alone or in any combination). Involvement of supraclavicular lymph node is considered metastasis. ¡§ ¨ä¤¤ after at least 1 regimen of anticancer therapy (i.e. chemotherapy or target therapy, either alone or in any combination). Ó¤H²q´ú¬OnÅý¸~½FÁY±o§ó¤p ©Î°»´ú¤£¨ì ¦A¨Ó¬I¥´822 ¥i¯à¦]¬°©È§ÜÅé®Ä»ù¤£¨¬ ? ¤@´ÁÁ{§É¥´¤¾¯ ( weeks 1, 2, 3, 7, and 19 ) ¤j®a¥i°Ñ¦Ò¬Ý¬Ý ¦U±wªÌ§ÜÅ骺©µÄò±¡ªp http://www.pnas.org/content/98/6/3270/F2.large.jpg ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/7/1 ¤U¤È 05:38:54²Ä 317 ½g¦^À³
|
£~£~¤j¯E¤ÍÌ ¶¶«K¸ò¤j®a¤À¨É PD229ªº¨Æ¥ó¤p§Ì¯uªº¦³³Q¾_¾Ù¨ì ¦ý±q¹Ú¤¤Åå¿ô,§NÀR,ºCºC«ä¦Ò¤@¨Ç°ÝÃD«áµo²{ ¤£¬O¥P¤¦,¬O¨}ÃÄ Áö¹ï¯f¤H¦Ó¨¥µLªk¤@°w¨£®Ä ¦ýY½T©w¦³®Ä,©T©w¤@¬q®É¶¡°lÂÜ.¬I¥´¥ç¥i¹F¨}®Äªº¸Ü ¨º»ò,Cliff¤j´¿»¡ªº"¼µ¦º"´N¥i¯à¥X²{¤F «¢«¢«¢ ¯E¹©¥[ªo ¥H¤WÓ¤H²q´ú,§ë¸ê½Ð¦Ût·ÀI |
|
|
·|û¡G£~£~10134649 µoªí®É¶¡:2015/7/1 ¤U¤È 05:02:33²Ä 316 ½g¦^À³
|
¥H¤U³oÓ½×½Õťť´Nºâ¤F,§Ú¤]¨S¿ìªkÃÒ¹ê:§ÚèÅ¥¤@¦ì¤j®v»¡,±N¨ÓÀ³¸Ó¯f¤H©|¥¼°µ¤ÆÀø«e´N¬I¥´OBI-822,§_«h¤ÆÀø·|¯}Ãa§K¬Ì¨t²Î,¤@¦ý§K¬Ì¨t²Î¾D¨ü¤ÆÀø¯}Ãa,OBI-822ªºÀø®Ä´N¨ü¼vÅT«Ü¤j¡C³oÓ¸ÕÅ窺¯f¤H¬O§_³£¥ý°µ¹L¤ÆÀø?¨º¬O«ÜÁV¿|ªº¨Æ°Ú!¥t¥~,©µ¿ð®ÄÀ³¬O§_·|¤Ï¦Ó¥ý¨Ï´c¤Æ¦AÂà¦n?³o¼Ë¬O§_LR´f¥X²{«Ü¦h? +++++++++++++++++ ¤Þ¥Î : ©µ¿ð®ÄÀ³Delayed Onset ®Ú¾Ú¥xÆW¤u»È2015/6/25³ø§i¡A¦]¥D°Ê¦¡§K¬Ì¤ÏÀ³ì²z¬OÂǥѥ~¨Ó§Ü쪺¨ë¿E¡A¥v¥Íª«Åé²£¥Í§ÜÅé¡A¶i¦Ó¹F¨ì§í¨î²ÓMªº§@¥Î¡A¦ý±Ò°Ê¦¹§K¬Ì¤ÏÀ³³q±`»Ýn2~3Ӥ몺®É¶¡¡A±À´ú¥»¸ÕÅ祧¡¬ù»Ý13¶g¡C¦]¦¹Y»P¹L¥h±`¥Îªºªº¤ÆÀøÃĪ«»P¼Ð¹vÃĪ«¬Û¸û¤§¤U¡A¥D°Ê§K¬ÌÀøªkªº°_®Ä´Á¸ûªø¡A¤@¥¹¨ä³Q¦³®Ä¶}±Ò«á¡A¨äÀø®Ä¥i¯àÓÅãµÛ¡A§@¥Î®É¶¡¥i¯à§óªø¡C ®Ú¾Ú¤Wzªº»¡©ú¡Aºô¸ô¤W§ä¨ì Primary and Secondary Response against T-dependent Antigenªº¹Ïªí¡C¹Ïªí»¡©ú·íª½±µ¥´¤J²£¥Íªº§ÜÅéªì©l¬O¥ý¤ÞµoIgM¡A¦A±µµÛ¤ÞµoIgG¡A¦ý¬O¨âªÌªº§ÜÅé¤ô¥³£¤£¬O«Ü°ª¡Cª½¨ì¯f¤H¦Û¤vªº§K¬Ì¨t²Î³Q¿Eµo¤§«á¡A²£¥Í¤G¦¸ªºIgM(§ÜÅé¤ô¥»P²Ä¤@¦¸¬Û¦P)»PIgG(§ÜÅé¤j´T¥X²{)¡A§Ú²q´ú¬O§_Àù²ÓMªº®ø¥¢(NED)¬O§_»P¦¹¤G¦¸¤Þµo¦³Ãö¡H |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/7/1 ¤U¤È 03:22:01²Ä 315 ½g¦^À³
|
¬P¨°¤jªºOBIºô»x¦³§ó·s ¦³¿³½ìªº¯E¤Í¥i¶i¥h¬Ý¬Ý ¥t¥~ ½Ð°Ý¦³¯E¤Í°Ñ¥[³Ìªñ³o¤@¦¸¯Î°|ªøªººtÁ¿¶Ü(²Ä¤Q¤©¡¬ü¬wµØ¤H¥Íª«¬ì¾Ç¾Ç·|°ê»Ú¾Ç³N¬ã°Q·|) ©Î¦³§ó§¹¾ãªº¸ê®Æ¶Ü ÁÂÁ |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/7/1 ¤W¤È 09:27:16²Ä 314 ½g¦^À³
|
¸É¥R ¥Ó¤j ÁÂÁ±z´£¨Ñªº¸ê°T |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/7/1 ¤W¤È 09:07:27²Ä 313 ½g¦^À³
|
Cliff¤j,ÁÂÁ±z °e³ø¤j,ÁÂÁ±z ·Q»P¤j®a°Q½×¤@¤U°e³ø¤j´£¨Ñªº833¸ê®Æ ¦b¥x¤jªþ³]Âå°|Û²z©eû·|104¦~2¤ë13¤éªº¼f¬d¤¤ §ÚÌ¥i¥H¬Ý¨ìOBI-833²Ä¤@´Á±N¨Ó¬O¥H³v¨B¤É°ª¾¯¶qªº¤è¦¡¶i¦æ ¥t¥~,¼f¬dªº¨Mij¬O "×¥¿«á³q¹L" ½Ð°Ý¥i¥H¬Ý¥X"×¥¿"ªº¤º®e¤°»ò¶Ü ÁÂÁ |
|
|
·|û¡G¥Ó¥|®ü10139653 µoªí®É¶¡:2015/6/30 ¤W¤È 11:41:56²Ä 312 ½g¦^À³
|
¦å²GÀË´ú¯ØŦÀù §Ö¤F §@ªÌ¡i¤¤¥¡ªÀÛ´°¤G¤Q¤¤éºî¦X¥~¹q³ø¾É¡j | ¥xÆW·s¥Í³ø ¡V 2015¦~6¤ë27¤é ¤W¤È12:00 ¬ì¾Ç®a¬Û«H¡A¥L̤w§ó±µªñ¥H¦å²GÀË´ú¯ØŦÀù¡C¯ØŦÀù¬O³ÌÃø¦´Áµo²{»PªvÀøªºÀù¯g¤§¤@¡C ^°ê¼s¼½¤½¥q·s»Dºô¡]BBC News¡^³ø¾É¡A¬ã¨s¤HûºÙ³o¶µÀË´ú¬O¤@¶µ¡u«¤j¶i®i¡v¡A¯à§ä¥X¸~½FÄÀ©ñªº·L¤pÀôª¬¯×ªÕ¡C®Ú¾Úµoªí¦b¬ü°ê¡u¦ÛµM¡v¡]Nature¡^´Á¥Zªºªì¨B¬ã¨s¦¨ªG¡AÀË´úªº·Ç½T«×°ª¹F¦Ê¤À¤§¦Ê¡C ±M®aªí¥Ü¡A¬ã¨s¦¨ªG«D±`¬ð¥X»P³Ð·s¡A¦ýn¦¨¬°Á{§É¤WªºÀù¯gÀËÅç¡A®£©ÈÁÙ»Ýn¶i¤@¨B§ï¶i¡C ¯ØŦÀùªºªì´Á¯gª¬¤£©úÅã¡Aµ¥¨ì±wªÌ¹îı¨ì¨Å餣¾Aªº®ÉÔ¡AÀù²ÓM©¹©¹¤wÂX´²¨ì¥þ¨¡BÃø¥HªvÀø¡C ¬ü°ê¼w¦{¤j¾Ç¡]University of Texas¡^¦w¼w´ËÀù¯g¤¤¤ß¡]Anderson Cancer Centre¡^¬ã¨s¹Î¶¤À˵ø¸~½F¯×ªÕM¥~Åé¡]exosomes¡^ªº¯S¦³¯S¼x¡C ¥L̪`·N¨ì¡A¯ØŦÀù±wªÌÅ餺¬YºØºÙ§@proteoglycan glypican-1ªº³J¥Õ½è¿@«×¸û°ª¡C ¬ã¨s¤HûÀËÅç¤G¤C¡³¤Hªº¦å²G¡Aµo²{³o¶µÀËÅç¯à°Ï§O¥XÀù¯g¡B¯ØŦ¯e¯f©Î¨ä¥L°·±d°ÝÃD¡A·Ç½T«×¹F¦Ê¤À¤§¦Ê¡C «ÂI¬O·Ç½T«×¹F¦Ê¤À¤§¦Ê¡C ¬Ý¨ÓÁÞ¤À¤lÀË´ú¥¼¨ÓªºÄvª§ªÌ·|¶V¨Ó¶V±j¤j¡C¯E¹©n¥[ªo¤F¡I |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2015/6/29 ¤W¤È 09:22:31²Ä 311 ½g¦^À³
|
¬Ý¨ìCliff¤jªº¶K¤å ¯u¶}¤ß¡I |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/6/29 ¤W¤È 12:33:36²Ä 310 ½g¦^À³
|
Âû¦Ø¤@½g ¹¤§µL¨ý¡A±ó¤§¥i±¤¡A¬Ý¤F§O¥¢±æ¡A¨S¬Ý¤£·l¥¢¡C¤£·Q¥¢±æªº¡A½Ð´N¦¹¸õ¹L¡C ¨âÓ¤ë«eªº·s»D¡]2015/04/14¡^¡AWHOµoªí¤½¶}©IÆ~¡A§Æ±æ¦U®a¬ã¨s³æ¦ì§âÁ{§É¸ÕÅ窺µ²ªG½T¹ê¦a¤½¶}¤½¥¬¡A¤£ºÞ¸ÕÅçµ²ªG¬O¦n¬OÃa³£¸Óµoªí¡A¥H´£°ªÁ{§É¸ÕÅ窺³z©ú«×¡A¥Øªº¦b¥[³t¬ì¾Çªº¶i¨B¡C ¡uWHO calls for increased transparency in medical research¡v¡]http://www.who.int/mediacentre/news/notes/2015/medical-research-transparency/en/ ¡^¡]µù#1 WHOÁn©úì¤å¡^ ²[»\¤T¶µ©IÆ~¡G¡]µù#2¡^ 1. Á{§É¸ÕÅ窺µ²ªGÀ³©ó¸ÕÅçµ²§ô«á12Ӥ뤺¤½¥¬¡C 2. ©IÆ~¥H«e¥¼µoªíªº¸ÕÅçµ²ªG¤]À³¤½¶}¡C 3. ©IÆ~¬ÛÃö¾÷ºc©Î¬F©²¨ãÅ鸨¹ê³o¶µ±¹¬I¡C ¤@¶µ¬ã¨sÅã¥Ü¡A¤@¨Ç¨ü¸ÕªÌ¶W¹L500¦ìªº¤j«¬Á{§É¸ÕÅç¡Aµn°O¦bClinicaltrial.govºô¯¸¥B¦b2009¦~«e§¹¦¨ªÌ¡A¦³23%ªº¸ÕÅç¨S¦³¥Z¸ü³ø§i¡C¦Ó2006-2012¦~¶¡¡A°w¹ï¤ºØ¯e¯f©Ò¬ãµoªº¬Ì]Á{§É¸ÕÅ礤¡A¥u¦³29%¦bWHO«Øijªº24Ӥ뤺¥Z¸ü³ø§i©ó¦P¾«¼f¬dªº´Á¥ZùØ¡C °ê»ÚÁ{§É¸ÕÅçµù¥U¥¥x¦³§U©ó´£¤É³z©ú«×¡C WHO©ó2005¦~±À°ÊÁ{§É¸ÕÅç»Ýµù¥U¡A¤§«á¤S«Ø¥ß°ê»ÚÁ{§É¸ÕÅçµù¥U¥¥x¡]International Clinical Trials Registry Platform¡^¡A±`±`¦¬¯Ç¨Ó¦Û©óClinicalTrials.gov, ISRCTN registry, EU Clinical Trials Register, Australia New Zealand Clinical Trial Registry, Pan African Clinical Trial Registry and Clinical Trial Registries from China, India¡Kµ¥°Ï°ì©Î°ê®aµù¥U¥¥xªº¸ê®Æ¡C ¥H¤W¤º®e¦P®É¤]ºî¦X¥H¤Uªº³ø¾É½sĶ¦Ó¦¨¡G¡uhttp://www.alltrials.net/news/who-calls-for-all-clinical-trial-results-to-be-published/ ¡v µù¡G #1¡uWHO Statement on Public Disclosure of Clinical Trial Results¡v¡G¡]http://www.who.int/ictrp/results/WHO_Statement_results_reporting_clinical_trials.pdf?ua=1 ¡^ #2 1.says results from clinical trials should be publicly reported within 12 months of the trial¡¦s end, 2.calls for results from previously unpublished trials to be made publicly available, and 3.calls on organisations and governments to implement measures to achieve this. |
|
|
·|û¡Gchen605310138636 µoªí®É¶¡:2015/6/19 ¤U¤È 08:21:37²Ä 309 ½g¦^À³
|
Cliff¤j ³qª¾§A¤@¤U "¯E¹©·|º¦¨ì5112¤¸¦¨¬°¥xÆW¤§¥ú¶Ü¡H"ª© ¦³·sªº °T®§¥X²{ §A§Ö¬Ý¬Ý "¤p¤k«Ä"´£¨Ñªº |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/6/17 ¤U¤È 11:53:34²Ä 308 ½g¦^À³
|
HI Cliff ¤j.. ±z¨S¤í¤pªº.¯à©M±z¹ï¸Ü.¬O¤pªººa©¯.. «D±`¤F¸Ñ±zªº¥Î¤ß.©Ò¥H¯àÀ´±zªº·P¨ü..¦ýÁÙ¬O§Æ±æ±z¯àÄ~Äòµ¹¤j®a«ü¾É. ¯E¹©§Y±N¶i¤JÃöÁä®É´Á.¯u¤ß§Æ±æ¯à±o¨ì±z±M·~ªº·N¨£. 쥻·Q¥´¤@½g15000¦rªº·PÁ¤å.¦ý³o½ú¤l¥´¹Lªº¤¤¤å+¤é¤å+¼w¤å+«X¤å+...¥[°_¨Ó¤]¨S15000¦r (²³æÁ¿=¤pªº¨S¯à¤O¥´¥X³o¼Ëªº¤å³¹) ¦ý¯u¤ßÁÂÁ±z. |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/6/16 ¤W¤È 02:07:16²Ä 307 ½g¦^À³
|
³o¨Ç¤]¬O¡K Sara Hurvitz, MD¡G 2015¦~¡G ¡uhttp://opencme.org/course/exploring-science-and-understanding-data-expert-perspectives-emerging-research-breast-cancer- ¡v ¡uhttp://www.gotoper.com/conferences/ibc/meetings/13th-annual-international-congress-on-the-future-of-breast-cancer ¡v 2014/5¤ë¡G ¡uhttp://www.realcme.com/cms/node/516950 ¡v 2013/6¤ëUCLA¡Gì¨Ó¦p¦¹¡A¦o¬O¡K ¡uhttp://www.cancer.ucla.edu/Index.aspx?page=1391 ¡v ¡uPrincipal Investigator: Hurvitz, Sara Sponsor Name: Obi Pharma Inc. Award Title: Double-Blind, Randomized Phase II Trial of Active Immunotherapy with Globo H-Klh (Opt-822) in Subjects with Metastatic Breast Cancer ¡v Hope S. Rugo , MD¡G ASCO¡G¡uhttps://coi.asco.org/Report/ViewAbstractCOI?id=152404 ¡v |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/6/16 ¤W¤È 01:25:10²Ä 306 ½g¦^À³
|
¥Xª©¤j¡G 1. ¡u·í«Å¥¬¸Ñª¼«á.·|¥l¦^¥þ³¡ªº¸ÕÅç¯f±w.¤×¨ä¶W¹L2¦~ªº.§@¤@¦¸²Î¤@ªºÀËÅç.ÁÙ¬O¥u¦¬¶°²{¦³¸ê®Æ°µ§PŪ?¡v³oÓ°ÝÃD»Ýn¥h°Ý°Ý°ª¤H¡A°Ý¨ìªº®ÉÔ¤@©w§i¶D±z¡C 2. ¡u¤j¦ò½×¡v§Ú¤]¦P·N¡A¹ê»Úªº±¡ªp¸ò±z©Ò»¡ªºÀ³¸Ó¬Û¥h¤£»·¡C 3. ³o¤@½g¤]¬O¦b¡u´¦ÅS¡vÄæ¸Ì¦³OBI Pharma¡A¡uhttps://endo.confex.com/endo/2015endo/webprogram/Paper19567.html ¡v¬Ý¨Ó±qÁ{§ÉÂå®v/¾Ç³N¬É¤U¤âªº³o¤@©Û¡A±i¸³ÁÙ¥i¥H¬O¡u±iÀ´¡v¡A¼ô½m±o«Ü¡Aº¥º¥¦a¬Ý±o¨ì¤@¨Ç°Ê§@¤F¡A¥un»P¡umetastatic breast cancer¡vªg¤WÃ䪺¡A§Y¨Ï¬O¤º¤Àªc¡]¥Òª¬¸¢¡^ªº³õ¤l¡A¤]¥i¥H¨Ó¤À¤@ªMün¨DÃÙ§U¤@¤U¡C¤µ¦~ASCO´Á¶¡¡A¥i¿×PD-1¾Õ³õ¡A«Ü¦n©_¨º¨Ç±M®a¤ß¤¤¦³¨S¦³Globo H¡H³s¡u§Y±Nµ²§ôÁ{§É¸ÕÅ窺¥þ²yBlockbusterÃĪ«TOP 15¡v¹w´ú2020¦~ªº¾P°â®i±æ¡A³£¤£¨£822Âܸñ¡A¹ê¦b¤£¥i«äij¡C 4.¨º¨â½gCMPsªº¤å³¹¦Ñ¹ê»¡³£«ÜÃøŪ¡KÃø²£¤¤¡K |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/6/16 ¤W¤È 12:28:27²Ä 305 ½g¦^À³
|
Hi Cliff¤j.. ¨º¨â½g§Ú¯uªº¦³»{¯u·Qn¬ÝÀ´.¦ý¬OÁÙ¬Oµ¥±zªº¯»¶êw¨ß§a.. ¥ýÁ°Õ.. ÁÙ¦³¤@°Ý?? ·í«Å¥¬¸Ñª¼«á.·|¥l¦^¥þ³¡ªº¸ÕÅç¯f±w.¤×¨ä¶W¹L2¦~ªº.§@¤@¦¸²Î¤@ªºÀËÅç. ÁÙ¬O¥u¦¬¶°²{¦³¸ê®Æ°µ§PŪ? |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/6/16 ¤W¤È 12:17:23²Ä 304 ½g¦^À³
|
Hi ¦U¦ì¤j.. ¤@½gÃö©ó¨ÅÀùªº³ø§i.. http://www.oncologypractice.com/specialty-focus/breast/single-article-page/advanced-breast-cancer-paclitaxel-bests-nab-paclitaxel-ixabepilone/66669f2ba6980e6129985acbf7948c95.html «GÂI¦b"©ÜÅS"¨Æ¶µùØ. ¤£ª¾¤pªº¸ÑŪ¬O§_¥¿½T. ¦³³o¦hÃļt¦V³o¦ì¤j¦ò°^Äm»ªo¿ú. ¤@¨Ç«n¦~·|.³o¦ì¤j¦ò¦n¹³º¡¦³¼vÅT¤O. http://www.oncologypractice.com/home/article/sabcs-2014-dr-hope-s-rugo-gives-her-top-picks/e678eb85aada858641576bcd267b57fc.html §Æ±æ¦bªñ´Áªº¦³ÃöÀù¯g¦~·|¤W.¥ý´À822¥ý¤W¨Ç¹w§i¤ù. (¤½¥q¦b«Å¶Ç¤è±.¶}©l¦³¨Ç°Ê§@¤F) |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/6/12 ¤U¤È 01:01:55²Ä 303 ½g¦^À³
|
¥Xª©¤j¡A³oÓ¤j«v°Ý¡A»Ýn´X¤Ñªº®É¶¡¡C ¦³¿³½ìªº¤H¥i¥H¥ý¬Ý¬Ý³o¨â½g¡G 1.¡uCarbohydrate-mimetic peptides for pan anti-tumor responses¡v ¡]http://journal.frontiersin.org/article/10.3389/fimmu.2014.00308/full ¡^2014/1¤ë 2.¡uImmune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine¡v ¡]http://www.pnas.org/content/109/1/261.full ¡^³o¤@½g¨ä¹ê¦b2014/12¤ë¥ª¥k³Q²q·Q¤j´£¥X¨Ó¹L¡A¨ºÓª©¦ü¥G¤w³Qª©¥D§ô¤§°ª»Õ¤F¡C¥¦¸Ì±©Ò¥ÎªºÁÞ§Üì´N¤£¦A¬OMUC1ªºì«¬¡A¦Ó¬O¦X¦¨Ãþ¦ü¥¦ÁÞ¤À¤l¤ù¬qªº¤@¬qÀÀÁÞÐ`肽¡Aµo²{¤p¹«¤¤¥i»¤µo¥X¸û¦hªºIgG¡A¤£¦P©ó¤@¯ëÁÞ§Üì¥Dn»¤µo¥XIgMªº©R¹B¡C¡]¥H«e´XÓ¥HMUC1쫬°µªº¹êÅç³£¥¢±Ñ¡^ |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/6/11 ¤U¤È 10:10:49²Ä 302 ½g¦^À³
|
Hi Cliff¤j.. ·j¯Á¤F¥b¤Ñ¹ê¦b§äµL¬ÛÃö.½Ðì½Ì¤pªº¯à¤O¤£¨¬.¦³ÃöCMPs¡]Carbohydrate Mimetic Peptides¡^.¤è«Kµ¹¤j®a¤¶²Ð¤@¤U¶Ü?? |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/6/10 ¤U¤È 02:53:27²Ä 301 ½g¦^À³
|
CC¤j¡G ¥þ¤å¦b³o¸Ì¡G ¡u¥xÆWn¦¨¬°¥@¬É¤§¥ú¥þ¾a¯E¹©³o¤ä¤F¡vªºª©± ¡u·|û¡G¼·¯}®ö10133749 µoªí®É¶¡:2015/4/13 ¤W¤È 06:25:57¡v ¡u¯E¹©¦XÁa³s¾î ÃÄ¥´¥@¬É¤j¾Ô 2015-04-13 03:04:43 ¸gÀÙ¤é³ø °OªÌ¶À¤å©_¡þ¥x¥_³ø¾É¡v ·í®É´N¬O¬Ý¨ì³o¤@«h¡A§Ú¤~²q¡uÀÀ¦üÁÞ§Üì·|¤£·|¬OCMPs¡H¡]Carbohydrate Mimetic Peptides¡^¡v ¥Xª©¤j¡G ±z¯«¡I¨S¿ù¡A¬O¦P¤@¥ó¨Æ±¡¡A¥u¬O³Õ¤h½×¤å¶È´N¨ä¤¤¤@ºØ×¹¢¤è¦¡¡]¦bGH¤W¥[¤J¹ï¦ìµv°òf¤þ®ò»Ä(pNO2Phe)¡^¨Ó°µ°Q½×¡C¦Ó¤¤¬ã°|«Ý±ÂÅvªº§Þ³N«h²[»\¦h¶µ×¹¢¡]¦bGH¤W¥[¤JÅ|´á©Î¬t×¹¢¡^¡C |
|
|
·|û¡GCC10139226 µoªí®É¶¡:2015/6/10 ¤W¤È 11:24:19²Ä 300 ½g¦^À³
|
Cliff¤j ¡A°Ñ¦Ò°e³ø¤j5/8¸ò¥xÁÞ¤j4/22ªºµo¨¥ ¥iª`·NÃöÁä¦r"ÀÀ¦üÁÞ§Üì" 2014¦~´¿¦³¤@¬q¯Î±Ò´f°|ªøªº±M³X´£¨ì¯E¹©¥¿¦bµû¦ô»P¤¤¬ã°|Ä~Äò¦X§@¡u²Ä¤T¥N¡v²£«~ ¤¤¬ã°|¹Î¶¤§â³Ì·s¤@¥N²£«~ªº§Üì§ó´«¡A·s¤@¥Nªº§ÜìÀÀ¦üÁÞ§Üì¦ý¤ñÁÞ§ÜìÁÙ±j¡A¥iÅý§ÜÅé¹ïÀù²ÓMªº§ðÀ»¡A¤£ª¾¹D¬O¤£¬O«ü³oÓ? ¥H¤U¬O±M³X¤º®e(¥Ø«e§ä¤£¨ì¥þ¤å¡AÁٽЦU¦ì§ä¬Ý¬Ý¬Oþ¸Ìªº±M³X?) ¯E¹©¦XÁa³s¾î ÃÄ¥´¥@¬É¤j¾Ô 2015 04 ³X°Ý °Ý¡G¯E¹©ªº¥þ²y¥¬§½¦³¦ó³W¹º¡Hµª¡G³o¥i¥H±q¨â¤è±¨Ó½Í¡A²Ä¤@Ó´N¬O¥«³õµ¦²¤¡A¨ä¦¸¬O²£«~½uµ¦²¤¡A§ÚºÙ¬°¡uÂX¤j¾ÔªG¡v¡C¥«³õ¤è±¡A¬ü°ê±N¦³°Ê§@¡A¥¿¦Ò¼{§äþ¨Ç¦X§@¹Ù¦ñ¡B¨ÖÁÊþ¨Ç³q¸ô¡F¤j³°Á{§É°¨¤Wn¶}©l¡A¥¼¨ÓªF«n¨È¡B¥xÆWªº³W¹º¡A¤]³£¦³¸¡®×¡C ¦A¨Ó¬OÂX¤j¾ÔªG¡CÄ´¦p¡A¦P¤@Ó²£«~822¡A§Ú̱N¥H¨ÅÀùªvÀø¬°°ò¦©¹«e±À¡A·íµM³o¤]¤À¨âÓ¤è¦V¡A¤@¬O¡uÁa²`ªº±À¡v¡A¤À§O±À¥X¦U´Á¨ÅÀù¡]¥|¤T¤G¤@´Á¡^ªºªvÀø²Õ¦X¡A¥]¬AÀù¯g¹w¨¾¡C¥t¤@Ó¬O¡u¾î±ªº±À¡v¡A§YÂX¤j¾AÀ³¯g¡AÄ´¦p±q¨ÅÀùÂX¥R¨ì§Z±_¡B¯ØŦ¡BGÀùµ¥»â°ìªvÀø¡C °£¤F³æ¤@²£«~¤õ¤OÂX¥R¡A²£«~²Õ¦X¤]·|Ä~ÄòÂX¤j¡A°£¤F822¡B833ªº¤@¡B¤G¥N¥D°Ê§K¬Ì§ÜÀùªvÀø¬Ì]¥~¡A¯E¹©¥¿¦bµû¦ô»P¤¤¬ã°|Ä~Äò¦X§@¡u²Ä¤T¥N¡v²£«~¡A¤w¸g¦³¦¨ªG¡C²Ä¤T¥N¬Ì]¥¿¥Ñ¤¤¬ã°|¶}µo¤¤¡A³Ìªñ´Nnµoªí¡A³oÓ²£«~¦b»s³y§ÜÅé¤Wªº¯à¤O§ó±j¡C¤¤¬ã°|¹Î¶¤§â³Ì·s¤@¥N²£«~ªº§Üì§ó´«¡A·s¤@¥Nªº§ÜìÀÀ¦üÁÞ§Üì¦ý¤ñÁÞ§ÜìÁÙ±j¡A¥iÅý§ÜÅé¹ïÀù²ÓMªº§ðÀ»§ó±Ó·P¡C |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/6/10 ¤W¤È 10:21:49²Ä 299 ½g¦^À³
|
Hi Cliff¤j.. Ãö©óGlobo Hªº¤Æ¾Ç×¹¢¦n¹³±z»P¥xÁÞ¤j¤w¸g°Q½×¹L¤F ¤£ª¾¥H¤U¨â½g¬O§_¬O¦P¤@¬ã¨s.. http://proj1.sinica.edu.tw/~otl/index.php?t=9&group_id=22&article_id=1457 http://ntur.lib.ntu.edu.tw/handle/246246/257446#.VXeb750VFjo |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/6/10 ¤W¤È 12:18:35²Ä 298 ½g¦^À³
|
³o¤@Ó±M§Qµo¥¬¤é¬O2015/05/12èµo¥Í¦b³Ìªñ¡C¥¦ªº§Üì²Õ¦¨¬OGlobo H-DT/C34¡C ¨Æ¹ê¤W³oÓ±M§Q¬O¦X¨Ö¤F¤Uzªº±M§QA»PB¡F¦n¹³½Í¤£¤W¬O·s±M§Q¡C A¡^ 2009¦~6¤ë16¤é¥Ó½Ðªº¡uCompositions for inducing immune responses specific to globo h and ssea3 and uses thereof in cancer treatment US 20090317411 A1¡v¡]http://www.google.com.tr/patents/US20090317411 ¡^ B¡^ 2009¦~8¤ë6¤é¥Ó½Ðªº¡uGlobo H and related anti-cancer vaccines with novel glycolipid adjuvants US 8268969 B2¡v¡]http://www.google.com/patents/US8268969 ¡^ Y²Ä¤T¥N¯uªº¬OGlobo H-DT/C34¡A¨º¤j®aÀ³¸Ó¹ï¥¦«Ü¼ô±x¡C ¥Xª©¤j¡A¬Ý¬ÝÁÙ¦³¨S¦³·sµo²{¡H |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/6/9 ¤U¤È 10:46:59²Ä 297 ½g¦^À³
|
"¯E¹©ªº²Ä¤T¥N¬Ì]¤]±NnÅS±¡A¾Ö¦³¥þ·s§ó±jªº³J¥Õ»P§Üì¡A¥¿¥Ñ¤¤¬ã°|¶}µo¤¤¡Aªñ´Á±Nµoªí¡C" ¬O³o¶Ü??? http://www.google.com/patents/US9028836 |
|
|
·|û¡G±Û«a10139522 µoªí®É¶¡:2015/6/8 ¤U¤È 06:50:21²Ä 296 ½g¦^À³
|
Cliff¤j¤j¡A¦b§Ú¤ß¤¤²z·QªºOBI-822¸Ñª¼¤é´Á¬O¬ù¸¨¦b2016¦~2¤ë¥ª¥k¡A©¡®ÉPFS¦³¾÷·|¬D¾Ô¯E¤Í̼ÖÆ[ªº¼Æ¾Ú¹w¦ô¡A¦]¦¹OBI-822¸Ñª¼«á°ê»Úµoªíªººµo¡A§Ú»{¦P±z©Ò´£ªº2016 IGCS¦b¸²µå¤ú¨½´µ¥»¾÷·|³Ì°ª¡C |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/6/8 ¤U¤È 06:31:02²Ä 295 ½g¦^À³
|
Hi Cliff ¤j.. Å¥¨ìÃö©ó888ªº´£°Ý.®Æ·QÀ³¸Ó´N¬O±z©Ò´£ªº. ¥u¥i±¤®É¾÷¥¼¨ì.±z©Ò´£ªº°ÝµªÃD.¿à½à¥Î¬O«DÃD¦^µª¤F.. ÁÙ¦³"¯E¹©ªº²Ä¤T¥N¬Ì]¤]±NnÅS±¡A¾Ö¦³¥þ·s§ó±jªº³J¥Õ»P§Üì¡A¥¿¥Ñ¤¤¬ã°|¶}µo¤¤¡Aªñ´Á±Nµoªí¡C" ³oÓ"ªñ´Á"¤ñ·Q¹³ªº¤[¤F¤@ÂI.. ¨Ó²q¤@¤U±zªºÃD¥Ø... °²¦p822¦b2016Q1«e¯à¦³¼Æ¾Ú.2016.7¤ëªº¥xÆW¥Í§Þ®i¬O¤@ӫܦnªº®É¾÷. (OBI´N¬O·R¥xÆW..¥ô¦óªº²Ä¤@¦¸³£n¦b¥xÆW) |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/6/8 ¤U¤È 04:09:57²Ä 294 ½g¦^À³
|
¥Xª©¤j¡G ³o¦¸ªÑªF·|°Ý¨ì¤FOBI-888ªº¶i«×¡A¿à§B»¡¥¦¬O¤½¥q¦Û¦æ¬ãµoªº²£«~¡A»P¥Í§Þ¤¤¤ß¬ãµoªº§ÜGH§ÜÅ餣¤@¼Ë¡A¬ù¦b1.5¦~«á·|¥Ó½ÐIND¡C ¦Ü©ó¼s®Ä©Ê§Ü¥Í¯À¶i«×¡A°Ý¤F¨Sµª¡A¥i¯à¤K¦rÁٯʤ@ºJ¡C©|¥¼µ²ªGµLªk½×±ÄªG®É¾÷¡C ¬ðµM·Q¨ì-- 2015 ASCOè¶}§¹¡APD-1¤ÎCTLA-4¹L¨¬·¥ú¡AY822¦~©³¸Ñª¼¡A¤£ª¾n¸g¹L¦h¤[ªº¼Æ¾Ú¤ÀªR¡A¤~·|¦b°ê»Úµoªí¡H 2016 ASCO meeting 6/3-6/7¦bªÛ¥[ôÁ|¦æ¡AºKn¥²¶·¦b2016 Feb´£¥X¡A¦ü¥G»°¤£¤W®Éµ{¡C Abstract Submission Deadline¡GFebruary 2, 2016 at 11:59 PM (EST) 2016 ASCO Annual Meeting¡GJune 3-June 7, 2016 ¤j®a¨Ó²q¤@²q¡A²Ä¤@¯¥·|¦bþÓ³õ¦XÃzµo¡H 1.³æ¿W¶}°ê»Ú°OªÌ·| 2.¬YÓ¸~½FÂå¾Ç·|¡]2016 ASCO¨Ó¤£¤Î¤F¡F2016 IGCS¡H¡^ 3.ª¾¦W°ê»ÚÂå¾Ç´Á¥Z¡]NEJM¡HPNAS¡HLancet oncology¡Hand others¡H¡K¡^ 4.¥Ó½ÐTFDAÃÄÃÒ¤ñ¸û«n 5.»°§Ö¸òFDA¶}·|°Q½×¥þ²y¤T´Á¸ÕÅç¤ñ¸û«n 6.¡H¡H 2016 IGCS¡GThe International Gynecologic Cancer Society¬O¨â¦~¤@¦¸ªº·|ij¡F2014/11¦b¿D¬w¶}¹L¡A¤U¤@¦¸2016¦b¸²µå¤ú¨½´µ¥»¡A¾÷·|·|¤£·|°ª¤@ÂI¡H |
|
|
·|û¡G±Û«a10139522 µoªí®É¶¡:2015/5/29 ¤U¤È 01:59:33²Ä 293 ½g¦^À³
|
¸É¥R¤@ÂI¡A¯E¹©ÄYÂÔ¿í¦uÁ{§ÉÛ²z³W½d¡A²³©Ò¬Òª¾¡A¬JµM¥ý«e¤£´¿³zÅS¹ê»ÚPD¤H¼Æ¡AµM«á©~µM»´©ö¦b®ü¥~²³ø¤¤掲ÅS¡A½Ð°Ý³o¬O§_¦³¹H±`²z¡Hµo¨¥¤Hªí¥Ü¡A¨Æ¹ê¤W³o¶µ¼Æ¾Ú®Ú¥»¤£¥ÎÅã¥Ü¥X¨Ó¡A³o¦¸³y¦¨»~·|©Ò¥Hºò«æ¦VÂd¶R¤¤¥XºM±¼P22¡A¹ê»Ú¤WªºPD±o¥Ñ¿W¥ß¤¤¤ßµo§Gªº¬O¥¿½T¸ê°T¡C |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/5/28 ¤U¤È 11:15:39²Ä 292 ½g¦^À³
|
OBI-858¦n¹³¥ý§l¤Þ¨ìª`¥Ø¤F.. http://www.businesswire.com/news/home/20150527006704/en/Research-Markets-Global-Muscle-Spasticity-Pipeline-Report#.VWcvTZ0VFjp ¦ý¬O¥þ³¡§¹¾ã¸ê®Ænªá¿ú¤F..¯¸¦bªù¤f¬Ý¬Ý´N¦n.. |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/5/18 ¤W¤È 11:29:26²Ä 291 ½g¦^À³
|
Hi Cliff¤j.. ¬d¤F¤@¤U§Ú̪º"¬ãµo³B¸ê²`³Bªø ¿à«Ø¾±"¸ê¾ú©M³ÌªñªººtÁ¿©Mµoªí. ¦b¥xÆW§K¬Ì¾Ç¬É¦ü¥G¥i¥HºÙ"Åv«Â"¤F. Ãö©ó888ªººÃ°Ý.ªÑªF·|§Ö¨ì¤F..¤pªº¼È®É´N¤£¶Ã²q¤F.. ºô¸ô§ä¤@¨Ç543.©Ó»X±z¤Î¦U¦ì¤j.À°¦£À˵ø¨Ã²Ó¤ß¦^µª. °¸¦³¤@¨Ç¤p·Qªk.¦ý¥´¦rºC¤S¤£·|¾ã²z.ÁÙ¦n¦³¦U¦ì¤j³o»ò¥i¾a.. ¯à°µÓ°e³øªº¤wºâ¦Û¤v¶Kª÷¤F.. ³s¯Zµ²§ô.¤pªº¥ý§i°h¸É¯v¥h¤F... |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/5/14 ¤W¤È 01:06:25²Ä 290 ½g¦^À³
|
°e³ø¤j¡A¤p§Ì±q¦¹n§ï´LºÙ±z¬°¡u¥Xª©¤j¡v¡A±æ½Ð¯º¯Ç¡A¦P®É®ü²[¡C ¶µ¦¸2¬O§d³Õ¤ht³dªº¨S¿ù¡A©Ò¥H©Î³\¤p§Ì¥h¦~¦bª©ÀYªº¤º®e°O¿ý¦³ÂI²V¶Ã³_»~¡AÃþ¦ü±i«a§õÀ¹¡F¶µ¦¸5ªºÂù¯S²§©Ê§ÜÅé¬O®}³Õ¤ht³dªº¡F²{¦b¨ì©³þ¤@Ó»P888¸û¹³§Ú¤]·d¤£²M·¡¤F¡C¦Ó¥B§d³Õ¤h¨ºÃä¡A¥h¦~³QK¤F¡A²{¦b·Q¦h°Ý¤w¨S«ü±æ¡F®}³Õ¤h¥Ø«e¦b°ê¥~¡A¤@®É¤]¨S±o°Ý¡C ©Ò¥H¥Xª©¤j¡A´N¬Ý§AªºÅo¡I |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/5/14 ¤W¤È 12:37:58²Ä 289 ½g¦^À³
|
Àô²y¤ë¥Z¦³°l³o¦¸¦X§@»¡©ú·|.§Æ±æ¤U´Á¯à¦³¬ÛÃö³ø¾É.. http://www.gbimonthly.com/activity/activity_dcb150430.html |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/5/14 ¤W¤È 12:31:23²Ä 288 ½g¦^À³
|
Hi Cliff¤j.. ¶µ¦¸2 §ÜGlobo H³æ®è§ÜÅé¶}µo§Þ³N ªº §d¨Î«° ³Õ¤h´N¬O¥»ª©ÀYªº§d³Õ¤h http://nrpb.sinica.edu.tw/sites/default/files/event/20150408_104%E5%B9%B4%E5%BA%A6%E7%A0%94%E7%99%BC%E6%88%90%E6%9E%9C%E7%99%BC%E8%A1%A8%E6%9A%A8%E7%94%A2%E5%AD%B8%E7%A0%94%E5%90%88%E4%BD%9C%E8%AA%AA%E6%98%8E%E6%9C%83%20%E6%B4%BB%E5%8B%95%E8%A8%8A%E6%81%AF.pdf |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/5/9 ¤U¤È 03:03:34²Ä 287 ½g¦^À³
|
Hi Cliff¤j.. ±z¤Ó«È®ð¤F.þ¦³³o»ò±M·~ªº"J¨¥¶Ã»y" ¤pªº¤]»{¬°¨ä¤¤ªº"Globo H³æ®è§ÜÅé¶}µo§Þ³N"¥i¯à«D888 ¥u¬O±q®É¶¡ÂI±À´ú.¤½¥qªº¤½¶}»¡©ú®Ñ¸Ì¤]ºÙ888¬O¦Û¦æ¶}µoµL¶·µ¹Åv§Qª÷. ¦ý³o¼Ëªº§Þ³Nn³Q§ÞÂà.¬°§K¥H«áªºÄvª§©Î±M§Q©x¥q¤½¥q¤è±.ÁÙ¬Onª`·N¤ñ¸û¦n.. (²¦³º¥xÆW¦³¨Ç¤½¥q¶R§Þ³N¬O¬°¤F½æ¤½¥q) ·|¤£·|"¶µ¦¸5.Àù¯g¤§Âù¯S²§©Ê§ÜÅé"¤~¬O²Ä¤T¥N?? ¥H¤W"J¨¥¶Ã»y"¼Ð·Ç¥Ü½d.. |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/5/9 ¤W¤È 06:39:44²Ä 286 ½g¦^À³
|
»¹«¤j ÁÂÁ±z ¤p§Ì«D±`¬Û«H¥L«Ü¬°Ãø¡A¯uªº¬O¤å¦rº»§r.... ¦pªG¥i¥H¡A½ÐÀ°¤p§ÌÂà¹F ¨¬°¤@¦ìŪªÌ ¤p§Ìªº¨ØªA»P·PÁ¤§¤ß¡A¯u¬OÃø¥H¨¥ªí ¦A¦¸·PÁÂ¥L¤Î»¹«¤j |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/5/9 ¤W¤È 01:50:00²Ä 285 ½g¦^À³
|
°e³ø¤j¡G ¤µ¦~3/3¤WÂdªk»¡·|µ²§ô«á¡A¶]¥h°Ý¬ãµoªøTony Yu¦³Ãö888¡A¥Lµª¡uÁÙ¦b½Í¡K¡v¡A¬°¤°»ò¡H¬O¤£¬OBi-specific antibody¡H°Ó·~¾÷±KµL¥i©^§i¡C ¥Ø«e¥i½T©wªº¬O¨º±iexcel²M³æ¡AºI¦Ü2015/4/27¤î¡A³£©|¥¼§ÞÂà¥X¥h¡A¨ÆÃö²£·~¾÷±K¡A±ý±o¨ä¸Ô«Ü³Â·Ð¡An¯dÓX¡Bµ¥¼fX¡Bñ¦PX®Ñ»P«OX¨ó©w¡K¹HIªì°J¡A©ñ±ó¡K¡A¥h¦~©³¦]ª©ÀY¤å¤w¸g³Q¡K ²³æ¦a»¡¡A¶µ¦¸5§Æ±æ³Ì¿@¡]¯Â²q´ú³Ì¦Û¥Ñ¡^ ¡u§Þ³N¯S¦â¡GÀù¯g¤§Âù¯S²§©Ê§ÜÅé °w¹ïÀù²ÓM¶i¦æ·s¥@¥N¼Ð¹vªvÀø¡A§Q¥ÎÂù¯S²§©Ê§ÜÅ黤¾É¬¡¤ÆT²ÓM¨Ã°w¹ïÀù²ÓM¶i¦æ¬r±þ¡A¥i°§C§ÜÅéÃĪ«¨Ï¥Î¶q¡A¨Ã°§C°Æ§@¥Î¡C¡v ¡u¥iÀ³¥Î½d³ò¡G·s¥@¥NÀù¯g¼Ð¹vªvÀø¡A¦p¡G¨ÅÀù¡B¤j¸zª½¸zÀù¡B¯ØŦÀù¡v °Ñ¦Ò¥»ª©2015/1/3¤U¤È05:22:42ªº¶K¤å¡A³oÓ§ÜGHªºÂù¯S²§©Ê§ÜÅé¡A¤@Áu¥i§ìGH¡A¥t¤@Áu¥i§ìCD3¡AÓ¤Hı±o§Þ³N¼h¦¸¸û°ª¡A¾Ô°«¤O¸û¨¬¡C ·íµMÁÙ¦³¥t¤@ºØ¥i¯à¡A´N¬O»Pªí®æ¤¤ªº²Î²ÎµLÃö¡A¦Û¦æ¬ãµo¨«¦Û¤vªº¸ô¡C¨º»òÁô¼~¬O¡Aþ¤Ñ³Q¨ä¥L®a¥Í§Þ¤½¥q§â³o¤@¶µÂù¯S²§©Ê§ÜÅé§ÞÂà¦^¥h¡A¨º«áªG±N¦p¦ó¡H ¶µ¦¸2©O¡H¬O¯Â§ÜGH mAb¡A¤Ó¶§¬K¡A¾Ô°«¤O»P§Þ³N¼h¦¸¤]¥i¯à§C¨Ç¡C¡uºî¦X²q´ú¡v¤£¬O¥¦¡C ¬K¹pÀWÅT¡A¤Þµo®ð¾÷ÄøÄø±ý°Ê¡A«ö±Ì¤£¦í³ºµM¶¶¶Õ°_¥ä¡AJ¨¥¶Ã»y¤@µf¡A¥H¤W¨Ó¦Û´Ý¯dªº¦L¶H¡A½Ð¤Å¬Û«H¡A¤@¤Á½Ð¬Û«H¤½¥qµo¥¬°T®§¤~¬O¡C |
|
|
·|û¡G¯ä¦Ñ¹«10139175 µoªí®É¶¡:2015/5/8 ¤U¤È 11:41:51²Ä 284 ½g¦^À³
|
Faith¤j ¤p§Ìªº¾Çªø»P±i¸g²z»á¦³¥æ¬y Âàz§Ú¾Çªø»¡ªº ±i¸g²z¦³³\¦h¬°Ãø¤§³B ³ø§i¤£¬O¥þ»ª ¥Ø¼Ð»ù»PPFS³Ì¬O¬°Ãø ·Q»¡ªº¸ÜÂæb¹Ïªí¤¤..... |
|
|
·|û¡G¯ä¦Ñ¹«10139175 µoªí®É¶¡:2015/5/8 ¤U¤È 11:27:37²Ä 283 ½g¦^À³
|
¤p§Ì¬Q¤Ñ¤~»¡¡G "¦³¦ì¤ñ®ü¥ý¥Í¦³¿úªº¤H¨C¤Ñ¥[½X¤d¸U¸êª÷¡A¤p§ÌÁÙ¦b°lÂܬd¸ß¤¤¡A®e¤p§Ì¦h¥´´X¤ä¹q¸Ü¦h°lÂÜ´X¤Ñ¦A¦V±z³ø§i" ¤µ¤Ñµª®×´N¸õ¥X¨Ó¤F ¦U¦ì¤j ¼í®õ¤£¬O¶R¦b³Í°ò¥x¥_ ¦Ó¬O¥xÆW¤u»Èxx»P¤¤«H°Uxx ³o¨âÓxx³£¤@¼Ë |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/5/8 ¤U¤È 10:55:39²Ä 282 ½g¦^À³
|
Cliff¤j¡B²q·Q¤j ¤p§Ì³Ìªñ´X¤Ñ¤w«ôŪ¤F¤é²±±i¥ý¥Íªº¤j§@ Ū§¹¤F«á¡A¹ï±i¥ý¥Í¥Ñ°Jªº·q¨Ø ¤p§ÌŪªº¬O3¤ë27¤é¦@17¶ªºª©¥» ±i¥ý¥Í¤ÀªR±o«D±`¸ÔºÉ ¥i¬Ý¥X¥Lªº¥Î¥\¡A¤p§Ì¦Û¹Ä¥±¦p ¤]nµ¹±i¥ý¥Í¤j¤jªºÆg ¦b¦¹¡A¤p§Ìn×¥¿£¸¤U¤§«eªº»¡µü ¡uºÉ«H®Ñ¤£¦pµL®Ñ¡v ¦ý¦pªG¡u³s³o¥»®Ñ³£¨SŪ¹L¡A¨S¦³µû½×ªº¸ê®æ¡v «á±³o¥y»¡ªº´N¬O¤p§Ì¦Û¤v¡AºF·\§r¡ã¡ã |
|
|
·|û¡Gwison3710140346 µoªí®É¶¡:2015/5/8 ¤U¤È 10:04:55²Ä 281 ½g¦^À³
|
µØ¤H¤Úµá¯S¥X¤â¥[½X¯E¹©¤F. |
|
|
·|û¡G«Øcc10140016 µoªí®É¶¡:2015/5/8 ¤U¤È 09:44:10²Ä 280 ½g¦^À³
|
¼í®õ¥þ²y¡G¤½§i¥»¤½¥q¨ú±o¥xÆW¯E¹©¥Í§ÞªÑ¥÷¦³¤½¥q´¶³qªÑªÑ²¼ |
|
|
·|û¡Gmoncler4710135258 µoªí®É¶¡:2015/5/8 ¤U¤È 09:38:38²Ä 279 ½g¦^À³
|
¤p¤ß¶}°ª¨«°ª°l¤£¦^¨Ó.. |
|
|
·|û¡Gmoncler4710135258 µoªí®É¶¡:2015/5/8 ¤U¤È 09:31:05²Ä 278 ½g¦^À³
|
¤j¦ÑÁó¥X¤â¤F,¤pªL¥J¸÷¦w§a! ¤µ¤Ñ³Í°ò¥x¥_¶R¤£¤Ö®@! ¤Ñ¤Ñ¦³¤H¦n¤ß¶}°ªµ¹§A½æ,¤p¤ßþ¤Ñ½æ¸¶}°ª¨«¶}°ª°l¤£¦^¨Ó... |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/5/8 ¤U¤È 09:09:31²Ä 277 ½g¦^À³
|
¼í®õ¥þ3/31~5/8¨ú±o¯E¹©91¸UªÑ¡Ap3.02»õ¤¸ (2915)¼í®õ¥þ¤½§i¥»¤½¥q¨ú±o¥xÆW¯E¹©¥Í§ÞªÑ¥÷¦³¤½¥q´¶³qªÑªÑ²¼ 1.ÃÒ¨é¦WºÙ:¥xÆW¯E¹©¥Í§ÞªÑ¥÷¦³¤½¥q 2.¥æ©ö¤é´Á:104/3/31~104/5/8 3.¥æ©ö¼Æ¶q¡B¨C³æ¦ì»ù®æ¤Î¥æ©öÁ`ª÷ÃB: ¥æ©ö¼Æ¶q910,000ªÑ ¨C³æ¦ì»ù®æ332.28¤¸ ¥æ©öÁ`ª÷ÃB302,375,500¤¸ 4.³B¤À§Q¯q¡]©Î·l¥¢¡^¡]¨ú±o¦³»ùÃÒ¨éªÌ¤£¾A¥Î¡^:¤£¾A¥Î 5.»P¥æ©ö¼Ðªº¤½¥q¤§Ãö«Y:«DÃö«Y¤H 6.¨´¥Ø«e¬°¤î¡A²Ö¿n«ù¦³¥»¥æ©öÃÒ¨é¡]§t¥»¦¸¥æ©ö¡^¤§¼Æ¶q¡Bª÷ÃB¡B«ùªÑ¤ñ¨Ò¤ÎÅv§Q¨ü±¡§Î¡]¦p½è©ã±¡§Î¡^: «ùªÑ¡G2,171,648ªÑ ª÷ÃB¡G712,193,306ªÑ «ùªÑ¤ñ¨Ò¡G1.27¢H Åv§Q¨ü±¡§Î¡GµL 7.¨´¥Ø«e¬°¤î¡A¨Ì¡u¤½¶}µo¦æ¤½¥q¨ú±o©Î³B¤À¸ê²£³B²z·Ç«h¡v²Ä¤T±ø©Ò¦C¤§¦³»ùÃÒ¨é§ë¸ê¡]§t¥»¦¸¥æ©ö¡^¥e¤½¥q³Ìªñ´Á°]°È³øªí¤¤Á`¸ê²£¤ÎÂkÄÝ©ó¥À¤½¥q·~¥D¤§Åv¯q¤§¤ñ¨Òº[³Ìªñ´Á°]°È³øªí¤¤Àç¹B¸êª÷¼ÆÃB: ¥e¤½¥q³Ìªñ´Á°]°È³øªí¤¤Á`¸ê²£¤§¤ñ¨Ò¡G47.56¢H ¥e¤½¥q³Ìªñ´Á°]°È³øªí¤¤ÂkÄÝ©ó¥À¤½¥q·~¥D¤§Åv¯q¤§¤ñ¨Ò¡G58.25¢H ³Ìªñ´Á°]°È³øªí¤¤Àç¹B¸êª÷¼ÆÃB¡G2,748,807,000¤¸ 8.¨ú±o©Î³B¤À¤§¨ãÅé¥Øªº:§ë¸ê 9.¥»¦¸¥æ©öªí¥Ü²§Ä³¸³¨Æ¤§·N¨£:¤£¾A¥Î 10.¥»¦¸¥æ©ö¬°Ãö«Y¤H¥æ©ö:§_ 11.¸³¨Æ·|³q¹L¤é´Á:¤£¾A¥Î 12.ºÊ¹î¤H©Ó»{©Î¼fp©eû·|¦P·N¤é´Á:¤£¾A¥Î 13.¨ä¥L±Ô©ú¨Æ¶µ:µL |
|
|
·|û¡G¦h¦h10137435 µoªí®É¶¡:2015/5/8 ¤U¤È 08:39:50²Ä 276 ½g¦^À³
|
¼í®õ¥þ¨ú±o¯E¹©910±i «ùÄò¬Ý¦n |
|
|
·|û¡G¸U¤¸10031351 µoªí®É¶¡:2015/5/8 ¤U¤È 05:55:49²Ä 275 ½g¦^À³
|
½Ð°Ýyunyun¤j F ¶}ÀYªº¤½¥q¬O§_§t¦³¦Ê³f¦¨¦çÃþªÑ¡H ¥Í§Þ¦³¥]§t¤p¯E¶Ü¡H À°ªB¤Í°Ýªº ·PÁÂ¥ý |
|
|
·|û¡GYunyun10140355 µoªí®É¶¡:2015/5/8 ¤U¤È 05:40:54²Ä 274 ½g¦^À³
|
Ä~ÃÄµØ ÁÙ¦³¨â¤ä¥Í§ÞªÑ ¦~©³«e¬O±µ¤U¨Ó¬O¤T¤äF¦rÀY ±N¦¨¬°«¶Ë®`¦UªÑ ÂÔ·V.(ÃT³½ªð¶m) |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/5/8 ¤U¤È 02:13:05²Ä 273 ½g¦^À³
|
°e³ø¤j¡A±ßÂI¦A¸ò±z½Í¡C |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/5/8 ¤U¤È 01:54:27²Ä 272 ½g¦^À³
|
°e³ø¤j ±z¯uªº¤]«Ü·|»`¶°¸ê®Æ Æg ÁÂÁÂÅo |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/5/8 ¤U¤È 01:35:49²Ä 271 ½g¦^À³
|
¦U¦ì¤j¤j.. ±i¸³©Ò´£¨ìªº ¯E¹©¦XÁa³s¾î ÃÄ¥´¥@¬É¤j¾Ô 2015-04-13 ""²Ä¤T¥N¬Ì]¥¿¥Ñ¤¤¬ã°|¶}µo¤¤¡A³Ìªñ´Nnµoªí¡A³oÓ²£«~¦b»s³y§ÜÅé¤Wªº¯à¤O§ó±j¡C¤¤¬ã°|¹Î¶¤§â³Ì·s¤@¥N²£«~ªº§Üì§ó´«¡A·s¤@¥Nªº§ÜìÀÀ¦üÁÞ§Üì¦ý¤ñÁÞ§ÜìÁÙ±j¡A¥iÅý§ÜÅé¹ïÀù²ÓMªº§ðÀ»§ó±Ó·P¡C"" 104¦~«×¤½§i¸gÀÙ³¡§Þ³N³B¬ì§Þ±M®×¥i²¾Âà§Þ³N17µ§¤Î±M§Q19µ§ µo§G¤é´Á¡G2015/04/27 http://www.dcb.org.tw/en_msg.aspx?a=4&i=1007 ¦³¨S¦³¥i¯à¬O¨ä¤¤¤§¤@?? |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/5/8 ¤U¤È 01:15:23²Ä 270 ½g¦^À³
|
§ó¥¿¬OOBI-888 |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/5/8 ¤U¤È 01:14:41²Ä 269 ½g¦^À³
|
Cliff¤j.. http://www.dcb.org.tw/en_msg.aspx?a=4&i=1007 ¸Ì±¦³"Globo H³æ®è§ÜÅé¶}µo§Þ³N"¬O©MOBI-833¦³Ãö¶Ü?? |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/5/8 ¤U¤È 12:55:27²Ä 268 ½g¦^À³
|
¦³ªÅ¤S·Q½m¥\ªº¤H¥i¥H°Ñ¥[¡A¥i¥H·í±½Ð¯q§d©v¯q³Õ¤h³á¡I¤p§ÌµLªk¤À¨ ¡uhttp://app.sinica.edu.tw/iaocalendar/pub_eventShow.php?_op=?eventID:2350 ¡v ¤¤¥¡¬ã¨s°|°ò¦]Åé¬ã¨s¤¤¤ß¬¡°Ê¸Ô²Ó¸ê°T Event Information ¬¡°Ê°T®§³Ì«á§ó·s®É¶¡ : 2015-05-07 16:56:54 ¬¡°Ê¦WºÙ Topic¡G Development of Carbohydrated-based Vaccines ¶}©l¤é´Á Starting Date¡G 2015-05-28 ¡]¶g¥|¡^ 15:00 µ²§ô¤é´Á Ending Date¡G 2015-05-28 16:00 ¬¡°Ê¦aÂI Venue¡G °ò¦]Åé¬ã¨s¤¤¤ß1¼ÓºtÁ¿ÆU 1F Auditorium, Genomics Research Center ºtÁ¿ªÌ©m¦W Speaker¡G §d©v¯q°Æ¬ã¨sû Dr. Chung-Yi Wu ¥D«ù¤H©m¦W Host¡G ¹ù°êµ¾ Kuo-Shiang Liao PhD Student ¬¡°Êºô§} Website¡G ²¤ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/5/6 ¤W¤È 11:50:53²Ä 267 ½g¦^À³
|
Cliff¤j ¤åÄm¤è±§A³Ì±M·~ ,¥i½Ð§A¨ó§U¤j®a¸ÑŪ¤@¤U³¯³Õ¤hºtÁ¿ºõn ÁÂÁ : ¥H¤U±^¤å·j´M GHCer plays triple roles in serving as a cancer antigen (including breast cancer stem cells), as an immune checkpoint and as an angiogenic factor, thereby propelling the ongoing multi-national phase II/III clinical trial of globo H vaccine in breast cancer |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/5/3 ¤U¤È 05:16:33²Ä 266 ½g¦^À³
|
2015/05/07¡G¡uhttp://crdd.tmu.edu.tw/app/news.php?Sn=33 ¡v ¬Û®t¤¦~¡A¤£ª¾¤º®e¦³¦ó®t²§¡H²K¥[¤FOBI-822ªº¸gÅç»P¼Æ¾Ú¡H 2010/05/15¡G¡uhttp://www.cos.org.tw/db/edu/1946.pdf ¡vpage 14/52 |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/4/27 ¤W¤È 11:43:09²Ä 265 ½g¦^À³
|
Cliff¤j ÁÂÁ±z ±z¤w¸ÑÄÀªº¬Û·í²M·¡¤F ·PÁ |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/4/27 ¤W¤È 11:18:45²Ä 264 ½g¦^À³
|
Faith¤j¡G ¨ä¹ê¤@¶}©lŪ¨º½g¤å³¹®É¡A¤]¦³¸ò±z¤@¼Ëªº·Pı»PºÃ°Ý¡A¦ý¬O«á¨Ó¦hŪ´X½g¬ÛÃöªº¤å³¹«áµo²{¨ä¹ê³oºØ¦b©x¯à°ò¤W¥H¬t/Å|´á/f°µ¥[¤W/¸m´«ªº°µªk¡A¦b¦³¾÷¤Æ¾Ç¦X¦¨ªºÀ³¥Î¬O¥qªÅ¨£ºD¨Ã«D¿W³Ð¡C ¦Ó¬°¦ó¹ïGH°µ×¹¢¡H§Úı±o¬O¦]¬°¾ãÓOBI-822ªººc¦¨¦¨¤À¤¤¡A¨ä¥L¯à°Êªº/©ö°Êªº³£°Ê¹L¤F¡A©Ò¥H½ü¨ì§ïÅÜ×¹¢GHªº³¡¥÷¡C ¤@´Á¸ÕÅç³]pùØ¡A§â±wªÌ¤À¦¨¤T²Õ¡A¨ä¤¤Group1&2ªº®t²§¬O¤ñ¸ûGH»PKLH¤§¶¡ªºÁäµ²¡A¬Oª½±µ¦nÁÙ¬O¥æ¤e¦n¡HGroup2&3ªº®t²§¬O¤ñ¸ûÃĪ«¾¯«¬¬O¦s©ó¹ÆQ¤ô¤¤ÁÙ¬Oá´¹¶J¦s¦n¡H ¨ì¤F¯»¶ê½g®É¡A¤S¬ã¨s¤FGH»PKLHªºÁäµ²¤ñ¨Ò¦h¤Ö¤ñ¸û¦n¡H¤]¤ñ¸û¤F¤£¦PªºÄâ±a³J¥Õ©Î¦õ¾¯¦óªÌ¸û¦n¡HªLªLÁ`Á`¡A¥þ¨¤W¤U¯à¡u·L¾ã§Î¡v³£°µ¤F¡A¦ÛµM³Ñ¤U×¹¢GH¬Ý¯à§_¤ñ¸û®e©ö»¤µo¸û¦hªºIgG¡C |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/4/27 ¤W¤È 07:47:58²Ä 263 ½g¦^À³
|
Cliff¤j ¤p§Ì¥u¬O²q´ú,¦Ü©ó¬O§_¦³¦¹¥i¯à,¯uªº¸ß°Ý°|ªø¤~¯à¸Ñµª¤F ¦pªG¥i¥H°Ý¨ìªº¸Ü,¬O§_¥i¥H¶¶«K½Ð±Ð¥L³o½g(¤p§Ì²q³Ì«á¤@¦ì§@ªÌ¬O¯Î°|ªø,³Ì¤jªº©ñ³Ì«á,¤W¦¸±z±Ð¹L§ÚÌ) http://www.ncbi.nlm.nih.gov/pubmed/25371992 ¨ä¤¤³o¥y,¦ü¥G¦³´£¨ì position " After Balb/c mice injection, the immune response was studied by a glycan array and the results showed that modification at the C-6 position of reducing end glucose of Globo H with the fluoro, azido, or phenyl group elicited IgG antibody response to specifically recognize Globo H (GH) and the GH-related epitopes, stage-specific embryonic antigen 3 (SSEA3) (also called Gb5) and stage-specific embryonic antigen 4 (SSEA4)." ½Ð¨ó§U½Ð±Ð°|ªø ³Ìªì¬°¦ó·|·Q×¹¢ GH ?¬O§_µo²{¤F¤°»ò?(¬O¤°»ò°Ê¾÷·Qn¥h×¹¢ GH?) ¦pªG¦]¬ã¨s©|¥¼¥¿¦¡µoªí,ÁÙ¤£¯à¤½¥¬,±z´N¥ý«O¯d´N¦n ÁÂÁ±z |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/4/27 ¤W¤È 12:10:43²Ä 262 ½g¦^À³
|
Faith ¤j¡G §Úª¾¹D¦P¤À²§ºcª«¡A¥u¬O¦~¥N¤[»·¡A¸Ó§Ñªº/¸ÓÁÙªº³£§Ñ/ÁÙ±o®t¤£¦h¤F¡C¤£¹L·í¤»Ó¤»ºÒ¿}³s¦¨¤@¦ê®É¡A·|¦³²§ºc¦¡ªº°ÝÃD¶Ü¡H·|¶i¤@¨B¾ÉP§ÜÅéµ²¦Xªº±µ¦X§xÃø¶Ü¡H§Ú¤£ª¾¹D¡C¦³¾÷·|¦A°Ý°Ý°|ªø¬Ý¬Ý¡C Globo H¡G¡uhttp://www.pnas.org/content/105/33/11661/F1.large.jpg ¡v |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/4/26 ¤U¤È 10:28:41²Ä 261 ½g¦^À³
|
¶Â´ËªL«á±ªº±mi ¥H«e«Ü¦h¯E¤Í¦b°Q½×822¤T´ÁÁ{§É¦¨¥\,¼ÆÈ¥X¨Ó«á¦X²zªÑ»ù¬O¦h¤Ö? ²³»¡¯É¯Æ,¯Ê¥F¼Ð·Ç,ª½¨ì¬Ý§¹±i¸³°Ó·~©P¥Z±M³X«á,¤ß¤¤¤~¦³¤@Ó©ú½Tµª®×,¤@Ó¶i¤J¤T´ÁÁ{§Éªº¤j«¬ÃÄ,³æ¤@²£«~¦~À禬¼ç¤O¶W¹L¤Q»õ¬ü¤¸¡A¤T´ÁÁ{§É¦¨¥\,¼ÆÈ¥X¨Ó¥H«á¡A¤½¥qÁ`¥«ÈÀ³¸Ó¬O5¨ì10ÓBillion¡]10»õ¬ü¤¸¡^¡A¤]´N¬O50»õ¬ü¤¸¨ì100»õ¬ü¤¸¤§¶¡,§Ú©l²×¬Û«H¤@¦ì¦b¬ü°ê¥Í§Þ¬É30¦h¦~,¬Ý¹LµL¼Æ¥Í§Þ¤½¥q¬ãµo¦¨¥\ªºÃĪ«,¥Lªºµû¦ô¬Oȱo«H¿àªº, ·PÁ°e³ø¤j«e¨Ç¤é¤l´£¨Ñªº¸ê°T,¤]·Q½Ð±Ð Á`¥«È50»õ¬ü¤¸¨ì100»õ¬ü¤¸¤§¶¡´«ºâªÑ»ù¬O¦h¤Ö? |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/4/26 ¤U¤È 10:11:14²Ä 260 ½g¦^À³
|
Cliff¤j ¤À¤lªº§Î¦¡¡B¤¸¯À¡Bµ²ºc¯uªº«D±`¶ø§®»P½ÆÂø ¦A¸É¥R¤@ÂI ¥k±Û¿}§Y¸²µå¿}¡A¦]¸²µå¤¤¦³¦¹ºØ¿}¡A©Ò¥H¥s¸²µå¿}¡C¥k±Ûªº·N«ä¬O«ü¦¹ºØ¸²µå¿}¦b°¾¥ú·¥±¤Wªº¥úªi¦V¥kÂà(¶¶®É°w¤è¦V)ªº¨Æ¹ê¡C¥ª±Û¿}¤SºÙªG¿}¡A¦b°¾¥ú·¥±¤Wªº¥úªi¬O¦V¥ªÂ઺(¤Ï®É°w¤è¦V)¡C¥ª±Û¿}©M¥k±Û¿}©Ò§tªººÒ²B®ñ¤¸¯À¼Æ¥Ø¬Û¦P¡A¦ý¨âªÌ¤¸¯Àªº±Æ¦C¦¸§Ç¤£¦P¡A¦]爲¤¸¯À±Æ¦C¦¸§Çªº¯Ê¥F¨ó½Õ¡A©Ò¥H´N³y¦¨°¾¥ú·¥±¥úªiªºÂ\°Ê¤è¦V¤F¡A»¡¨Ó¹ê¦b¦³½ì¡C ¦pªG¡A§Ú̱N¨ÅÀù»P§Z±_ÀùªºGH¤À¤l±Æ¦C¡A¤ñÀÀ¦¨¸²µå¿}»PªG¿}¡A³£¬O¦P¤À²§ºcª«¡]Åé¡^ ¥L̳£¦³GH,¦ý«o¦]¨ä¤¤ªº±Æ¦Cµ²ºc¤£¦P¡]þ©È¬O£¸ÂIÂIªº¤£¦P¡^ ´N¥i¯à³y¦¨¤F822¥´¤J«á¡AµLªk¥¿¤¤¹v¤ßªº²{¶H ¤p§Ì«D±M®a¡A¥u¯à´N©Òª¾³¡¤À¥h²q´ú¡B°Q½× ¤]¦]¦¹¡A¯E¹©Y¯uªº¦b¨ÅÀù¦¨¥\¤F ¨º¯u¬O¤£±o¤Fªº¤@¥ó¤j¨Æ ¥H¤W²L¨£¡A¶È¬O²q´ú¡A¥i¯à¦³¿ù»~¦Ê¥X¡A©|½Ð¥]²[ |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/4/26 ¤U¤È 04:51:41²Ä 259 ½g¦^À³
|
×¥¿¥y¤l Ãþ¦ü¸²µå¿}»PªG¿}¬OÄÝ©ó¦P¤À²§ºcª« Sorry ¥´¤Ó§Ö±`¥´¿ù^_^ |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/4/26 ¤U¤È 02:09:23²Ä 258 ½g¦^À³
|
¸É¥R ¦P¤À²§ºcª« ¤À¤l¦¡¬Û¦P¦ý¦]ºc³y¬Û²§¡A¦Óª«²zªº©Î¤Æ¾Çªº©Ê½è¬Û²§ªºª«½è¡A¨âөΨâÓ¥H¤W¦s¦b®É¡A³o¨Ç¤Æ¦Xª«¤¬¬Û¤§¶¡ºÙ¬°¦P¤À²§ºc¦¨¡]Isomer¡^³oºØ²{¶HºÙ¬°²§ºc²{¶H¡]Isomerism¡^¡C²§ºc²{¶H³Ìªì«Y©ó¦è¤¸¤@¤K¤G¤T¡ã¤@¤K¤G¥|¦~¥ª¥k¡AA.Wohler»PJ¡DLiebig¤À§O¬ã¨s©Ê½è§¹¥þ¤£¦PªºÙæ»Ä»È»P¹p»Ä»È¡AµM¨âªÌªº¤À¤l¦¡§¡¥i¥HAgGONªí¥Ü¦Óµo²{¡C§ó©ó¤@¤K¤T¤@¦~¡AJ.Berzelius±oª¾°s¥Û»Ä»P¸²µå»Ä¤]¦³¦P¤@²Õ¦¨¡C¦p¦¹¦³¦P¤@²Õ¦¨ªºª«½èºÙ¤§¬°Corps Isomeriques¡AĶ¬°¦P¤À²§ºcª«¡A²ºÙ¬°²§ºcª«¡A¦Ó³oºØ²{¶H´NºÙ¬°²§ºc²{¶H¡Cªì´Á®É¡A±N²Õ¦¨¤À¤lªºì¤l¤ñ²v¬Ûµ¥ªºª«½è¥ç¥]§t©ó²§ºcª«ºÙ©I¡A¦ý²{¦b¥Dn¥H¯U¸q¸ÑÄÀ¡C²§ºcª«ªº¬ã¨s¹ï©óºc³y¦¡¡Bì¤l»ù²z½×ªºµo®i¨ã¦³«Ü¤j¼vÅT¡C°_ªìµo²{ºÒ¤Æ¦Xª«¤§¶¡¦³¦h¼Æ²§ºcª«¦s¦b¡A¦ýÀHµÛ°t¦ì¤Æ¦Xª«¡]Coordination Compound¡^¤Æ¾Çªºµo®i¡A¼sªxªº³Qµo²{©ó¦³¾÷¤Æ¾Ç¤ÎµL¾÷¤Æ¾Ç¦U¤è±¡C¤@¡B¦³¾÷¤Æ¦Xª«¤O±¡G¦³¦p¤A¾J»P¤G¥Ò¶¡©Ò¨£ªººc³y²§ºc¡]Structural Isomerism¡^¡A§Y¨ã¦³¦P¤@²Õ¦¨»P¦P¤@¤À¤l¶q¤§¨âӤƦXª«¡A¥i¥H¤£¦Pºc³y¦¡ªí¥Ü®É¡A¤¬¬Û¤§¶¡ºÙ¬°ºc³y²§ºc¡^¡A¤S¦p¤AñQ¤A»Ä¤Aधଫ¬¡]Keto Form¡^»P²m¾J«¬¡]Enol Form¡^¤§¶¡ªº¤¬Åܲ§ºc¡]Tautomerism¡^¡A§Y¤AñQ¤A»Ä¤A঳ଫ¬¤Î²m¾J«¬¨â«¬¦s¦b¡A²m¾J«¬»Pଫ¬¦U¬°¤@ºØ»Ä¡A¸ÑÂ÷«á¥Í¦¨¦@¦Pªº³±Â÷¤l¡A¥ç§Yଫ¬»P²m¾J«¬«Y¸g¥Ñ³±Â÷¤l¤¬Åܪº¤¬Åܲ§ºcª«¡C¤S¥ßÅ鲧ºcª«¡]Stereoisomer¡^¦³¦p°s¥Û»Ä©Ò¨£ªº¥ú¾Ç²§ºc¡]Ãè¹³²§ºc[Optical Isomerism]¡A³oºØ²§ºcª«¤@¯ë¨ã¦³¥ú¾Ç¬¡©Ê¡^¡A¤G´â¤Æ¤AñQªº´X¦ó²§ºc¡]Geometrical Isomerism¡A¤SºÙ¬°Cis-trans²§ºc¡A§Y¥Ñµ²¦X©óÂùÁä¤Wªº¸m´«°òªº°t¸m©Ò¥Í¦¨ªº²§ºc²{¶H¡A¦b¦³¾÷¤Æ¾Ç¤W¦³®ÉºÙ¬°¤A²m²§ºc[Ethylenic Isomerism]¡^µ¥¡C¾¨ºÞ¦³¾÷¤Æ¦Xª«¥Dn¥ÑºÒ¡B²B¡B®ñ¡B´áµ¥¤Ö¼ÆºØÃþªº¤¸¯À©Òºc¦¨¡AµM¤Æ¦Xª«ªººØÃþ«D±`Ác¦h¤D¦]¦¹¤§¬G¡C¤G¡B°t¦ì¤Æ¦Xª«ªº²§ºc²{¶H¸û¼ôª¾ªÌ¡A¦³ÄÝ©ó¥ßÅ鲧ºc¡]Stereoisomerism¡A¦ì¸m²§ºc[Position Isomerism]¡^ªº´X¦ó²§ºc¡]Cis-trans ²§ºc¡^»P¥ú¾Ç²§ºc¤Î¥±²§ºc¡]Plane Isomerism ¡ACis-trans²§ºc¡^µ¥¡C¤S°t¦ì¤l¡]Ligand¡^ ¦]°t¦ì§Î¦¡µ¥ªº¬Û²§¡A¦Ó²£¥Íªº¼s¸qªººc³y²§ºc¡A¤wª¾ªÌ¦³Â÷¤l¤Æ²§ºc¡]Ionization Isomerism¡^¡BÆQ²§ºc¡]Salt Isomerism ¡A¯U¸qªººc³y²§ºc¡^¡Bì¤l»ù²§ºc¡]Valence Isomerism¡^¡B»E¦X²§ºc¡]Polymerization Isomerism¡^¡B¤ô¦X²§ºc ¡]Hydration Isomerism¡^¡B°t¦ì²§ºc¡]Coordination Isomerism¡^¡B°t¦ì¦ì¸m²§ºc ¡]Coordination Position Isomerism¡^¡B°t¦ì¤l²§ºc¡]Ligand Isomerism¡^¡B¾ô¦¡²§ºc¡]Bridge Isomerism¡^µ¥²§ºc²{¶H¡C¤T¡Bì¤l®Öªº²§ºc²{¶H¡A§Y¦³®Ö²§ºc¡]Nuclear Isomerism¡^¦s¦b¡C |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/4/26 ¤W¤È 11:51:47²Ä 257 ½g¦^À³
|
Cliff¤j «D±`ÁÂÁ±z¡AÃö©ó¡uGHªº±Æ¦C§Ç¦ì¡v¬O¤p§Ìªº²q´ú Ãþ¦ü¸²µå¿}¡A¦P¤À²§ºc ©Ò¥H¶i¤J¤HÅé«á¥u¦³50%¯à³Q¤HÅé§l¦¬ ¦]¬°¤W¦¸±z´£¨ì¨º½g¬ã¨s³ø§i Åý¤p§Ì¹ï©ó¬°¦ó§â¸£µ¬°Ê¨ìGH¤W°_ºÃÄu ¤~¦³³o¼Ëªº²q´ú¡A¥u¬O¤£ª¾¹D¬O§_»P¸²µå¿}ªº¹D²z¬Û¦P ¦ý¤p§Ì¤~²¨¾Ç²L¡A±`²q¿ù¡A©|½Ð¥]²[ |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/4/26 ¤W¤È 11:18:21²Ä 256 ½g¦^À³
|
4/2¶K¤åªº°¨°ºÂå°|±i¥D¥ô¦bÂå¾Ç·|ªº§Z±_ÀùªvÀøªì³ø¡A¶È²[»\33¦ìªºªì¨B¤ÀªR¡A¦¬®×¤H¼Æ¨ì¤F3/3ªk»¡·|¤W©Ò´£¨ì¤w¦¬63¦ì¡A¹wp¥þ³¡¦¬®×±N¶W¹L¦Ê¦ì¡A©Ò¥Hµ²½×©|¦b¥¼©w¤§¤Ñ¡A¨S¦³§ó¸ÔºÉ§ó¶i¤@¨Bªº¼Æ¾Ú«ÜÃø¤U©w½×¡A¦óªp´N§Z±_Àù¦Ó¨¥¡An¹F¨ì¦h¦n¤~ºâ¦n¡HÃa¨ì¦hÃa¤~ºâ¥¢±Ñ¡H³o«ÜÃø¦ôºâ¡A¤Ï¥¿¬O¶}©ñ©Ê¸ÕÅç¡Aµ¥«Ý´N¬O¤F¡C Faith¤j¡G ¡u·íªì822¬O§_¦³¹ï¤p¹«°µ§Z±_Àùªº¸ÕÅç ©Î822´¿¹ï¤p¹«°µªºÀù¯g¸ÕÅ禳¬ã¨s³ø§iªº¥]¬Aþ¨Ç¡v §Ú¨S¦³§ä¨ìOBI-822¹ï¤p¹«Àù¯g¸ÕÅ窺¸ê®Æ ¥uª¾¹DOBI-822³oÓ°t¤è¡A°µ¹L¤HÃþªºÄáÅ@¸¢Àù»P¨ÅÀùªº¤@´ÁÁ{§É¸ÕÅç¡A Ó¤H²q´ú¤p¹«³¡¤À¡A¥i¯à°µ¹LÄáÅ@¸¢Àù¡B¨ÅÀù¡B¶Â¦â¯À²ÓM½Fµ¥¡A¦ý§Ú¨Ã¨S¦³§ä¨ìª½±µÃÒ¾Ú¡A¯Â²q´ú¦Ó¤w¡C ¥t¥~±z©Ò¿×¡uGHªºµ²ºc±Æ§Ç¬Û·í½ÆÂø,¦]¦¹¤p§Ì²q´ú,§Z±_Àù»P¨ÅÀùªºGH±Æ§Ç¨Ã¤£¬Û¦P,¾ÉP¼vÅT¤F822ªºÃĮġv¡A¡K¡K ¡u¶i¥h¤HÅé·|¶i¦æ²Ä¤@¤ÏÀ³,¦ý¥Ñ©óGH±Æ¦C§Ç¦ì¤£¦P,¾ÉPµLªk¥¿¤¤¹v¤ß¡v¡K¡K ¡u¦b³£¾Ö¦³GHªº16ºØÀù¯g¤¤,þ¨ÇGHªº±Æ§Ç¬O¬Û¦P©Î¬Ûªñªº¡H¡v ©Ò¿×¡uGH±Æ¦C§Ç¦ì¡v©Ò«ü¬°¦ó¡H·Q¤F´X¤ÑÁÙ¬O¨SÀ´¡C Rabbit¤j¡G ¬Ý¨ì¤F±zªº¤¯¡A¤]¬Ý¨ì¤F±zªº§Ô¡F¡]¤£·|¬°¤F·Q¨ú±o¸ê®Æ¦Ó¤£¾Ü¤â¬q¡^ ÂåªÌ¤¯¤§¤ß¡A¤£¹L¦p¦¹¡C ¤ß¤¤Ãh¤¯¡A§Î¦P»PÂå¦P°M¡C »¡¨ìÃh¤¯¡A·Q°_¥Í§Þ¤j©M©|ĬÃh¤¯³Õ¤h¡A¥¨¬Pâf¸¨¡A´Ý©À¡K¡F¤W¶gŪ¨ì¦Ûµo¥\ªL§µ©v±Ð±Â¡u±qÀù¥½¨ì§¹¥þ±d´_¡v¡A¤]¬O60·³¥ª¥k¿©±w¥½´Á²O¤ÚÀù¡A¤£¹L²{¦b¤w¸g²¬Â¡¡FOBI-822¹ïsolid tumor¸û¦³§Æ±æ¡A¹ï²O¤ÚÀù¿W¼¬±|¡C ¤p©_¤j¡G ªY½à/¸r¼}±zªºÅÞ¿è±À²z¯à¤O¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/4/24 ¤W¤È 12:15:47²Ä 255 ½g¦^À³
|
§ó¥¿»P¸É¥R §Z±_ÀùÁ{§É¤G´Á¥i¯à¤À²Õ§ì¾¯¶q»PÃÄ®Ä,³Ì«á·|§ä¥X³Ì¨Î³Ì¦³®Ä¾¯¶q¶i¤J¤T´Á (ªÑªF·|¦A°Ý²M·¡) http://www.cancer.org/treatment/treatmentsandsideeffects/clinicaltrials/whatyouneedtoknowaboutclinicaltrials/clinical-trials-what-you-need-to-know-phase2 in a typical phase II clinical trial, all the volunteers usually get the same dose. But some phase II studies do randomly assign participants to different treatment groups, much like what¡¦s done in phase III trials (see the next section). These groups may get different doses or get the treatment in different ways to see which provides the best balance of safety and effectiveness. (¤G´ÁÁ{§É©Ò¦³¨ü¸Õ¨Ï¥Î¬Û¦P¾¯¶q,¦ý¦³¨Ç¤G´ÁÁ{§É·|ÀH¾÷¤À¬£¨ü¸Õ¨ì¤£¦P²Õ§O,³o¨Ç²Õ§O¥i¯à·|¨Ï¥Î¤£¦P¾¯¶q©Î¤£¦PªvÀø¤èªk¨Óµû¦ô¦w¥þ©Ê»P¦³®Ä©Ê¶¡ªº³Ì¨Î¥¿Å²Õ§O ) |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/4/23 ¤U¤È 11:02:20²Ä 254 ½g¦^À³
|
Faith¤j ¯E¹©2015¦~3¤ë16¤éè¥XÄl¼öÄËÄ˪º¤WÂd»¡©ú®Ñ¦³ÃöOBI822§Z±_Àù¦³«Ü¸Ô²Ó»¡©ú¦p¤U,¦p¦³ºÃ°Ý6¤ë3¤éªÑªF·|¦A°Ý²M·¡¤£¥²¶Ã²q´ú,§xÂZ¦Û¤v,§Úªº¬Ýªk¬O:ÀÀ©óµu´Á¶¡¦V¥_¬ü¡B¼Ú¬w¤ÎªF¨È¦a°Ï¤§·sÃÄ¥DºÞ¾÷Ãö¥Ó½Ð¶i行Á{§É¤T´Á¸ÕÅç,,¤G´Á¬O¤À²Õ§ì¾¯¶q»PÃÄ®Ä,³Ì«á·|§ä¥X³Ì¨Î³Ì¦³®Ä¾¯¶q¶i¤J¤T´ÁÁ{§É,¤G´Á¼Æ¾Ú¨S¦³¬Û·íÀu²§¤Î´x´¤,¯E¹©¤£´±¥Ó½Ð¤T´ÁÁ{§É, ¥Ø«e¶i«×: ¦Û 102 年 10 ¤ë°_»P°¨¶¥Âå°|¦X§@ OBI-822 §Z±_ÀùÁ{§É¤G´Á¡A³z¹L¦¹Á{§É¤G´Á¦¬¶°¤§¨ã°Ñ¦Ò»ùȪº¼Æ¾Ú¡A¥xÆW¯E¹©ÀÀ©óµu´Á¶¡¦V¥_¬ü¡B¼Ú¬w¤ÎªF¨È¦a°Ï¤§·sÃÄ¥DºÞ¾÷Ãö¥Ó½Ð¶i行Á{§É¤T´Á¸ÕÅç¡A¥H¥[³t¤½¥q²£«~©ó§Z±_Àùªº¬ãµo³t«×¡C ¥«³õ©w¦ì: ¥HÀù¯gÁÞ§Üì Globo H ¬°¼Ðªº¤§Àù¯g¬Ì]¡A¨Ì¾Ú¤¤¬ã°|©ó¬ü°ê°ê®a¬ì¾Ç°|°|¥Z PNAS µoªí¸ê®Æ¡AGlobo H ¾A¥Î 50%~90%¤§§Z±_Àù±Ú¸s ÃĪ«¯S©Ê: OBI-822 ÄÝ©óÀù¯g¥D°Ê§K¬ÌÀøªk¡A¦¹Àøªk¥H²ÓMÀùÅÜ®Éªí±¤j¶qªí²{ªº¦hÁÞÅé§Üì Globo H ¬°¼Ðªº¡A¥i¥H¤Þµo§K¬Ì²ÓM²£¥Í¥i¹ï§Ü§Z±_Àù²ÓMªº§ÜÅé¤Î¬¡¤Æ¬r©ÊT²ÓMµ¥§K¬Ì²ÓM¡A¶i¦ÓºR·´§Z±_Àù²ÓM¨Ã¨¾¤îÀù¯g´_µo¡C Ävª§Àu¶Õ: ¥Ø«e¥þ²y©|¥¼®Öã¥ô¦ó¤@Ó§Z±_Àù¥D°Ê©ÊÀù¯g§K¬ÌÀøªk(Àù¯gªvÀø©Ê¬Ì])¡A¦]¦¹ OBI-822 ¦b¥«³õ¤WµL¬ÛÃþ¦ü¤§²£«~¡A¤Z¬O Globo H§Üì§e¶§©Êªº±wªÌ³£¥i±µ¨üOBI-822 ªvÀø¡A¤j¬ù¥e¤F§Z±_Àù±Ú¸sªº 50%~90%¥H¤W |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/4/23 ¤U¤È 10:18:54²Ä 253 ½g¦^À³
|
¤£¦n·N«ä¤W¤@½g³Ì«á¤@¥yªº»¡µüקï¤@¤U ¥H¤W¥ß½×¦b°²³]ªü®¶¤j¹Ú¹Ò¤§¤j³¡¤ÀÁ{§É±wªÌ¬Ò¤£¦p¹w´Á¬°¯u¤§«e´£¤U²q´ú ¦A¦¸ÁÂÁªü®¶¤j ÁÙ¦³ªü¬Â¤j Ps:¤p§Ì¸g±`²q¿ù¡AÁ٬߯E¤Í̤À¨É·Qªk |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/4/23 ¤U¤È 09:12:51²Ä 252 ½g¦^À³
|
ªü®¶¤j,ÁÂÁ±z ¤p§Ì¦³¨Ç·Qªk»P¤j®a¤À¨É,¥ý¬ÝCliff¤j¤§«e´£¨ìªº³o½g ½Ð°Ñ¦Ò¡G 2014/11/9 ¤U¤È 05:57:57 ¡]OBI-822, OBI-833¥H¥~ªº²£«~¡^ ¡uRabbit¤j¤j¦b¤T¤Ñ«e§ä¨ìè¥XÄlªº·sªF¦è¡C¡]http://www.ncbi.nlm.nih.gov/pubmed/25371992 ¡^ ¡uImmunogenicity study of Globo H analogues with modification at the reducing or non-reducing end of the tumor antigen ¡v ¯»¶ê½×¤åùا⤣¦Pªº¦õ¾¯¡BÄâ±a³J¥Õ°µ¤ñ¸û¡A§ä¥X³Ì¨Îªº²Õ¦XGH-DT/C34¡A¤]´N¬OOBI-833¡C ³o¦^§â¸£µ¬°Ê¨ìGH¤W±¡Aª½±µ¦bGH¤W°Ê¤â¸}¡A¥[¤W¤£¦Pªº¦¨¤À°µ×¹¢¡A¥Øªº¬O§Æ±æ²£¥Í§ó±jªºIgG¤ÏÀ³¡A§â¬Ì]ªº¹Ú§ó©¹«e±À¶i¤@¨B¡C¡v 1.¤p§Ì·í®É·Q,¬°¦ó§â¸£µ¬°Ê¨ìGH¤W±,¬O¤£¬Oµo²{¤F¤°»ò¡H 2.§ÚÌ°²³]ªü®¶¤j»¡ªº¬O¯uªº,¨º«Ü¦³¥i¯à¤½¥q¤]¦´Nµo²{¤F,GHªºµ²ºc±Æ§Ç¬Û·í½ÆÂø,¦]¦¹¤p§Ì²q´ú,§Z±_Àù»P¨ÅÀùªºGH±Æ§Ç¨Ã¤£¬Û¦P,¾ÉP¼vÅT¤F822ªºÃÄ®Ä 3.FDA²Ä¤@´Á°µªº¬O¨ÅÀù»PÄáÅ@¸¢Àù,¨âªÌ®ÄªG«Ü¦n,¦]¦¹¥i±À½×,¨âªÌªºGH±Æ¦C«Ü¬Ûªñ©Î¬Û¦P 4.¤W¦¸Cliff¤j´£¨ìªº¨º½g½×¤å¤¤,§Z±_Àù¥´822½T¹ê´£ª@¤FIgM,Yªü®¶¤j¹Ú¬°¯u,¨º¬°¦óµL®Ä¡H¤p§Ì²q´ú,¥´¶i¥h¤HÅé·|¶i¦æ²Ä¤@¤ÏÀ³,¦ý¥Ñ©óGH±Æ¦C§Ç¦ì¤£¦P,¾ÉPµLªk¥¿¤¤¹v¤ß... 5.¨º»ò,¦b³£¾Ö¦³GHªº16ºØÀù¯g¤¤,þ¨ÇGHªº±Æ§Ç¬O¬Û¦P©Î¬Ûªñªº¡H³o´Nȱo¬ã¨s¤F 6.¤p§Ì»{¬°,Àu¯ÊÂI³£¦³,ÀuÂI¬O¤½¥q´£¦µo²{,¥i´£¦¶i¦æ¥t¤@¶¥¬qªº¬ã¨s,¥t¥~,¥¼¨Ó822¦b¨ÅÀùªºÃÄ»ù¤è±¥i¯à·|´£°ª¤F¡]³oÂIn¥J²Ó«ä¦Ò¤~·|À´¡^;¯ÊÂI¬O¥Î¦b¥t¥~14ºØÀù¯gªºn¥i¯àn©Ôªø®É¶¡¨Ó¶i¦æÁ{§É¬ã¨s¤F 7.¤p§ÌÁÙ¬O«Ü¬Ý¦n822¥Î¦b¨ÅÀù¤è±ªº¦¨®Ä,¥ú¨ÅÀù´N°÷ÅåÆv°÷¼µ¤F,¨ä¥L¥²¶·ºCºC¨Ó¤F,¥i±¤¯f¤Hnµ¥¤F ¥H¤W,¤p§ÌJ¶Ã²q´ú,¯E¤Í̤@°_°Q½×,©Î³\´N³Q§Ú̬ã¨s¥X¨Ó¤F(¥H¤W¥ß½×¦b°²³]ªü®¶¤j¹Ú¹Ò¬°¯u¤§«e´£¤U²q´ú) |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/4/22 ¤U¤È 09:15:57²Ä 251 ½g¦^À³
|
¤p©_¤j ±z«È®ð¤F¡A¬O±z»P¥ò´º¤jÁÙ¦³¦h¦ì¦n¯E¤Í¦b¬ã¨spȮɡA¤p§Ì¤~·N·|¨ìªº ©Ò¥H¸ÓnÁÂÁ±zÌ µL®Äªº¤ñ¨Ò¤p§Ì²q´úÀ³¸Ó¤£°ª ¦]¬°°w¼Æ¡B¾¯¶q»P²Ä¤@´Á¬Û¸û³£¼W¥[¤F¡I ¥t¥~¤p§Ì¤§«e´£¨ìªº¦]´_µo¤H¼Æ¤Ö¡A¸Ñª¼®Éµ{¦³±oµ¥¡A ¤p§Ì²q´ú¡A¦pªG´_µo¤H¼Æ£¸ª½«Ü¤Ö¡A³Ì«áªº¸Ñª¼®Éµ{´Nn¬Ý¤½¥q¥H349¤H©Î284¤Hpºâ «ö·Ópµe¡A³Ì«á£¸¦ì¯f¤H¦¬§¹®×Æ[¹î2¦~ªºPFS ¦p¦¹´«ºâ¬ù¸¨¦b2016ªº8¤ë©Î3¤ë¥ª¥k¡A¦pªG¯à¨ì©ú¦~¦A¸Ñª¼ ¨º¯u¬O¤£±o¤Fªº£¸¥ó¨Æ¡A¦]¬°ÁÙ¦³osn¦Ò¶q¶i¨Ó¡IÅåÆv§r¡I ¥H¤W¤p§Ì²L¨£ |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2015/4/22 ¤U¤È 08:53:04²Ä 250 ½g¦^À³
|
Faitf¤j¡A ±zªGµM¬O¥Î¥\ªº¸ê²`¯E¤Í ¨£·Lª¾µÛ ¤p§Ì±ß¤F±z¦n´X¨B ³o¤ñ¨Ò·¥«n ¥B¥u¦³¤j¶qÁ{§É¤~¯à¨ú±o ÁÙ¦n¤£¬O¤Ó°ª ¤Ñ·N§a¡I |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/4/22 ¤U¤È 06:26:24²Ä 249 ½g¦^À³
|
¤p©_¤j ¶W´Îªº¡A¦P¼Ëªº¹D²z¤p§Ì¦b3¤ë29¤é¦bpºâpȨº½g¤]µoªí¹L ¦³±zªº©IÀ³§ó¦³·P¡A¥H¤U¬O¤p§Ì¥ý«eªºµoªí ¡u¤p§Ì³Ìªñ´X¤Ñ¸g¦U¦ìªº«üÂI«á¡A§ËÀ´¤F¤@¥ó«nªº¨Æ ¦b¡u¹êÅç²Õ¡v¤¤ §Ú̬ݨ쪺¡m´_µo¡n¤H¼Æ¬O¥]¬A ´_µo+µL®Ä ©Ò¥H´_µo¤H¼Æ¥²»Ý¤j©óµL®Ä¤H¼Æ¡A¸Ñª¼¥X¨Ó¤~¦w¥þ ©Ò¥H¯uªº«æ¤£±o¡A¦ý±i¸³¬O«D±`¦³¸gÅ窺¥Í§Þ°ª¤â ¥L±a»âªº¹Î¶¤¤@©wȱo§ÚÌ«H¿à¡v |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2015/4/22 ¤U¤È 02:03:27²Ä 248 ½g¦^À³
|
¦U¦ì¤j¡A «e´X¤é¦b°Q½×±¡¹Ò©M½u¯Á®É¡Aµoªí®É¶¡:2015/4/16 ¤U¤È 03:31:44¡A±o¨ì¹êÅç²Õ¤¤¥´¤F822«o¨S²£¥Í§ÜÅ骺±wªÌ¤ñ¨Ò¤£¯à¤Ó°ªªºµ²½×¡A§_«h·|¹H¤Ï¥Ø«e©ÒÆ[¬d¨ìªº²{¶H¡A¨Ò¤l¤¤Y25%ªº±wªÌ¨S¦³²£¥Í§ÜÅé¤ÏÀ³¤w¸g¹H¤Ï½u¯Á¡A¥²¶·±À½¡A¤ñ¨ÒÀ³¸Ó¦A°§C¡A³Ì¦³¥i¯àªº¤ñ¨Ò¬O10%~15%¡C ³Ìªñ©¿µMÁp·Q¨ì¡A±i¸³ªº³Ì¨Î¸Ñª¼®É¾÷¡A°£¤Fµ¥«Ý¦³§¹¾ãªºPFS»PpȪº¦Ò¶q¥~¡AI«á¥i¯à¦³¤@Ó«Ü«nªº¦]¤l¦b«×¶qµÛ¡A³oÓ¦]¤l´N¬O¡A¥´¤F822«o¨S¦³²£¥Í¨¬°÷§ÜÅ骺±wªÌ¦b¹êÅç²Õ¤¤ªº¤ñ¨Ò¬O¦h¤Ö¡H ³oÓ¦]¤l¥u¦³³z¹L¤j¶qªºÁ{§É¹êÅç¤~¯à±oª¾¡A³oÓ¤ñ¨Òªº°ª§C±N¤j¤j¼vÅT²ÎpªºpÈ¡A ¦b822¹ï¹êÅç²Õ¤¤¦³®Ä±Ú¸sªºÃĮĤ£Åܪº±¡ªp¤U¡A¤£¦Pªº¤ñ¨Ò·|§e²{¤£¦Pªº²Îp¼Æ¦r¡A¤ñ¨Ò¶V°ª¡A¹êÅç²Õ§e²{ªºPFS·|¥´¸û¦hªº§é¦©¡ApȤ]·|¸û¤j¡A822¦bMBC¥i¥H¾A¥Îªº±Ú¸s¤]·|¸û¤p¡C Áp·Q¨ì³oÓ¤ñ¨Ò°ª§Cªº¦]¤l¡A¤~Åé·|¨ì±i¸³¦bªk»¡¤¤©Ò»¡¡ApÈ´Nºâ¨S¦³¹F¨ì0.05¡AY¯f¤H¨S¦³¦w¥þÅU¼{¡A¦Ó¥BÀø®Ä¨ãsignificant¡AÁÙ¬O·|㤩conditinal approval ¡A³o´N¬O³ÌÃaªºª¬ªp¡A¤]´N¬O»¡¸Ñª¼®ÉpȹF¤£¨ì0.05¡A³o´N¬O³Æ®×¡C ¥t¥~YK»¡ªº4Ó±¡ªp¡A±¡ªp4¥i¥H±Æ°£¡A±¡ªp3¨ä¹ê´N¬O±i¸³Á¿ªº³ÌÃaªº±¡ªp¡A¦³®Ä¡A¦ý¤£²Å¦X¹w´Á¡A´N¥Î¦³ªºµ²ªG¡A¥h¾Þ§@³]p¤U¤@ÓÁ{§É¹êÅç¡C³oI«áÆ[¹îªº¦]¤l´N¬O¡A¡y¥´¤F822«o¨S¦³²£¥Í¨¬°÷§ÜÅ骺±wªÌ¦b¹êÅç²Õ¤¤ªº¤ñ¨Ò¬O¦h¤Ö¡z¡A¦pªG¦¹¦¸Á{§É¹êÅç±wªÌ¬O¬D¹Lªº¡A¹êÅç²Õ¥u¦¬¯à²£¥ÍGH§ÜÅé¤ÏÀ³ªº±wªÌ¡A¨º»ò¨Ì·ÓpȪººâªk¡A¤£ºÞ¹êÅç²ÕªºPFS¬O¥u¦³9Ó¤ë¡A©Î1XÓ¤ë©Î2XÓ¤ë¡Apȳ£·|©úÅã¤p©ó0.05¡A¤£P©ó²£¥ÍYK©Ò»¡ªº¬J¥i¯à¬O±¡ªp1©Î±¡ªp2©Î±¡ªp3ªº¤TºØ¥i¯à¡C¦pªGpȦ³¾÷·|¬D¾Ô¤p©ó0.001¡A´N¤£¥i¯à·|¤j©ó0.05¡F¦pªGpÈ¥i¯à¤j©ó0.05¡A´N¨S¦³¾÷·|¬D¾Ô¤p©ó0.001¡C¤@¼ËªºÃĮġAnÅý¹êÅ窺²Îpµ²ªG¦³³o»ò¤jªº¥i¯à®t²§¡AI«á¼vÅTªº¦]¤l´N¬O¡y¥´¤F822«o¨S¦³²£¥Í¨¬°÷§ÜÅ骺±wªÌ¦b¹êÅç²Õ¤¤ªº¤ñ¨Ò¬O¦h¤Ö¡z¡A¦]¬°822ªº¹êÅç²Õ¨Ã¨S¦³¬D¹L¥Ø¼Ð±Ú¸s¡A¦ý¤]¬O¦]¬°Ãø¬D¥Ø¼Ð±Ú¸s¡A¦]¬°GH¨t²ÎÁÞ§Üì¦bMBC¤H¤f¤ñ¨Ò¹F98%¡A¤£¥Î¿z¿ïBiomarker¡A¦ý¹ê»Ú¯à²£¥Í¨¬°÷§ÜÅ骺¤H¤f¤ñ¨Ò¨S¦³¸g¹L¹êÅç«h¤£ª¾¡C ±i¸³¦b¤W¬P´Áªº´CÅé±M³X¤¤´£¨ì¡A¥´ºâ»PFDA°Ó¶q¡A´£¦±Ò°Ê¥þ²y¤T´Á¡C¥¼¸Ñª¼¡A¨S¼Æ¾Ú¡A«o·Ç³Æ±Ò°Ê¥þ²y¤T´Á¡A¦ü¥G¸ò¤§«eªº»¡ªk¥Ù¬Þ¡A¨ä¹êY¤w¸gª¾¹DÃĤ@©w¦³®Ä¡Aµ¥¼Æ¾Ú¬O¬°¤Fµ¥¬Ý¬Ý¬O§_»Ýn«·s³]p¥þ²y¤T´Á(±¡ªp3)¡A¦pªG¬O±¡ªp1©Î±¡ªp2ªº¸Ü¡A¤Ï¥¿³£¬On°µ¥þ²y¤T´Á¡A¥ý°Ó¶q¥i¥H¬Ù¤U¤£¤Ö®É¶¡¡CY¡y¥´¤F822«o¨S¦³²£¥Í¨¬°÷§ÜÅ骺±wªÌ¦b¹êÅç²Õ¤¤ªº¤ñ¨Ò¬O¦h¤Ö¡z³o¤ñ¨Ò¤£°ªªº¸Ü¡A´N¤£¶·«·s³]p¡A¥i¥H¸ò¥xÆW¤T´Á¤@¼Ë¡A¥þ¦¬¡C °²³]¤½¥q¦bÆ[¹î´_µo¤H¼ÆªºÅܤƤ¤¡A¤w¸g¤jP¥i¥H²q¨ì³oÓ¤ñ¨Ò¦b¹w´Á¤§¤ºªº§C¡A¨º»ò´£¦±Ò°Ê¥þ²yÁ{§É¤T´Á¬O¥i²z¸ÑªºÁ|°Ê¡A¦]¬°¸Ñª¼«áªº¼Æ¾Ú©Ò«ü¥ÜªºÁ{§É³]p¤è¦V¬O¤@¼Ëªº¡C ¹êÅç²Õ¤¤¨S¦³¨¬°÷°ª¤ñ¨Òªº±wªÌ¦³¨¬°÷°ªªºPFS¡A´_µo¤H¼Æ©M¸Ñª¼®É¶¡´N¤£·|¬O¥Ø«e©ÒÆ[¹î¨ìªº²{¶H¡C ¥H¤W¬O¤p§Ìªº±À·Q¡A¨Ñ¦U¦ì¤j°Ñ¦Ò¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/4/22 ¤U¤È 12:31:38²Ä 247 ½g¦^À³
|
ÁÂÁÂCliff¤jÄÀºÃ ·j´M: ¯E¹©¦XÁa³s¾î ÃÄ¥´¥@¬É¤j¾Ô (¬Ý¨Ó¯E¹©¤@¤G¤T¥NÃÄ,¦hÄ¥»ôµo,ÃÄ¥´¥@¬É) °£¤F822¡B833ªº¤@¡B¤G¥N¥D°Ê§K¬Ì§ÜÀùªvÀø¬Ì]¥~¡A¯E¹©¥¿¦bµû¦ô»P¤¤¬ã°|Ä~Äò¦X§@²Ä¤T¥N²£«~¡A¤w¸g¦³¦¨ªG¡C ²Ä¤T¥N¬Ì]¥¿¥Ñ¤¤¬ã°|¶}µo¤¤¡A³Ìªñ´Nnµoªí¡A³oÓ²£«~¦b»s³y§ÜÅé¤Wªº¯à¤O§ó±j¡C¤¤¬ã°|¹Î¶¤§â³Ì·s¤@¥N²£«~ªº§Üì§ó´«¡A·s¤@¥Nªº§ÜìÀÀ¦üÁÞ§Üì¦ý¤ñÁÞ§ÜìÁÙ±j¡A¥iÅý§ÜÅé¹ïÀù²ÓMªº§ðÀ»§ó±Ó·P¡C |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/4/22 ¤U¤È 12:08:33²Ä 246 ½g¦^À³
|
½Ð°Ñ¦Ò¡G 2014/11/9 ¤U¤È 05:57:57 ¡]OBI-822, OBI-833¥H¥~ªº²£«~¡^ ¡uRabbit¤j¤j¦b¤T¤Ñ«e§ä¨ìè¥XÄlªº·sªF¦è¡C¡]http://www.ncbi.nlm.nih.gov/pubmed/25371992 ¡^ ¡uImmunogenicity study of Globo H analogues with modification at the reducing or non-reducing end of the tumor antigen ¡v ¯»¶ê½×¤åùا⤣¦Pªº¦õ¾¯¡BÄâ±a³J¥Õ°µ¤ñ¸û¡A§ä¥X³Ì¨Îªº²Õ¦XGH-DT/C34¡A¤]´N¬OOBI-833¡C ³o¦^§â¸£µ¬°Ê¨ìGH¤W±¡Aª½±µ¦bGH¤W°Ê¤â¸}¡A¥[¤W¤£¦Pªº¦¨¤À°µ×¹¢¡A¥Øªº¬O§Æ±æ²£¥Í§ó±jªºIgG¤ÏÀ³¡A§â¬Ì]ªº¹Ú§ó©¹«e±À¶i¤@¨B¡C¡v ¡]¸É¥R»¡©ú¡G·í¦~¤p§Ì¥H¬°OBI-833¬OGH-DT/C34¡A·íµM«á¨Óª¾¹D¬O¿ùªº¡^ ÁÙ¦³¡G 2014/12/16¤U¤È04:31:20 ¡]¤é²±µû¦ô³ø§ipart.2¡^ ¡u¡K¡K§Ú¤]¨Ó¡u²q·Q¡v¤@¤U¡G¡K¡K 3. ¥t¥~¨º½g×¹¢GHªº¬ã¨s¤¤¡A¤]§âf°ò¥[¤JGH°µ×¹¢¡A¤£¹L®ÄªG«Ü®t¡A©Ò²£¥Í¸û¦hªºIgG§ÜÅ鳺µM¬O°w¹ïf°ò¦Ó«D°w¹ïGH¡C³Ì«á¥Ñ¦bGHªº¸²µå¿}ºÝ6¸¹ºÒ¥[¤JÅ|´á¡]N3¡^×¹¢¡A©ÎªÌ¦bGHªº¸²µå¿}ºÝ¥[¤J¬t¡]F¡^×¹¢¡A³o¨â«¬¥i¥H»¤µo¸û쫬¦h5%ªº¸ÉÅé¨Ì¿à«¬¬r±þ§@¥Î¡CY§ï¦bGHªº¥t¤@ºÝ¡A©¥Ä¦ÁÞºÝ6¸¹ºÒ¡A¥[¤JÅ|´á©Î¬t×¹¢¡A´N¸òGH쫬µL¬Æ®t²§¡C¡]5%ªº®t§O¶q¹ê¦b¤£¤j¡^¡v |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/4/22 ¤W¤È 11:23:21²Ä 245 ½g¦^À³
|
ºÃ¦ü§ä¨ì GH-DT/C34 ¬ÛÃö¬ã¨s½×¤å Publication Date (Web): November 5, 2014 Immunogenicity Study of Globo H Analogues with Modification at the Reducing or Nonreducing End of the Tumor Antigen §Æ±æ¦³°ª¤â¸ÑŪ¤@¤U Our data suggest a new potential approach to cancer vaccine development. ¦bÀù¯g¬Ì]µo®i¤W§Ú̪º¸ê®ÆÅã¥Ü¥X¤@Ó¦³¼ç¤Oªº¤èªk http://pubs.acs.org/doi/abs/10.1021/ja508040d |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2015/4/20 ¤U¤È 05:37:16²Ä 244 ½g¦^À³
|
·PÁÂCliff¤jÄÀºÃ¡I |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/4/20 ¤U¤È 04:49:57²Ä 243 ½g¦^À³
|
ADI-PEG-20¤w¦³¦h¶µÀù¯g¾AÀ³¯g¦b¶i¦æÁ{§É¸ÕÅç¡C¬d¨ì¥Î©ómelanomaªvÀøªº¤@´Á³ø§i¡]Arginine-depleting therapy with pegylated arginine ¡^¡A38¦ì¨ü¸ÕªÌ¤¤¡A¦³11¦ì°û©Ú¥ÎÃÄ«eªº¤Á¤ù¡A¾ÉPµLªk±oª¾Àù²ÓMªººëÓi¤B¤G»Ä¦X¦¨–¡(argininosuccinate synthetase,¡FASS)ªº¦³µL¡A¤£ª¾¹D¸Ó½s¤J¹êÅç²ÕÁÙ¬O¹ï·Ó²Õ¡A¥u¦n¥H³Ñ¾lªº27¦ì¯Ç¤J¤ÀªR¡C¡]11/38³o¤ñ¨Ò¤£§C¡^¡CÓ¤Hı±oµ²ªG´¶´¶¡A¦³¿³½ìªº¤H½Ð¦Û¦æ°Ñ¬Ýì¤å¡C ì¤å¡uhttp://www.nature.com/bjc/journal/v106/n9/full/bjc2012106a.html ¡v¡C ¡]¥Îgoogle½Ķ¬ì¾Ç¤å³¹«~½è¤£¨Î¡A¦r¦r¤¤¤å«o±`¥y¥y¤£³q¡A«Øij¬Ý¬Ý´N¦n¤£¾A¶K¤å¡^ |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2015/4/20 ¤U¤È 01:50:19²Ä 242 ½g¦^À³
|
About ADI-PEG 20 ADI-PEG 20 is a biologic being developed by Polaris Group to treat cancers, especially those carrying a major metabolic defect that renders such cancer cells, unlike normal cells, unable to internally synthesize arginine. Because arginine is one of the 20 amino acids that are essential for protein synthesis and survival of cells, it is believed these cancer cells become dependent upon the external supply of arginine to survive and grow. ADI-PEG 20 is designed to deplete the external supply of arginine, which causes arginine-dependent cancer cells to die while leaving the patient¡¦s normal cells unharmed. Multiple cancers have been reported to have a high degree of arginine-dependency. |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/4/20 ¤W¤È 07:44:21²Ä 241 ½g¦^À³
|
¯E¹©ªºÃĬO·s¤@¥NªºÁÞ¤À¤l·sÃÄ¡A«Ü¦h¤j¤j¬Ý¹L¯Î±Ò´fªºÁÞ¤À¤l¥@¬Éª¾¹D¡A ¬ü°êµo®i³J¥Õ½èÃĨӧÜÀù¤w¸gÃÒ©ú¬O¥¢±Ñ,¦ÑÁÚªº³J¥Õ½èÃĦp¦ó»P¦~»´»ª¬ü ¬¡¤O«C¬KªºÁÞ¤À¤l·sÃĪ§ÆA |
|
|
·|û¡G«Øcc10140016 µoªí®É¶¡:2015/4/20 ¤W¤È 06:35:50²Ä 240 ½g¦^À³
|
¤µ¤Ñ°_¤FÓ¤j¦ ¬Ý¨ì¤F³o.... ¥_·¥¬Pªð¶m §ÜÀùÃıN°Ý¥@ 2015-04-20 04:01:45 ¸gÀÙ¤é³ø °OªÌ¶À¤å©_¡þ¥x¥_³ø¾É ¥_·¥¬PÃÄ·~¦^¨Ó¤F¡A¸³¨Æªø§d§B¤å±N«Å¥¬¡A¤½¥q¹w³Æ³W¹º¦^¥x¤WÂd¡A®µ§ÜÀù·sÃħ޳N¥¥x¡uADI-PEG 20¡v¡]¥H¤U²ºÙADI¡^¤w¦b¥þ²y§¹¦¨11ÓÁ{§É¸ÕÅç¡AÁÙ¦³11Ó¥¿¦b¶i¦æ¤¤ªºÁ{§É¸ÕÅç¡A°w¹ï¤Q¦h¶µÀù¯g¾AÀ³¯g¦P®É¶i¦æ´ú¸ÕªºÀu¶Õ¡A·~¬É»{¬°¡A¸Ó²£«~¦³¾÷·|·m¦b¯E¹©¤§«e¡A¦¨¬°µØ¤H²Ä¤@Ó°ê»Ú©Êªº³J¥Õ½è·sÃÄ¡C ADI±N§¹¦¨¥þ²y¦h°ê¦h¤¤¤ßÁ{§É¤T´Á¨xÀù¸ÕÅç¡A¦b¬ü°êª¾¦WÀù¯g¤¤¤ßMSKCC»â¾É¤U¡A¦b¬ü¡B¥x¡B^¡B¸q¡B¤¤¡B Áú¦U°ê¾ú®É¤T¦~¥b¦@¦¬¿ý636¦W¥½´Á¨xÀù¯f¤H¡A¨ä¤¤¥xÆW´N¦³194¤H¡A¤½¥q¹w´Á¦b¤µ¦~©³§¹¦¨¼Æ¾Ú¤ÀªR¡A¦pªG¤@¤Á¶¶§Q¡A¥i±æ©ú¦~¤U¥b¦~¦b¬ü¡B¼Ú¡B¥x¨ú±oÃÄÃÒ¡C ¦Û2005¦~¥H¨Ó¡A©Ò¦³ADI°w¾¯³£¬O¥Ñ¥_·¥¬PÃÄ·~¦b¬ü°êªº¥_¥[¦{¤l¤½¥qDesigneRx Pharmaceuticals¥Í²£¡C¦´ÁªºÁ{§É¬ã¨sµÛ«©ó³æ¤@ªvÀø¡A¥]¬A¨xÀù¡B¶Â¦â¯À¥Ö½§Àù¥H¤ÎªÍ¶¡¥ÖÀùªºÁ{§É¤G´Á³£¦³¨}¦nÀø®Ä¡C¦b¥xÆW§ó¦³¥H®¦·OÀøªk¤è¦¡¡]compassionate use¡^¥Ó½Ð¯S³\¶i¤f¦Ó¦h¦¸¦¨¥\ªv¡¨xÀù¥½´Á±wªÌªº¬ö¿ý¡C¥Ø«e±N§¹¦¨ªº¥þ²y¨xÀù²Ä¤T´ÁÁ{§É¸ÕÅç¡A¤]¬O¥H³æ¤@¥ÎÃÄ¡B²Ä¤G½uªvÀø¼Ò¦¡¡C ³Ìªñ´X¦~¥_·¥¬PÃÄ·~»P¬ü¡B^¡B¥x¦U¦a20¦hÓÀù¯g¤¤¤ß¤Î¤j¾Ç¦X§@¡A±´°Q¥HÁp¦X¥ÎÃĤ覡±NADI»P¤@ºØ©Î¦hºØ¤ÆÀøÃĪ«²Õ¦X°w¹ï¦UºØÀù¯g¶i¦æªvÀø¡Aµo²{Áp¦X¥ÎÃĹï¦hºØÀù¯g¥i¹F¨ì§ó¥[ÅãµÛªºÀø®Ä¡C ¥Ø«e¥¿¶i¦æ¤¤ªºÁp¦X¥ÎÃÄÁ{§É¸ÕÅç¡A¥]¬A¦b¬ü°ê§ÜÀù¤¤¤ßMD Andersonªº¶Â¦â¯ÀÀù¡B¤l®cÀVÀù¡B¨xÀù¡BÁxºÞÀù¡B¨ÅÀù¡A¦bMSKCCªº¯ØŦÀù¡B¨xÀù¡A¦b¥[¦{¤j¾ÇªºÄáÅ@¸¢Àù¤Î«D¤p²ÓMªÍÀù¡A¥H¤Î¦b^°êÛ´°BartsÂå°|»P¼C¾ôªºªÍ¶¡¥ÖÀù¡B«D¤p²ÓMªÍÀù¡B¤Î¸£Àù¡C¤½¥q§ó³W¹º¦b¤µ¦~²Ä3©u®i¶}²Ä¤GÓ¥þ²y¦h°ê¦h¤¤¤ßªº²Ä¤T´Á¨xÀùÁ{§É¸ÕÅç¡A¸Ó¸ÕÅç±N¥HADI·f°t¶¶¹`¡]cisplatin¡^°µ¤@½uªvÀø¡Aª½±µ©M¥Ø«e°ß¤@¤W¥«ªº¨xÀùÃĹp¨F¥Ë¡]Nexavar¡^°µ¹ï¤ñ¡C ¥_·¥¬P¶°¹ÎºX¤U¾Ö¦³¥_·¥¬PÃÄ·~¥H¤ÎÃö«Y¥ø·~·çµØÃÄ·~¡A¨âªÌ³£¬O·sÃĶ}µo¤½¥q¡A¦ý«eªÌ»EµJ§ÜÀù¥ÎÃĶ}µo¡A«áªÌ«h¦P®É¨ã³Æ³J¥Õ½èÃĶq²£¯à¤O¡C·çµØ°£«ù¦³¥_¥[DesigneRx¼t¥~¡A¤]¦b¤j³°¦¨³£°ª·s¦è°Ï«Ø³]¥¼¨Ó¥i¥H¨ÑÀ³¥þ²y¥«³õ»Ý¨Dªº·s¼t¡C·íªì§d§B¤å¦]¦U¶µ¦]¯ÀÅfµM±Ë¥x´N³°³]¼t¨¯W³Æ¹Á¡A¥L³zÅS¡A¥¼¨Ó¤´§Æ±æ§â¨ä¥L¾÷·|¯dµ¹¥xÆW¡A´«¨¥¤§¡A¦^¥x¤W¥«Âd¶È¬O§Ç¦±¡C ¤£ª¾¦U¦ì¤j¤j¦³¦ó¬Ýªk~¦n¹³¨S§ä¨ì¤w¤½¥¬½T©wªº¼Æ¾Ú~ ¥t¤@½gµ²§À®É©~µM¥X²{³o¬q¸Ü.. µØ¤HÁÙ¨S¦³¤@®a·sÃĤ½¥q¦³¸ê®æ¡u¿W¥e¡v ¥Ø«e¥«±¤WÁÙ¦³§ó±jªºÀøªk¶Ü?¦³§ó±jªº¤w¶i¤J¤@´Á¤F¶Ü? ÃÄ«~¤£¥i¯à¿W¦û§a!²¦³º¤HÅé°ò¦]²ÓM³£¤£¦P,¬Û¦PªºÃĦ³¤H¦³Àø®Ä,¦³¤H´N¨SÀø»Ã~©Ò¥H¤~·|°µ¼Æ¾Ú¤ÀªR,¨Ó»{©wÃĪºÀø®Ä¬°¦ó~ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/4/19 ¤U¤È 11:05:18²Ä 239 ½g¦^À³
|
Faith¤j ®Ñ¤¤´£¨ì¦s¬¡²vÀ³pºâ¨ì¥h¦~¤C¤ë¥xÆW¤j¾ÇºtÁ¿¬°¤î¡A¦pªG¦p®Ñ¤¤©Ò¨¥¤j®a§óÀ³°í«H¦Û¤v¥ý«e§PÂ_¡A ¬ü°ê¤G´Á®ÄªG¦³¬Û·í¤ô·Ç¤~´±¦V¬ü°êFDA¥Ó½Ð¤T´Á ¤£½×YK©Ò´£¬O²Ä¤@ºØ©Î²Ä¤GºØ±¡ªp«á±³£»Ý¸É¥æ¤T´ÁÁ{§É¸ê®Æ ´£«e±Ò°Ê¡AÀ³ÄݧQ¦h¡AÓ¤H¬ã§P²Ä¤TºØ±¡ªp¾÷²v¤p©ó5% ²Ä¥|ºØ±¡ªp¾÷²v¬O0 |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/4/19 ¤U¤È 08:52:13²Ä 238 ½g¦^À³
|
ªü®¶¤j ±zªº¹Ú¤p§Ì²Ê²Lªº¸ÑŪ¬OÓ¦n¹Ú¡AÁÂÁ±z ¯E¤ÍÌ ¤§«e´CÅé³X°Ý±i¸³®É´£¨ì OBI-822¥´ºâ¡uªñ´Á·|§ä¬ü°ê¹«~ÃĪ«ºÞ²z§½¡]FDA¡^°Ó¶q¡A¦³¾÷·|´£«e±Ò°Ê¡C¡v´£«e»PFDA°Q½×²Ä¤T´ÁÁ{§Éªº¨Æ©y ¤p§Ì¥ý«e¤]»P¤j®a¤@¼Ëªº·Qªk¡A¤G´ÁÁÙ¥¼¸Ñª¼¡A«ç´N¥Ó½Ð¤T´Á¤F©O ³Ìªñ¤ÏÂЫä¦Ò«á¡A¤p§Ì²q´ú¦p¤U ¤§«e¤p§Ì¦b§ì´_µo¤H¼ÆÁ`§ì2¦¨¡A¦ý¤½¥q©Î´CÅ餽§iªº¼Æ¾ÚÁ`¤ñ¤p§Ì§ì±o¤Ö ©ó¬O¥Î1¦¨¨Ó§ì¡A³ºµo²{®t¤£¦h¡I¦pªG¯u¦p¦¹ ¤p§Ì»{¬°¤½¥q¥i¯à¤]µo²{n¹F¦w¥þ¸Ñª¼¼Æ¾Ú¥i¯à¦³±oµ¥¤F ¬°¤F¤£¾á»~±µ¤U¨Óªº¶i«×¡A¤@Ãäµ¥«Ýªº¦P®É¡A¤]¤@Ãä°µ²Ä¤T´Á µ¥²Ä¤G´Á¸Ñª¼µ²ªG¤@¥X¨Ó¡A¥i°¨¤W°µ±µ¤U¨Óªº¤u§@¡A¤§«eFDA¤]¦³Ãþ¦üªº¨Ò¤l¡A¤p§Ì¤£¦AÂØz ¥H¤W¬°¤p§Ìªº²q´ú»P¤j®a¤À¨É |
|
|
·|û¡G¤ý£«¬Â10136621 µoªí®É¶¡:2015/4/19 ¤U¤È 04:55:35²Ä 237 ½g¦^À³
|
·í±Ï´©ª÷¥D¡K¤¨l¼Ù¾ß¨ì¯E¹©ª÷Âû¥À 2015-03-23 03:29:17 ¸gÀÙ¤é³ø °OªÌ¶À¤å©_¡þ¥x¥_³ø¾É ¦b¥Í§Þ»â°ì¡A¼í®õ¶°¹ÎÁ`µô¤¨l¼Ù§ë¸ê§Ü·R´þ¯f·sÃĤ½¥q¤¤¸Î¡BÁÞÃþ·sÃĤ½¥q¯E¹©¡A³£¤Þ°_¸ÜÃD¡A¦]¬°³o¨Ç¤½¥q³£¬O·í«eªº«ü¼Ð¡C¤¨l¼Ù»¡¡A¯E¹©ªº§Ü¨ÅÀù¬Ì]¦pªG¦¨¥\¡AÁÞÃþ·sÃıN³Ð³y·sªº¦a¥½u¡B¶}±Ò¤@Ó·s®É¥N¡C ¤¨l¼Ù»¡¡A§ë¸ê¯E¹©¬O¦]¬°2003¦~»{ÃѤ¤¬ã°|°|ªø¯Î±Ò´f¡A¯Î¤¶²Ð¯E¹©¸³¨Æªø±i©À·Oµ¹¥L»{ÃÑ¡AÂù¤èµ²¤U¤£¸Ñ¤§½t¡C«á¨Ó¡A¯E¹©¥xÆW¤l¤½¥qªº±M§Q§Þ³N³Q¬ü°ê¥À¤½¥qOptimerÁ»¿Ì¡A¥H²ö¶·¦³ªº¸o¦W±N±i»°¥X¸³¨Æ·|¡A¤~¦³¤¨§ë¤J±Ï´©ªº§Ç¦±¡C OPtimer·í®É«ù¦³¯E¹©43%¡A·í®Éªº¥D¨ÆªÌ¸gÀ礣µ½¡A¿³°_½æªÑªº©ÀÀY¡A±i©À·O§ä¨Ó¤¨l¼Ù¬Û§U¡A¥H¨CªÑ1¬ü¤¸»ù®æ¦Y¤U43%ªÑÅv¡C «·s¦^Áç«á±i©À·O¡u¥f°_¨Ó°µ¡v¡A§Ü¨ÅÀù·sÃÄOBI-822ªºÁ{§É¸ÕÅçµ²ªG«Ü¦n¡A«á¨Ó§óµo²{³oÓ§Þ³N¥¥x¦³16ºØÀù¯g¨ã³Æ¥i¿ë»{ªºÁÞ¤À¤l¡A§Y¬°biomaker¡C¨ä¤¤¡A±µ¨üÁ{§É¸ÕÅ窺27¤H¤¤¡A¬Æ¦Ü¦³¦ì¨ÅÀù¥|´Áªº¯f¤H¡A³o¨Ç¤H°£¤F¤@¦ì¨®º×¡B¤@¦ì¤£¨£Àø®Ä¦º¤`¥~¡A¨ä¥L¤H¥Ø«e¬¡±o¦n¦nªº¡C ¯E¹©¥Ø«e¦]¬°¸g¶O¦³¡A¥u°µ¨ÅÀù¡A¦]¬°¤@ÓÁ{§ÉÃĸÕÅç±qÀY¨ì§À¥i¯àn¤Q¦~®É¶¡¡Anªá¶O3»õ¨ì5»õ¬ü¤¸¡A³Ìªñ«o¥t¥~µo²{³oÓ²£«~¦b¯ØŦÀù¡BÄáÅ@¸¢Àùªºªí²{¤]¦³95%¥H¤Wªv¡²v¡C¥t¥~¡A³oÓ²£«~¤£¶È¥i¥HªvÀøÁÙ¯à°÷¹w¨¾¡A©ú¦~ÁÞÃþ·sÃÄ |
|
|
·|û¡G¤ý£«¬Â10136621 µoªí®É¶¡:2015/4/19 ¤U¤È 04:47:31²Ä 236 ½g¦^À³
|
Fith¤j ÁÂÁ§Aªº¸Ñ»¡.¤W¦¸¬Ý¨ì¤@½g³X°Ý¼í®õ¸³¨Æªøªº·s»D(»¡©ú·íªì¤@´ÁÁ{§É¸ÕÅç,¶È¤@¤H¨S¤ÏÀ³.¤@¤H¨®º×¦º¤`,¨ä¾l¨ì¥Ø«eÁÙ¬¡±o¦n¦n¬Ý)³o·s»D«Ü©Ç,n¦Û§Ú§PÂ_. |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/4/19 ¤U¤È 03:22:33²Ä 235 ½g¦^À³
|
¸É¥R ³o¤@¬q¦b³o¥»®Ñªº²Ä9¶ ¤p§Ì¤ÏÂЬݤF3¦¸ ¥L¯uªº¼g¤K¦¨ ¤p§Ì·QÀ³¸Ó¬Oµ§»~¡A¥|¦¨¤K¡A¼g¦¨¤K¦¨ |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/4/19 ¤U¤È 02:56:01²Ä 234 ½g¦^À³
|
ªü¬Â¤j ¤p§ÌºI¨ú¤@¬q¡A©Ò¥H¥i¯à¤£°÷²M·¡¡A¯Î°|ªøªº§¹¾ã¥y¤l¦p¤U¡]¨ú¦Û¯Î±Ò´f¡B³¯«Ø¤¯µ¥µÛ¡AÁp¦X³ø¥Xª©¡A2015¡AÀù¯g¯uªº¯à¹w¨¾¡^ ³oºØ¨ÅÀù¬Ì]ªºÁ{§É¸ÕÅç¹ï¶H¬O¥½´Á¯f¤H¡A²Ä¤@´Á¨ü¸Õªº27¦W±wªÌ¤¤¡A쥻¹Ø©R¶È³Ñ¤T¨ì¤»Ó¤ë¡A¦p¤µ¦³¤K¦¨¦Ü¤µÁÙ¦s¬¡¡A¨ä¤¤ÁÙ¦³¤HÀò±o®Úªv¡C¥Ø«e¦¹¬Ì]¤w¦b»OÆW§¹¦¨²Ä¤T´Á¤HÅé¸ÕÅ窺¤u§@¡A¦b¬ü°ê¤Î¨ä¥L¦a¤è¤]§¹¦¨¤G´Áªº¦¬®×¡A«Ü§Ö´Nª¾¹DÁ{§É¸ÕÅ礧µ²ªG¡C¾Ú§Ú©Òª¾¡A¦¹¬Ì]¤]±N´£¨Ñµ¹³¡¤ÀÀù¥½¯f¤H§@¬°¡u®¦·OÀøªk¡v¡]compassionate use)ÃÄ«~¡C§ó¦³®Äªº·s¤@¥NÀù¯g¬Ì]¤]±N¶i¦æ¤HÅé¸ÕÅç¡C ¤p§Ì¤]·Q¤F¸Ñ 1.²Ä¤@´Á¥u°lÂÜ10¦~¡A¯Î°|ªø»¡¦p¤µÁÙ¦³¤K¦¨¦Ü¤µÁÙ¦s¬¡¡A«üªº¬O2014¡H2015¡HÁÙ¬O...¡H 2.¦¹¬Ì]±N´£¨Ñµ¹¡u³¡¤À¡vÀù¥½¯f¤H§@¬°¡u®¦·OÀøªk¡v¡A«üªº¤S¬O¤°»ò¡H¤w¸g¶}©l½Í¤F¶Ü¡H §Æ±æ¦³¬ã¨sªº¯E¤Í¨ó§U´£¨Ñµª®×©Î²q´ú¬Ý¬Ý |
|
|
·|û¡G¤ý£«¬Â10136621 µoªí®É¶¡:2015/4/19 ¤W¤È 11:05:46²Ä 233 ½g¦^À³
|
Faith¤j (³oºØ¨ÅÀù¬Ì]ªºÁ{§É¸ÕÅç¹ï¶H¬O¥½´Á¯f¤H¡A²Ä¤@´Á27¦W±wªÌ....¡A¦p¤µ¦³¤K¦¨¦Ü¤µÁÙ¦s¬¡¡A¨ä¤¤ÁÙ¦³¤HÀò±o®Úªv),³o¥y¸ò¥H«eªº¤F¸Ñ¤£¦P,¥i§_¸Ñ´b? |
|
|
·|û¡Gªü®¶10139782 µoªí®É¶¡:2015/4/19 ¤W¤È 08:48:47²Ä 232 ½g¦^À³
|
¹Ú¨ì¼Ú¬w³¡¤À,¤]¥i¯à·|±Ä¨ÖÁʳq¸ô°Ó¦Û¤v¦æ¾P |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/4/19 ¤W¤È 07:50:51²Ä 231 ½g¦^À³
|
¯E¹©20¢°3¦~ªÑªF·|¤w«Å¥Ü¥H¥xÆW¬°¦W¥Ó½ÐÃÄÃÒ¡A¦b¦æ¾P³¡¥÷¬ü°ê ¥xÆW »´ä ¤¤°ê ³W¹º¦Û¤w¦æ¾P¡A ¤è¦¡¥i¦Û¤v¦¨¥ß¦æ¾P¹Î¶¤©Î¶R¤U¦³«~µPªºÃļt¨Ó¦æ¾P¡A¼Ú¤éÁú°ê¤¤«n¬ü¬wµ¥¦Û¤v¦æ¾P¥H¥~¦a°Ï³W¹º ±Ä¦æ¾P¦X§@ªº±ÂÅv¡A§Ú»¡ªº±ÂÅv¬O«ü¦U¦ì¤j¤j¦¤wª¾¹Dªº¦æ¾P¦X§@±ÂÅv ¦æ¾P¦X§@¼Ò¦¡¥i¥H«Ü¦h¤¸ |
|
|
·|û¡G«Øcc10140016 µoªí®É¶¡:2015/4/19 ¤W¤È 02:33:05²Ä 230 ½g¦^À³
|
¥xÆW¬F©²À³¶°¦X¥xÆW¥Í§Þ·sÃĬãµo¤½¥q ¦@°Ó¹ïµ¦ ¤£§é¤â¬q ¥´³q¼Ú¬w¤é¥»ªº¾P°â´ë¹D ¯E¹©¥i¶°¦X¥xÆW¥Í§Þ¤½¥q ¦@¦P¥X¸ê¶R¤U¬ü°ê¾P°â³q¸ô~ ´N¦n¤ñÄéµ@¤ô¹D¤@¼Ë ¥xÆW¥un¦³·sÃĤW¥« ´N§Q¥Î³o¦@¦P´ë¹D¿é°e¨ì»Ýn¾i¤Àªº¦a¤è ¥xÆWÃø±o¾÷·| ¦³¦nªº¬ãµo¦ì¶¥¦b°ê»Ú¤W À³¸Ó®i²{¯T©Ê~(±q¶¶©ÊÂàÅܦ¨¯T©Ê,§Ú¬O¥H¥xÆW¾ú¥vªº¨¤«×¨Ó¬Ý¥xÆW¦Ê©m) ¥xÆW¯à§_Âà¤j¤H À³¸Ó½ä¤@§â §O¦A·d±ÂÅv¤F! |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/4/18 ¤U¤È 11:49:02²Ä 229 ½g¦^À³
|
ªk»¡·|¤¤¤¸´I§ëÅU¦³¤@¥»³X½Í³ø§i·í¤¤pfizer &cellectisñq¦@¦P¶}µoCAR-TÃĪ«Pfizer¥H¤G¤Q¤K»õ¬ü¤¸¨ú±o¤Q¤ÓÃĪ«¶}µo ¥t¥~Pfizer¤]¥H¤G¤Q¤KÂI¤»õ¬ü¤¸»PMerckñqÀù¯g§K¬ÌÀøªk¨ú±oPD1¬ÛÃö¶}µo¥¥x ¦pªG¬O°ê»Ú¤jÃļtÀ³¤£§Æ±æ¥u±ÂÅv¨ÅÀù¤@¶µ¦p¬O¾ãÓ822¨t¦C±ÂÅv,¥H¯E¹©±i¸³®v¤jªþ¤¤¼Æ¾Ç°ª¤âÅÞ¿è²M´·¡A¦bÆF¬¡µ¦²¤¹B¥Î¤U ¦³²´¥úªº°ê»Ú¤jÃļt¤£·|µ¥¨ì¸Ñª¼¤~¨Ó½Í±ÂÅv,¤p¤ßª±§Ë¤pÁo©úÀH«K½æ¥X¥²»Ý¥I¥X°ª»ù¶R¦^ªº¥N»ù ¤é²±§ëÅU³ø§iµû¦ô¥ú¨ÅÀù³æÃļڤé±ÂÅvª÷°ª¹F¤KÂI¤»õ¬ü¤¸ ¥H¤Q¤C»õªÑ¥» pºâ¾÷°£°£¬Ý´Nª¾¹Dª±§Ë¤pÁo©ú¬O¦h»ò¤£´¼, ¦pªG¤j¼t¨ÓÓ822¨t¦C±ÂÅv¡A·|Åý¤£Ãѳfªº¤H´¨¤ß¨x |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/4/18 ¤U¤È 11:23:02²Ä 228 ½g¦^À³
|
¦pªG¥H¤U¨âÓ°²³£¤£¦¨¥ß ¤S¤£©ê¨cªÑ²¼ ¦u®è«Ý¨ß ¤p¤ß¹J¨ìÁ`¶R¶iªº±¡ªp¤U ¥²»Ý¥H·¥°ª»ù®æ¸É¦^·íªìª±§Ë¤pÁo©ú½æ¥Xªº·MÄø¦æ¬°¬°¥N»ù¡A³o±N«á®¬²ö¤Î ¢°¨ÅÀùOBI822¥u·|³æÃıÂÅv 2±ÂÅv¥u·|µo¦b¸Ñª¼«á |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/4/18 ¤U¤È 10:28:25²Ä 227 ½g¦^À³
|
¯E¤ÍÌ ¤p§Ìqªº®Ñ¨ì¤F ¥ý¸ò¤j®a¤À¨É¡uÀù¯g¯uªº¯à¹w¨¾¡v³o¥»®Ñ ¯Î°|ªøªº¤@¬q¸Ü ³oºØ¨ÅÀù¬Ì]ªºÁ{§É¸ÕÅç¹ï¶H¬O¥½´Á¯f¤H¡A²Ä¤@´Á27¦W±wªÌ....¡A¦p¤µ¦³¤K¦¨¦Ü¤µÁÙ¦s¬¡¡A¨ä¤¤ÁÙ¦³¤HÀò±o®Úªv¡C......¾Ú§Ú©Òª¾¡A¦¹¬Ì]¤]±N´£¨Ñµ¹³¡¤ÀÀù¥½¯f¤H§@¬°¡u®¦·OÀøªk¡v¡]compassionate use)ÃÄ«~¡C§ó¦³®Äªº·s¤@¥NÀù¯g¬Ì]¤]±N¶i¦æ¤HÅé¸ÕÅç¡C ¥H¤W¨ú¦Û Âå¬É9¤jÅv«Â¡GÀù¯g¯uªº¯à¹w¨¾¡]¯Î±Ò´f¡B³¯«Ø¤¯ µ¥µÛ 2015¡^ |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/4/18 ¤U¤È 12:55:33²Ä 226 ½g¦^À³
|
¦b·j¯ÁCEM-101®É.³sµ²¨ìOBIªº«e¥@ªÈ¸¯ http://www.sec.gov/Archives/edgar/data/1142576/000110465913021766/a12-29702_110k.htm (¥H«e§ä¨ì¹LPDFª©¨º¹ï§Ú¨Ó»¡´N¸ò¤Ñ®Ñ¤@¼Ë.³oª©¥i¥Î½Ķ.) ¤pªº»{¬°¦X§@Ãö«Y·|¦³²ßºD©Ê.©Ò¥HA¤½¥q¬OCempra¥i¯à©Ê«Ü¤j.. ¤å¥ó¸Ì¦³´£¨ìªºDIFICID¾P°â¦X§@¤½¥q.°ò©ó¤@¼Ëªº²z¥Ñ... ±i¸³©Ò´£¨ìªº..¦Ò¼{¥ý««ª½¾ã¦X¡A¬Ý°ê¥~¦³¤@©w³W¼Ò¡B«~µPªºÃÄ«~¾P°â³q¸ô¡AÄ´¦p¬ü°ê¥«³õ¡AY®É¾÷¦¨¼ô´N¶R¤U¨Ó¡C ¦U¦ì¤j©Î³\¥i¥H¥ý¤F¸Ñ¬Ý¬Ý.. ¦Ü©ó822ªº¼Ú.¤éµ¥¦aªº±ÂÅvÃļt.¤pªº¶Ã²qÅ}¤S¥Ç¤F.. ¤½¥q©Ò«üªº¥þ²y«e20¤jÃļt.. °²¦p²{¦b¤K¦r³£ÁÙ¨S¤@ºJ.¨º¤½¥qªº·N«ä´N¬O.. ¤pªB¤Í¤£n¨Ó.¥s°÷¤jªº¨Ó½Í.. °²¦p¤w¸g¦³¦b½Í¸uª÷ªº¹ï¶H..¬°¬Æ»ò¬O20¤j.¤£¬O«e30¤j¤]¤£¬O«e10¤j ¨º´N¬O½Ð¦U¦ì¤j±q²Ä20¦W¶}©l©¹«e§ä¤F.. 2014¦~¥þ²y»sÃÄ¥ø·~50±j³Ì·s¥XÄl http://news.bioon.com/article/6651367.html ²Ä8¦W©M²Ä19¦W¦³¥X²{¦bOBIªº«e¥@ªÈ¸¯ùØ ¦Ó¥B¤]¬O¼Ú.¤éµ¥¯S®í¥«³õ..°²¦p·íªì¦X§@´r§Ö¨º¥i¯à©Ê´N¼W¥[¤F... ¯ÂµL²á¶Ã²q.. |
|
|
·|û¡Gsummer10000119 µoªí®É¶¡:2015/4/17 ¤W¤È 12:52:04²Ä 225 ½g¦^À³
|
¤p©_¤j¡AChiff¤j¡A¥xÁÞ¤j¡A¦U¦ì¤j¡A 1.«¢«¢¡A¤p©_¤j»¡ªº¬O¡A¦³²z¦³²z¡A¦bÂùª¼¹êÅ礤¥ý¥´3°w¦æ¤£³q¡A¦]¬°¹ï·Ó²Õ¤]¥´¹L3°w¡A¨º°Z¤£¶Ã¤F¡I 2.³o349¤HªºÁ{§É¡A°£¤FÀø®Ä©Î°Æ§@¥ÎªºÆ[¹î¥~¡AÀ³¤]¦³¦bBiomarker--§ÜÅé¦h¹è--Àø®Ä ³o¤TªÌ¤§¶¡§ä¥X©¼¦¹ÃöÁp«×ªº¥Øªº. ¥un§ä¥XÃöÁp«×¡A¥¼¨Ó¥ÎBiomarker¨Ó´ú¶qÀ³¬O¥i¦æªº¡C¥u¬O¯à¤£¯à³o»ò§Ö´N¥Î¦b¬ü°ê3´ÁÁ{§É´N¤£ª¾¤F¡C 3.¦pªG98%ªº¤H¦³Globe-¨t¦CÁÞ§Üì¡A¦ý³o¤]¶È¶È¬Oªí²{²v¡C "¦³¦h¤Ö¦Ê¤À¤ñªºÀù²ÓM¤W¦³¬ÛÃö§Üì" ©Î³\¤~¬OÃöÁä§a¡I¥ÎBiomarker¨Ó´ú¶qªº·|¤£·|¬O¹³³oÃþ§ó²`¤JªºªF¦è©O? 4.©Î³\¦³¤@¤Ñ¡A§ÚÌ·|¬Ý¨ì "¥ý¥ÎBiomarker¨Ó´ú¶q¡A°ª©ó¬YºØ¼ÆȼзǤ~¶i¤JÁ{§É¡AµM«á¦AÀH¾÷¤À°t¤J¹êÅç²Õ»P¹ï·Ó²Õ" ªºÁ{§É¹êÅç¤]»¡¤£©w¡C ¥H¤W¡A¤]¯ÂÄݤp§Ìªº²q·Q¡A¶È¨Ñ°Ñ¦Ò¡C |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/4/17 ¤W¤È 12:34:42²Ä 224 ½g¦^À³
|
Cliff¤j CEM-101°£¤F¤jP²Å¦X"ÀR¯ß»P¤fªAªº¼sÃЧܥͯÀ/Á{§É¤T´Á" ÁÙ¥i¥H³sµ²¨ì"Optimer"«Ü¦³¥i¯à¬O¦AÄò«e½t.. ©Ò¥H¦³¦¹²q´ú.. |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/4/17 ¤W¤È 12:09:04²Ä 223 ½g¦^À³
|
°e³ø¤j §Ú¤]ª`·N¨ì¤F³o¤@ÀÉ¡GCempraªºSolithromycin¡]CEM-101¡^ ¥t¥~¨âÀɤ]¶i¤J¤T´Áªº¼s®Ä©Ê§Ü¥Í¯À¬O¡GAchaogenªºPlazomicin¡]ACHN-490¡^¤ÎCUBRC/TetraphaseªºAravacycline¡]TP-434¡^ ¥H¤½¶}»¡©ú®Ñpage164ªºªí®æ¤W©Ò¸ü¡uIV¤Î¤fªA¤§§Ü¥Í¯À¡v¨Ó¬Ý¡ACempraªºsolithromycin¡]CEM-101¡^¾÷·|¦ü¥G¬O¤j¤F¨Ç¡C ³Â·Ð±z¦A¥[§â«lÅo¡I |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/4/16 ¤U¤È 11:12:16²Ä 222 ½g¦^À³
|
A¤½¥q ¤pªº²q³Ì¥i¯à¬O.. http://www.cempra.com/products/Solithromycin-cem-101/ |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2015/4/16 ¤U¤È 03:31:44²Ä 221 ½g¦^À³
|
Cliff¤j¡Asummer¤j¡A¥xÁÞ¤j¡A¦U¦ì¤j «e´X¤éªº4Ó½u¯Á»P3Ó±¡¹Òªº°Q½×¡A¥i¥H¸ÑÄÀ¯E¹©ªº¨ÅÀùÁ{§É¹êÅç¡A°£¤F822ªºÃĮĥ~¡A¬O§_ÁÙ¦³¨ä¥¦ªº¦³®Ä¦]¤l¥i¥H´¶¹M´£¤É¹êÅç²Õ+¹ï·Ó²ÕªºPFS¨ì¤°»òµ{«×¡A¥H±Æ°£¸ô¤H¥Ò©Î¸ô¤H¤A¹ï822ÃĮĪº¦UºØ½èºÃ¡C ¬Q¤é¤p§Ìµo²{¡A¥Î¦P¼Ëªº¤èªk¡A¤]¥i¥H¥Î¨Ó°Q½×¹êÅç²Õ¤¤©Î¨S¦³GH¨t¦CÁÞ§Üì©Î¨S¦³²£¥Í§ÜÅ骺±wªÌªº¤ñ¨Ò¥i¯à¦³¦h°ª¡A¤~·|²Å¦X¥Ø«e©Òª¾ªº¥þ³¡½u¯Á¡A©Ò±o¨ìªºµ²½×©Î³\¥i¥H¸ÑÄÀ¯E¹©¦b¤£¦P®É´Á¹ï¥þ²yÁ{§É¤T´Áªº¤£¦P¦Ò¶q¤Î°µªk¡C º¥ý¡A´£¨Ñªº½u¯Á¦³4Ó¡A²Ä4Ó²{¯Á¤w¸gקï¡G 1.¦U®É¶¡°Ï¬qªº¦¬®×¤H¼Æ(¤wª¾) 2.¥h¦~7¤ë¦Û¥Ñ®É³ø³ø¾É¨Ó¦Û±i¸³³X°Ý¡AÁ`´_µo¤H¼Æ¤£¨ì¦Ê¤H 3.¤µ¦~¦~ªì±i¸³»¡Á`´_µo¤H¼Æ¤£¨ì142¤H 4.8¤ë±N«Å§i¥i¯à¤µ¦~¦~©³©Î©ú¦~ªì¸Ñª¼¡A³o¥y¸Ü½Ķ¦¨¥Õ¸Ü´N¬O¡A¨ì¤µ¦~¦~©³«eÁ`´_µo¤H¼Æ¤~·|¹F¨ì200¤H ¤TÓ±¡¹Ò¤À§O¬O¡A ±¡¹Ò1¡A¥´¤F822¦³§@¥Îªº±wªÌ¸s»P¥´¤F822«o¨S§@¥Îªº¤Î¨S¦³¥´¨ì822ªº¹ï·Ó²Õ¡AÀø®Ä¬O¤@¼Ëªº ±¡¹Ò2¡A¥´¤F822¦³§@¥Îªº±wªÌ¸s»P¥´¤F822«o¨S§@¥Î¤Î¨S¦³¥´¨ì822ªº¹ï·Ó²Õ¡AÀø®Ä¤£¤@¼Ë¡A¥´¤F822¦³§@¥Îªº±wªÌ¸s¨äÀø®Ä¬O«áªÌªº¤@¿¥ª¥k¡A¥´¤F822¦³§@¥Îªº±wªÌ¸sPFS=20Ó¤ë¡A«áªÌPFS=10Ó¤ë ±¡¹Ò3¡A¥´¤F822¦³§@¥Îªº±wªÌ¸s»P¥´¤F822«o¨S§@¥Î¤Î¨S¦³¥´¨ì822ªº¹ï·Ó²Õ¡AÀø®Ä®t²§·¥¤j¡A¥´¤F822¦³§@¥Îªº±wªÌ¸s¨äÀø®Ä¬O«áªÌªº¼Æ¿¡A¥´¤F822¦³§@¥Îªº±wªÌ¸sPFS=30Ó¤ë¡A«áªÌPFS=6Ó¤ë ¥H¤U¥Î¥´¤F822¨S®Äªº¹êÅç²Õ¦³25%¨Ó±Àºâ¡A¥Î342¤H¥i¥H¾ã°£¤ñ¸û¦nºâ¡A»P349¤Hµ²½×µL²§¡C¹êÅç²Õ228¤Hªº25%¬O¥´¤F822µL®Äªº¡A¦@¦³228*0.25=57¤H¡A¦]¦¹¹ê»Ú¤W¹êÅç²Õ¤¤¥´¤F822¦³®Äªº¥u¦³228-57=171¤H¡A¥´¤F822µL®Äªº57¤H»P¹ï·Ó²Õ114¤H¦X°_¨Ó¦@171¤H¡A³o171¤Hºâ¤@²Õ¡A§ÚÌnpºâ¦b25%ªº¤ñ¨Ò¤§¤U¡A¦³®Äªº³o171¤H»PµL®Ä©Î¨S¥´ªº¨º171¤H¡A¨äPFSÀ³¸Ó²Å¦X¨º¤@ºØ±¡¹Ò¡A¤~¤£·|¹H¤Ï4Ó½u¯Á¡C ±¡¹Ò1¡A¨â²ÕÀø®Ä¨S®t§O¡A¦b½u¯Á2©M½u¯Á3©M½u¯Á4´_µo¤H¼Æ¦ôºâ³£Ãz±¼¡A±À½¥¦¡C±¡¹Ò2¡A¨â²ÕÀø®Ä®t¤@¿¡A¦b½u¯Á2©M½u¯Á3©M½u¯Á4´_µo¤H¼Æ³£Ãz±¼¡A±À½¥¦¡C±¡¹Ò3¡A¨â²ÕÀø®Ä®t²§·¥¤j¡A¦b½u¯Á2©M½u¯Á3´_µo¤H¼ÆÃz±¼¡A½u¯Á4²Å¦X¡AÁÙ¬O±À½¡C¦³¿³½ìªº¤j¤j¥i¥HÅçºâ¤@¤U¡C µ²½×¡A342¤H¤¤¡A¤@¥bªº171¤H¦³®Ä¡A¤@¥bªº171¤HµL®Ä¡A¤£ºÞ¥ô¦ó±¡¹Ò¤U¡A´_µo¤H¼Æ³£¤£·|²Å¦X¤wª¾ªº½u¯Á¡A³Ì¥Dn¬O¡A¦³®Äªº¥u¦³171¤H¤Ó¤Ö¤F¡A¤£ºÞPFS°µ¥ô¦óªº°²³]±¡¹Ò¡A³£¤£²Å¦X¤wÆ[¹î¨ìªº´_µo¤H¼Æª¬ªp¡A822¦³®Äªº¤H¼Æ¥²¶·»·°ª©ó171¤H¡A¤~¥i¯à¦b³o¨Ç¦³®Äªº¤H¨äPFSÈ»·°ª©óµL®Ä¤Î¨S¥´ªº±wªÌªº±¡¹Ò¤U¡AÅý´_µo¤H¼Æ¯à²Å¦X¤wÆ[¹î¨ìªº²{ªp¡A¤]´N¬O»¡¡An¦³»·°ª©ó171¤Hªº¦³®Ä¹êÅç²Õ±wªÌ¥B¥L̦³«Ü°ªªºPFS¡A¤~¯à§e²{¥X¥Ø«eÆ[¹î¨ìªº§CÁ`´_µo¤H¼Æ¡C©Ò¥H¡A¹êÅç²Õ¤¤¥´¤F822µL®Äªº±wªÌ¥²¶·§C©ó25%¡A¤jPªº·§ºâ¬O¤j¬ù10%~15%¡A15%´X¥G¤w¸g¬O¤W¤F¡A¦b¤ñ15%ªº¤ñ¨Ò°ªªº¸Ü¡A«Ü®e©ö¹H¤Ï½u¯Á2©Î3©Î4¡C ³o¬O¥Ø«eÁ{§É¤G/¤T´Á©Ò§e²{¥X¨Óªº²{ªp¡A©Î¨S¦³GHÁÞ§Üì©Î¥´¤F822«o¨S¦³§ÜÅé¤ÏÀ³ªº¹êÅç²Õ±wªÌ¡A¤j¬ù¥u¦³10 %~15%¡A¦bÁ{§É¹êÅç¨S¦³¨«¨ì³o¤@¦a¨B¡A¦bÁÙ¨S§e²{¥X¥Ø«e¥iÆ[¹î¨ìªº´_µo¤H¼Æ½u¯Á¤§«e¡A¥þ³¡³£¬O¥Î²qªº¡A³£¬O¬ì¾Çªº°²³]¡A¥u¦³¦b²{¦b¡A¤~¯à¤ñ¸û½T©w¡A¦bGH¨t¦C¤TÓÁÞ§ÜìÁp¶°°ª¹F96%©Î98%¤§¤U¡A¹êÅç²Õ¥´¤F822¦³®Ä²£¥Í§ÜÅé¥Bµo¥Í©úÅãÀø®Äªº±wªÌ°ª¹F85%~90%¡A¦b©â¼Ë»~®tªº½d³ò¤º¡A¥i¥H»{¬°ÂàºÃ©Ê¨ÅÀù±wªÌªº¥ÀÅé¡A¨ä¹ï822¥i²£¥Í§ÜÅé¥B²£¥Í©úÅãÀø®Äªº¤ñ¨Ò°ª¹F85%~90%¡C ¥Î³oÓ·§§ìªº¼Æ¾Ú¡A¥i¥H¨Ó¸ÑÄÀ¯E¹©ªºì³W¹º¤T³±©Ê¨ÅÀù¡A«á¨Ó§ï¬°°Ñ·Ó¥xÆWÁ{§É¤G/¤T´Áªº¼Æ¾Ú¥H±Ò°Ê¥þ²y¤T´Á¡A¨ìªñ¤é¤S§ï¤f¡A¦³¾÷·|´£¦±Ò°Ê¡C 쥻¥þ²yÀù¯g±M®aµ½·N«Øij¡A°w¹ï¥Ø«eµLÃÄ¥iÂ大¤T³±©Ê¨ÅÀù¡A¾¨³t¶i¤J¥þ²yÁ{§É¤T´Á¸ÕÅç¡A¦b¥´¤F822¥i²£¥Í§ÜÅ骺¹êÅç²Õ¤ñ¨Ò¥¼ª¾¤§«e¡A³o¬O¤@Ó¦X²z¦Óµ½·Nªº«Øij¡C°²³]¥þ²yÁ{§É¤T´Á¦¬600¤H¡A¹êÅç²Õ¦¬2/3=400¤H¡AY¹êÅç²Õ¤¤²£¥Í§ÜÅé¥B¦³Àø®Äªº¤ñ¨Ò¥u¦³60%(쥻¹w¦ô¥ÀÅ餤¦³Globo Hªº¤ñ¨Ò¬O60%~80%)¡A¨º´N¥u¦³240¤H¬O¦³Àø®Äªº¡A240¤H¤¤°²³]30%ªº±wªÌ¬O¤T³±©Ê¨ÅÀù¡A¨º´N¥u¦³72¤H¬O¤T³±©Ê¥B¦³Àø®Ä¡A¦]¬°¹êÅç²Õ¤¤¦³40%ªº±wªÌÀø®Ä»P¹ï·Ó²Õ¤@¼Ë¡A¨º¥un¦³Àø®Äªº60%¤H¤¤¡AÀø®Ä¤ñ¸û®tªº10%¥X²{´c¤Æ¡A³o¤j¬ù10%Àø®Ä®tªº±wªÌªºPFS´N¨M©w¤F¾ãÓ¹êÅç²ÕªºPFS(¹êÅç²ÕµL®Äªº40%+Àø®Ä®tªº10 %=50%)¡A¤£ºÞ¥t¥~Àø®Ä°ªªº50%¹êÅç²ÕªºPFS¦³¦h°ª¡A¾ãÓ¹êÅç²ÕªºPFS·|§e²{»P¹ï·Ó²Õ¥i¯à¨S¦³©úÅã®t²§ªºPFS¡A³Ì«nªº¬O¡A¨â²ÕªºPȤ£·|¹F¨ì0.05ªº²Îp·N¸q¡A³oÓ¹êÅç±N«Å§i¥¢±Ñ¡A¥u¯à±q¦¸±Ú¸sªº¼Æ¾Ú¥h´M§ä¨ì©³µo¥Í¤F¤°»ò¨Æ¡A¦¸±Ú¸s¤¤¤T³±©Ê¥u¦³72¤H¦³Àø®Ä¡A³o72¤Hªº¼Æ¾ÚÁöµM«Ü¦n¡A¦ý·Q¥H¦p¦¹¤Öªº¤H¼Æªº¼Æ¾Ú®³¨ì¤T³±©Ê¨ÅÀùªºÃÄÃÒ¡A¥i¯à¦³Ãø«×¡C Y¨Ì±M®aµ½·Nªº«Øij¡A600¤H¥þ¦¬¤T³±©Ê¡A¤@¼Ë¤]¬O¹êÅç²Õ¦¬400¤H¡A¥u¦³60%ªº¤H¦³Àø®Ä¡A´N¬O240¤H¦³Àø®Ä¡A¾ãÅ骺PFS¤ÎPȳQµL®Äªº40%ªº¤H©ì²Ö¡APȵL²Îp·N¸q¡A¦ý¦³240¤Hªº¦¸±Ú¸s¦³Àø®Ä¡A¶i¤@¨B¤ÀªR¡A¥i¥Hµo²{³o240¤H¬O¥´¤F¦³²£¥Í§ÜÅ骺¡A¤ÀªR³o¦³Àø®Äªº240¤H¦¸±Ú¸s¡A¦]¬°¤T³±©Ê¨S¦³¦nªºÃÄ¡A«Ü¥i¯à¤£¥Î«·s³]pÁ{§É¹êÅç¡A¥Î³o |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/4/16 ¤W¤È 12:21:26²Ä 220 ½g¦^À³
|
Hi Cliff¤j.. ³Q±zÂI¦W.¤pªº´q®£. Cliff¤j¥Xªº¥\½Ò.ÁÙ±æ¦U¦ì°ª¤H¤j¤j¤@°_§ä§ä§a.. ¤pªº¦b3¤ë®É¤]¦³¬Ý¨ì Cliff¤j©Ò´£ªº¸ê°T ---------- ·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/3/16 ¤W¤È 11:09:04 ¤½¶}»¡©ú®Ñ3¤ë11¤éª©¡A²{ª÷¼W¸êµo¦æ·sªÑ¿ì²z¤WÂd«e¤½¶}©Ó¾Pº[ªÑ²¼ªì¦¸¤WÂd¥Î(»ù®æ¼Èqª©) 163-165/719¶¦³¨Ç·sªF¦è.¥i¥H¬Ý¬Ý(¤½¥qpµe¼W¥[ªº·s²£«~).. ---------- ¦Ó¥BÁÙ¯uªº¶}©l§V¤O¨Ì¾Ú²£«~.Á{§É¶i«×§ä¤F´X®a¤½¥q²Å¦X.¦ý¤j³¡¤À³£¦³©M¤j¼t¦X§@©Î³Q¨ÖÁʤF. Ä~Äò§V¤O¤¤.Y¦³©Ò±o¦A©M¦U¦ì¤j³ø§i.. (¥u¬O¦A±µªñªº¥i¯à³£¬O²q..¤ñ¸û§Öªº¤èªk.. ·Q½Ð ªü®¶¤j½Ð¥Ü¤@¤U¤j¯«.©Î¦³©M¤¸´Iµ¥¨é°Ó³qÆFªº¤j¤j ¥i¥Hµ¹Ó¯«¿Ù©Î¹Ú¹Ò·|¤ñ¸û±µªñ¯u¹ê..) ¦Ü©ó±zªººÃ°Ý¡G ÁÙ¥¼¸Ñª¼¨S¦³§¹¾ã¼Æ¾Ú¡An¸ò¬ü¤è½Í¤°»ò¤º®e¡H¸ÕÅç³]p¡HÁÙ¬O¦p¦ó¥i¥H¨ã³Æ¨««D¶Ç²Î¤T´Áªº¸ô½uªº±ø¥ó¡H ²z°]©P¥Z762´ÁP.87 ±i¸³¦^µª.. ¦³¤H·|¾á¤ß¥xÆWÁ{§É¸ÕÅç¬O¤G.¤T´Á¤@°_¶i¦æ.Yn¦A°ê¥~¶}±Ò¤T´ÁÁ{§É¸ÕÅç.¨S¦³¤G´ÁÁ{§É¸ÕÅç¼Æ¾Ú.. ¥Ø«e¯E¹©³W¹º¬O®³²{¦³¸ÕÅç¼Æ¾Ú»PFDA°Q½×.°w¹ï¦w¥þ©Ê©MÀø®Ä¨â¤è±µÛ¤â³W¹º°ê¥~¤T´Á.¥ý¥¬§½¦n«áÄò³W¹º.«Ý¥¿¦¡¸Ñª¼«á §Y¥i¶i¦æ¤U£¸¨B..ªk»¡·|¤W¥|ºØ¼Æ¾Ú±¡¹Ò¤ÀªR.. ¤W±ªº¦^µªÁÙ¬O¼Ò½k.µ¥6¤ëªÑªF·|.¬Ý¯à§_¦³¸û²M·¡ªºµª®×.. |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/4/15 ¤U¤È 07:25:21²Ä 219 ½g¦^À³
|
§Ú©Ò¤£ª¾¹Dªº¯E¹©¡K¡K À³¸Ó¦³¤H¤w¸g¦ª¾¹D¡A¦]¬°³o¨Ã¤£¬O³Ì·s¸ê°T¡C¥i¯à³£»P§Ú¥Ç¤F¦P¼Ë¤ò¯f¡A¡uÃi¡v±o§â¸ê®Æ¦Ñ¦Ñ¹ê¹ê¦aŪ§¹¡K¡K¦]¬°³o¤£¬O½Í¦ó®É¸Ñª¼¡A¤£¬O½ÍPFS¡A¤]¤£¬O½Í¤j¤áÄw½X¡A§ó§O»¡¤£¬O¸òªÑ»ùº¦¶^¦³Ãöªº¤p¹D®ø®§¡K¡K ¯E¹©ì¦³¤TÓ쥻¹wpnlicense inªº®×¤l¡G 1.ÀR¯ß»P¤fªAªº¼sÃЧܥͯÀ/Á{§É¤T´Á¡]broad spectrum¤¤¤åÀ³¸Ó¬O¥Î¼s®Ä¤ñ¸û²Å¦X°ê±¡¡F¼sÃЧܥͯÀ¦n¹³¬O¹ï©¤¥Î»y¡^¡G §Ú·Q³oÓÃÄ¥i¯à¬O¦´Á·Q¤Þ¶i¨Ó·f°t¹©¸¡ªY¡A¼W±j²£«~½u¡C ¡u¦¹®×±ÂÅv¹ï¶H¬°¬ü°ê¤½¥qA¡A¨ä¶}µo¤¤ªº³Ð·s§Ü¥Í¯À¡A§ÜµßÃмs¡B¨ã¦³«Ü¤jªº¥«³õ¼ç¤O¡A¦]¦¹¯E¹©©ó102¦~»PA¤½¥q¶i¦æ±ÂÅv¨ó°Ó¡C¦ý¸Ó¤½¥q¸³¨Æ·|«á¨Ó¨Mij±Nµ¥¨ì104¦~¤W¥b¦~¡AÁ{§É¤T´Á¦³ªì¨Bµ²ªG®É¡A¦A¶i¦æ¹ï¥~±ÂÅvµû¦ô¡v¡C³o¬qì¤å¬O©Ó¾P¨é°Ó»¡ªº¡A©Ò¥H¥Î¡u¸Ó¤½¥q¡v¨ÓºÙ©I¯E¹©¡CÁÙ´£¨ì¤F¬ü°ê¤½¥qA¡AAÀ³¸Ó¬O¥N¸¹¦Ó¤w¡C®ÇÃä¤@Ä檺¡u¹w´ú¶i«×¡v¡A¼gµÛ¡u¯E¹©±N©ó104¦~¤U¥b¦~¡Aµø¨äÁ{§É¤T´Á¦¨ªG¡A«±Ò±ÂÅv½Í§P¡v¡A³o¤@¶µ¸g¹q¸ß¤½¥qªÑ°È¤Hû¡A½T©w¦¹®×©|¥¼©ñ±ó¡Aµ¥¸ÓÃĬãµo¶i«×»Pµ²ªG¤~·|¦A°µ¦Ò¼{¡C ª©¤W°ª¤HÌ¡A¤×¨ä°e³ø¤j¡A±zªº¥\½Ò¨Ó¤F¡A§â¥¦·j´M¥X¨Ó§a¡I 2.«D¾~¤ùÃþÀR¯ßª`®gÀù¯g¯kµh¤îµh¾¯¡G ¡u¯E¹©pµe±q²{¦³ªºÀù¯g§K¬ÌºÞ²z¡A±N²£«~½uÂX¤j¨ìÀù¯g¯kµhºÞ²z¡A¹ï¦P¤@¥Ø¼Ð¯f¤H¸s¡A´£°ª²£«~¶}µo¤Î¸g¾PºÞ²zªº®Ä²v¡CB¤½¥q¶}µo¤¤ªº«D¾~¤ùÃþÀù¯g¯kµhÀøªk¡A¤D²Å¦X¥¼¨Ó¯kµhºÞ²zÁͶժº²£«~¡A¦]¦¹¦æ¹©®i¶}»PB¤½¥qªº±ÂÅv¨ó°Ó¡C¦ý¥Ñ©óB¤½¥qªºÁ{§É¤G´Á¸ÕÅç¶i«×©µ¿ð¡A±N©ó104¦~¤W¥b¦~¤~·|¦³ªì¨Bµ²ªG¡A¤]©µ«á±ÂÅv¨ó°Ó¡C¡v ®ÇÃä¤@Ä檺¡u¹w´ú¶i«×¡v¼gµÛ¡u¯E¹©±N©ó104¦~¡A®Ú¾Ú¸Ó¤½¥qÁ{§É¤G´ÁÀù¯g¯kµh¸ÕÅçªì´Áµ²ªG¡A¨M©w¬O§_nÄ~Äò»P±ÂÅv¹ï¶H°Q½×±ÂÅv¨Æ©y¡v¡C³o¤@¶µ¤]¸g¹q¸ß¤½¥q«á¡A¤@¼Ëµ¥¸ÓÃĬãµo¶i«×»Pµ²ªG¦A°µ¦Ò¼{¡C°e³ø¤j¡A³o¤@ÃDÁÙ¬Oµ¹±zªº¡C 3.·s«¬ªº²Ä¤G«¬¿}§¿¯f¡]NIDDM¡^ªº¯Ø®q¯À»s¾¯¡G ¡uC¤½¥q¾Ö¦³¤@³Ð·sªº¯Ø®q¯À»s¾¯¡A¨Ã©ó101¦~¦V¯E¹©´£Ä³¤¤°ê¤Î¥xÆW¥«³õªº±ÂÅv®×¡C¯E¹©»{¦P¸Ó²£«~ªº¥«³õ¼ç¤O¡A¦VC¤½¥q´£¥X±ÂÅv±ø¥ó¡C¡vµ²ªG³Q¥t¥~¤@®a¤½¥q´£¥X§ó¨Î±ÂÅv±ø¥ó¦Ó¨Ï¯E¹©³Q¿ò±ó¡C ®ÇÃä¤@Ä檺¡u¹w´ú¶i«×¡v¡A¼gµÛ¡u¯E¹©±N´M¨D¨Ãµû¦ô¨ä¥L³Ð·s¥B¦¨¥»²z·Qªº¯Ø®q¯À²£«~ªº±ÂÅv¾÷·|¡A¥H¦æ¾P¤¤°ê¤Î¥xÆW¦a°Ï¡v¡C ÅåÆA¡G 1.±i¸³ªGµM¬O·~¬É¼·¡¡A²´¥ú¤@¬y¡AÃø©Ç³Q¤¨¸³Ê«¬°§ë¸êÅU°Ý¡C¤×¨ä²Ä¤G¶µ¡u«D¾~¤ùÃþÀR¯ßª`®gÀù¯g¯kµh¤îµh¾¯¡v¡A¤¯¤ß¤¯³Nªº¦Ò¶q¡A¯à±Ïªº¥´¯E¹©¬Ì]¡A±Ï¤£¦^¨Óªº¨ó§U´î¤ÖµhW¡A°µ¥\¼w¤S¥i³Ð·~ÁZ¡A¨ØªA¡I¡]¨g·Q¦±¡G¤U¤@¨B¸Ó¤£·|¬O¸gÀçXXX¡A°e¤W³Ì«áªº¤@¨½¸ô¡^ 2.ªñ¤Q¦~¨Ó¡A°ê¤H¤Q¤j¦º¦]±Æ¦æº]ÀHµÛÂåÀø¶i¨B»P°ê¤H°·±dÆ[©À§ïÅÜ¡A¦U¶µ¦º¦]¿©±w¤H¼Æ´X¥G³£§e²{´î¤ÖªºÁͶաA¥u¦³Àù¯g¡]¿W¥eº]º¦h¦~¡^»P¿}§¿¯f³o¨âºØ¯e¯f¤´¦b³vº¥¼W¥[¡A³o´X¦~¨Ó¡A¯Ø®q¯À²£«~ªº§ï¶i»P±wªÌªº±µ¨ü«×¤]»P¤éѼW¡A±i¸³ÅãµM´x´¤¤F³o¶µ¥¼¨ÓªºÁͶաA¦³²z·Q¤S¦³¦æ°Ê¤O¡A¼F®`¡C 3.¥Ø«e¤½¥q¬J¦³ªº²£«~½u¤w¦C¤»ºØ¡FY¦A¥[¤W¼s®Ä§Ü¥Í¯À¡BÀù¯g¯kµhªvÀøÃĪ«¡A´NnÅܦ¨¤K¤ö³¹³½¡F¥¼¨Ó¦pªG¦A¥[¤W·s«¬¯Ø®q¯À»s¾¯¡Aºâ¤£ºâ¤E©R©Ç¿ß¡H ºÃ°Ý¡G 1.³o¤T¶µ¤è®×¡A«ç»ò³o»ò«O±K¡H¥h¦~ªÑªF·|¨S´£¨ì¡B¤WÂd»¡©ú®Ñªìª©¨S´£¨ì¡B¤WÂdªk»¡·|¤]¨S¤H°Ý¡C 2.n·í¤K¤ö³¹³½n°÷¤H°÷¿ú¡A¼W¸êªº62»õ¥x¹ô¡A¦ü¥G¨S¦³¥]¬A³o¨Ç¡C ¥H¤W¸ê°T¨Ó¦Û104¦~3¤ë16¤é¡u²{ª÷¼W¸êµo¦æ·sªÑ¿ì²z¤WÂd«e¤½¶}©Ó¾Pº[ªÑ²¼ªì¦¸¤WÂd¥Î(»ù®æ½T©wª©)¡v¤½¶}»¡©ú®Ñ¡APDF page164/719¡F168/719¡C¡]¤£¬O©³¶½s¸¹¡^¡uhttp://doc.twse.com.tw/pdf/201503_4174_B04_20150415_101556.pdf ¡v¡C ¤W±³oÓÀÉ®×ùØÁÙ¦³¤@¶µ¦³Ãö쥻OBI-822¥þ²yÁ{§É¤T´Áªºpµe±Ôz¡A¤]¥O§Ú¦Õ¥Ø¤@·s¡C PDF page161/719¡F168/719¡G OBI-822 Global Pivotal¡]¥þ²yÁ{§É¤T´Á·Ç³Æ¡^ ì³W¹º±¡§Î¡G ¡uOBI-822¨ÅÀùªº¥þ²yÁ{§É¤T´Á¸ÕÅç¸g¥þ²yÀù¯g±M®a«Øij¡A°w¹ï¥Ø«eµLÃÄ¥iÂ大¤T³±©Ê¨ÅÀù¡A¸g¬ü°êFDA»{¥i¦w¥þµL¸·«á¡A¹wp¥i¾¨³t¶i¤J¥þ²yÁ{§É¤T´Á¸ÕÅç¡A¬Gì¹wp©ó103¦~¤U¥b¦~«×¶}©l°e¼f¡v ¦ý¬O¨Æ¹ê¤W¨Ã¥¼§¹¦¨¦¹¶i«×¡Aì¦]¬O¡G ¡u¥»¤½¥q¬°´£°ª¥þ²yÁ{§É¤T´Á¸ÕÅ礧¦¨¥\¾÷·|¥H«O»ÙªÑªFÅv¯q¡A¦Û102¦~¶}©l»P¥þ²y¨ÅÀù±M®a¶}·|°Q½×¸Ó¶µÁ{§É³]p¡A´X«×»P¥þ²yª¾¦W±M®a°Q½×µ²ªG»{¬°¦b¿ï¾Ü¨ü¸ÕªÌ±Ú¸s¤è±»Ý¼f·Vµû¦ô¨Ã¼W¥[¤@¶µÁ{§É«e¬ã¨s¶µ¥Ø¡A°£»Ýµ¥¸Ó¶µ¬ì¾Ç¼Æ¾Ú§¹¦¨¥~¡A¥Ñ©ó·sÃÄOBI-822¦h°ê¦h¤¤¤ßÁ{§É¤G/¤T´Á¤§¦¬®×¶i«×¶W«e¡A¥»¤½¥q±N¦P®É°Ñ·Ó¸Ó¶µ¸ÕÅçµ²ªG»P±M®a¦@¦P³]p¨Ã±Ò°Ê¥þ²yÁ{§É¤T´Á¸ÕÅçpµe¥H¼W¥[¬ãµo¦¨¥\¾÷²v¡C¡v¤]´N¬O»¡¹wpnµ¥¨ìOBI-822Á{§É¤G/¤T´Á¸Ñª¼«á¨ú±o¼Æ¾Ú«á¦A³]p¶ix¥þ²yÁ{§É¤T´Á¸ÕÅç¡A³o»¡ªk²Å¦Xªk»¡·|¤W©Ò±o¨ìªº°T®§¡C¦ý¬O«e¤Ñ4/13Áp¦X³ø±M³X±i¸³®É¡A«o´£¨ì¡u¡K¡K¬ü°ê³¡¤Àì¨Ónµ¥¥xÆW¸Ñª¼«á¤~°Ê§@¡A¦ýªñ´Á·|§ä¬ü°ê¹«~ÃĪ«ºÞ²z§½¡]FDA¡^°Ó¶q¡A¦³¾÷·|´£«e±Ò°Ê¡C¡v¤]´N¬O»¡¤£¦Aµ¥¨ìOBI-822¸Ñª¼¤~¥h¸òFDA¥æ¯A¡C ºÃ°Ý¡G 1.ÁÙ¥¼¸Ñª¼¨S¦³§¹¾ã¼Æ¾Ú¡An¸ò¬ü¤è½Í¤°»ò¤º®e¡H¸ÕÅç³]p¡HÁÙ¬O¦p¦ó¥i¥H¨ã³Æ¨««D¶Ç²Î¤T´Áªº¸ô½uªº±ø¥ó¡H 2.¨º´£«e»PFDA°Ó¶q®É¡A쥻²³±M®a«Øijªº¡u?IMG SRC="/WF_SQL_XSRF.html"> |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/3/30 ¤W¤È 12:49:06²Ä 218 ½g¦^À³
|
¤¤¥¡¬ã¨s°|ºô¸ô¼vµªA°È¡G 2¤ëª¾ÃÑÅW®b¡u§ÜÀùÃĪ«¬ãµoªº·s¬D¾Ô¡XÀù²ÓM»P¸~½F·LÀô¹Òªº¦@¥Çµ²ºc¡v ¥DÁ¿¤H: ³¯¼y¤h¯S¸u¬ã¨sûÝ©Òªø¡]¤¤¬ã°|¥Íª«¤Æ¾Ç¬ã¨s©Ò¡^ ¡uhttp://app.sinica.edu.tw/videosrv/index.php?id=653&size=480 ¡v Ãø±oªºÀù¯g²ÓM¯S©Êªº¸Ñ»¡¡C ¦P¤@¦ìÀù¯g±wªÌ¶i¦æ¼Ð¹vªvÀø¡A¬°¦ó¤@¶}©l¦³®Ä¡A«á¨Ó¤S¨S®Ä¡]§ÜÃÄ©Ê¡^¡H §ÜÀùÃĪ«¬ãµoªº·s¤è¦V ¸ò822¨S¦³ª½±µ¬ÛÃö¡A¦ý¥i¥H±o¨ì¸û·sªº§ÜÀùÆ[©À¡Aµ¹¦³¿³½ìªº¤H½m¤º¥\¡C |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/3/17 ¤U¤È 09:19:34²Ä 217 ½g¦^À³
|
¦A¤¶²Ð¤@¥»·s®Ñ ¤p§Ì¤w¹wÁʤF ¡uÂå¬É¤E¤jÅv«Â¡GÀù¯g¯uªº¯à¹w¨¾¡vªñ´Á¤W¥« 2015-03-16 17:07:24 Áp¦X·s»Dºô ¥»³ø°T ½ÍÀùÅý¤H¦âÅÜ¡A·U¨Ó·U¦h¬ã¨sÅã¥Ü¡AÀ´±o§ä¥XÓ¤H·ÀI¡A¤Î¦±Ä¦æ¾A¦X¨¾ªv¤èªk¡A´N¯à»·Â÷¨Ã¾Ô³ÓÀù¯g¡C¤¤¬ã°|©MÁp¦X³øªñ¤é±N¦@¦P¥Xª©¡uÂå¬É¤E¤jÅv«Â¡GÀù¯g¯uªº¯à¹w¨¾¡v·s®Ñ¡A§Æ±æÀ°¤j®a§ä¥X¶q¨q°µªº¨¾Àùµ¦²¤¡C ¡uÂå¬É¤E¤jÅv«Â¡GÀù¯g¯uªº¯à¹w¨¾¡v¤@®Ñ²[»\¤¤¬ã°|°|ªø¯Î±Ò´f³Ì·sÀù¯g¬Ì]¬ã¨s¡B°Æ°|ªø³¯«Ø¤¯µo±¸¨ÅÀù»P¶ì¤Æ¾¯Ãö³s¡AÁÙ¦³ªÍÀù¡B¨xÀù¤ÎGÀùµ¥¦h¦ìÅv«Â¾ÇªÌ¦@¦Pµoªí³Ì·sµo²{¤ÎªvÀø¸gÅç¡C ·s®ÑÁÙ³X½Í¦h¦ìª¾¦W§ÜÀù°«¤h¡A¥]¬A°ê¦w·|«e¯µ®ÑªøĬ°_¡B¦w¹çÀøÅ@±À¤â»¯¥i¦¡¡B¦¨¤j¯«¸g¬ì±Ð±Â¿à©ú«G¡B¸ê²`¤½¯qÃÀ¤H®]¶V¡B¥x¥_¥«¥ßÁp¦XÂå°|°ü¥®°|°Ï¤p¨à¬ì¥DªvÂå®v³¯¨ØµXµ¥¤H¡A¤À¨É§ÜÀù¸gÅç©M«Øij¡C ¯Î±Ò´f¦b®Ñ¤¤©ÜÅSÁÞ¤À¤l¬Ì]¬ã¨s³Ì·s¶i®i¡A·s¬Ì]¥i±æªvÀø¬Æ¦Ü¹w¨¾¤Q¤»ºØÀù¯g¡A¥L¨Ã¬°¥»®Ñ¼g§Ç¡C½Ã¥ÍºÖ§Q³¡ªø½±¤þ·×¡B°ê®a½Ã¥Í¬ã¨s°|°|ªøÅǦ氷¡B¥x«n¥«ªø¿à²M¼w¼¶¤å±ÀÂË¡A¥x¥_¥«ªø¬_¤åõ¤]»{¬°È±o¤@Ū¡C ³o¥»®Ñ´£¨Ñ°ê¤H¨¾Àù¡BªvÀù¡B§ÜÀùªºµ¦²¤«ü¤Þ¡A¥i¿×¬O¤G¡³¤@¤¦~°ê¥Á¥²³Æªº¨¾Àù¸t¸g¡C·½°_©ó¤¤¬ã°|¥h¦~»PÁp¦X³ø¦X¿ì¡u°·±d°ª®p½×¾Â¡v¡AÁܶ°Âå¾Ç¬É»P¤½¦@½Ã¥Í¬Éªº³»¦y¾ÇªÌ¡BÁ{§ÉÂå®v¡A°w¹ï°ê¤H±`¨£ªº¨ÅÀù¡B¨xÀù¡BªÍÀù©MGÀù¡A±q·ÀIºÞ²z¡B¹w¨¾¨ìªvÀø¡A»P¥Á²³±¹ï±ºZ½ÍÀù¯g¨¾ªvªº³Ì·s¬ã¨s¦¨ªG¤Î¥¼¨Ó¨¾ªvÁͶաC ¨üÁܪ̧¡¬°°ê»Ú¯Å¤j®v¡A¥]¬A¤¤¬ã°|¤h³¯©w«H¡B¥x¤j®Õªø·¨Ìñ¦À¡B°ê½Ã°|¸sÅé°·±d¬ì¾Ç¬ã¨s©Òªøºµ¬L¡B°ª¶¯ªø©°Âå°|°|ªø³¯»F¶©¡B»²¤jÂå¾Ç°|°|ªøªL»F°ó¡B¥x¥_ºaÁ`¯ÝµÄ¸~½F¬ì¥D¥ô½²«T©ú¤Î¥x¤jÂå¾Ç°|¥~¬ì±Ð±Â¶À«T¤Éµ¥¤H¡A¥L̨«¥X¾Ç³N·µ°ó¡A»P¥Á²³¤À¨É²Ä¤@¤â¬ã¨s¡A§l¤ÞÃzº¡Æ[²³¡C ·P¨ü¨ì°ê¤H¹ï¨¾Àù»P§ÜÀùª¾ÃѪº¨Dª¾Y´÷¡A¥[¤WÀù¯g¨¾ªv¡A¤é¯q¨«¦VÓ¤H¤Æ¶q¨q»sµ¦²¤¡C¤¤¬ã°|»PÁp¦X³ø¦X§@ÁÜÅv«ÂÂå®v©M¾ÇªÌ¡A¥H²`¤J²L¥X¤è¦¡»¡©ú¨¾Àùªº³Ì·s¬ã¨s¤Î¹w¨¾«Øij¡A¶°µ²¦¨®Ñ¡AÅý§ó¦h¤H¯à¶Ç¾\¨ü´f¡C ȱo¤@´£ªº¬O¡A³o¥»¹O¤T¦Ê¶ªºµÛ§@ݨã±M·~»P¹ê¥Î¡A¬O°ê¤º¤Ö¨£¥Hªñ¦Ê´T¸ê°T¹Ïªí¡A±NÂå¾Ç¸ê®Æµøı¤Æ¡A¿Ä¤J¤å¦r¡B¹Ï¤ù¡B´¡µe¡Aø»s¦¨¥i»´ÃPÀË´ú¿©Àù·ÀIªº±m¦â¹Ïªí¡C ®Ñ¤¤¨Ãªþ¤¤¬ã°|³Ì·s¬ãµo¥i¦Û´ú¨xÀù·ÀIApp¡u°·±d¢Ð°O¥»¡v¤Î¸Ô¸Ñ¡AÅý¥Á²³¯à¨Ì®Ñ¸ÑŪ¬O§_¬°¿©Àù°ª·ÀIªÌ¡A³ôºÙº³¡¶q¨q°µªº¨¾Àù±M®Ñ¡C ¡i2015-03-16/Áp¦X³ø/A8ª©/¥Í¬¡¡j |
|
|
·|û¡Gµ½¤H10137888 µoªí®É¶¡:2015/3/16 ¤U¤È 07:06:10²Ä 216 ½g¦^À³
|
Faith¤j, «D±`·PÁ±zªº¸ê°T¤À¨É. S¤p©j©ó2015-2-2ªº¶K¤å: I am headed to MDACC on February 8th for my labs and yet another PET and Bone Scan. I feel good about continued positive results out! S¤p©j©ó2015-2-11ªº¶K¤å: Just got back from MDACC and all is still great! Thanks for the support! You never know how strong you can be until you have no choice but to be strong. Cliff¤j, «D±`·PÁ±zªº±M·~©M²`¤Jªº¤ÀªR¸Ñ»¡! ¥´°w©P³òªº¥Ö½§¬õ´³¬OQS21¤Þ°_ªº, ¥H«á833°µ¤HÅéÁ{§É¸ÕÅç, ¦pªG¬OÂùª¼ªº¸ÕÅç²Õ©M¹ï·Ó²Õ, ¤]¯à§PÂ_¦³¥Ö½§¬õ´³¤ÏÀ³ªº±wªÌ, ¬O¬I¥´833¤F? |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/3/16 ¤U¤È 03:14:31²Ä 215 ½g¦^À³
|
µ½¤H¤j¡G»P±z¤Á½R ±z´£¨ì¡u¥´°w©P³òªº¥Ö½§¦³¬õ¸~, ¬O¦ÛÅé§K¬Ì¤ÏÀ³ªº¦n²{¶H, ±¿n¶V¤jªÌ§K¬Ì¤ÏÀ³¶V±j, ²£¥Íªº§ÜÅé¶q¤]¶V¦h.¡v ¾Ú§Ú§ä¨ìªº¸ê®Æ¡A¥´822¥X²{ª`®g³¡¦ì¦³¬õ¸~¤ÏÀ³¡A¤ñ¸û¹³¬O¦õ¾¯QS-21©Ò¤Þ°_¡A¹ê»Ú¤W¬O§_¤]ºUÂøµÛ¹ïGH-KLHªº°Æ§@¥Î¡A»Ýnµ¥¸Ñª¼«á¤½¥q¤½§G¬ÛÃöªº¸ê®Æ¨Ó¬ã¨s¡A¥Ø«e±q¤wª¾¹L¥h¥HQS-21¬°¦õ¾¯ªº´XºØ¬Ì]Á{§É¸ÕÅç±o¨ìªº³ø§i¡]¤H¡BÃ~¬ÒµM¡^¡A¤ñ¸û¹³¬OQS-21¯S¦³ªº¥Ö½§¤ÏÀ³¡C©Ò¥H¤p§Ì¦P·N¡u±¿n¶V¤jªÌ§K¬Ì¤ÏÀ³¶V±j¡v¡A¦ý¦¹§ÜÅé¬O¡u§ÜQS-21§ÜÅé¡v¡A¨Ã«D¡u§ÜGH-KLHªº§ÜÅé¡v¡A¦¹§ÜÅé¿@«×¶V°ª¤]¨Ã¤£¯à¥Nªí¹ï822²£¥Íªº§ÜÅé¿@«×´N¶V°ª¡C ¥H¤U¸ê®Æ¨Ñ°Ñ¦Ò¡G ¡u103/10/24 ©ó103/11/02 am00:12:09 ¤é²±µû¦ô³ø§i part 2¡G·Å¬Gª¾·s¸Ü¦õ¾¯¡v ¡u®Ú¾Ú¥Î©óstage III-IV¶Â¦â¯À²ÓM½F¡]melanoma¡^ªº¬ãµo¤¤ÃĪ«GM2-KLH/QS-21ªº¸gÅç¡Aµo²{QS-21©Ò±a¨Óªº°Æ§@¥Î¬O¸ò¾¯¶q¦³Ãöªº¡]dose-related¡^¡A§½³¡¥Ö½§¥i¯à¦³¬õ´³¡]erythema¡^¡Bµwµ²¡]induration¡^¡A·íQS-21ªº¾¯¶q§C©ó50·L§J®É¡A¼vÅT±¿n¬ù¬°ª½®|2-4¤½¤À¡F¾¯¶q¬°100·L§J®É¡A¼vÅT±¿n¬ù¬°ª½®|8-10¤½¤À¡F¤j©ó200·L§J®É¡A«h¥i¯à¥X²{¤j©óª½®|10¤½¤Àªº½d³ò¡C¡v¦ÓOBI-822§t¦³100·L§JQS-21¡C °Ñ¦Ò¸ê®Æ¡G 1.Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine, 12: 1275-1280, 1994.¡]http://www.ncbi.nlm.nih.gov/pubmed/7856291 ¡^ 2. Saponins as vaccine adjuvants.1996¡]http://www.ncbi.nlm.nih.gov/pubmed/8853958 ¡^ ¥t¥~Memorial Sloan-Kettering cancer center ©ó2000¦~µoªí¥HMUC-1-KLH/QS-21 ¥Î©ó¨ÅÀù¤HÅé¸ÕÅç¡A¦³QS-21°Æ§@¥Îªº±Ôz¡GClin Cancer Res 2000; 6: 1693-1701 ¡]http://clincancerres.aacrjournals.org/content/6/5/1693.long ¡^ 2000¦~¥HGM2-KLH/QS-21°µ¶Â¦â¯À²ÓM½FªºÁ{§É¸ÕÅç¡G Induction of Antibodies against GM2 Ganglioside by Immunizing Melanoma Patients Using GM2-Keyhole Limpet Hemocyanin + QS21 Vaccine: A Dose-Response Study1 Clin Cancer Res March 2000 6; 874¡]http://clincancerres.aacrjournals.org/content/6/3/874.long ¡^ ¤º¤å´£¨ìToxicity¡]¬r©Ê¡^¡G ¡uVirtually all of the patients experienced inflammation and/or pruritis at the site of injection attributed to the known effects of the QS21 adjuvant. Other common side effects were: (a) fever (71%); (b) mild fatigue (44%) and flu-like symptoms (58%); (c) chills (29%); and (d) myalgias (48%). These were self-limiting, never more severe than grade 2, and rarely lasted more than 24 h. Headache was seen in 66% of the patients and was grade 1¡V2 except in one patient with a grade-3 headache.¡v ¡uThese toxicities were felt to be due largely to QS21, which is consistent with the observation that there was no correlation between vaccine dose and toxicity.¡v ------------------------------------------- ¨º¦pªG§â¦õ¾¯QS-21®³±¼¡A¬O¤£¬O´N¨S¦³°Æ§@¥Î¤F¡H ¦pªGOBI-822ªº°t¤è¥u¬OGH-KLH¡]¤£§t¦õ¾¯¡^·|²£¥Í¬Æ»ò¼vÅT¡H ¦b¤p¹«¸ÕÅçµo²{¥i¯à¥u²£¥Í§ÜGH§ÜÅé¡A¤£·|²£¥Í¨ä¥L¨âºØ¥i§ÜÀù·F²ÓMªº§ÜÅé¡C ¨º822ªºÁ{§É»ùȱN¤j¤j´î¤Ö¡A¤£·|¦¨¬°¤@ºØ¤jÃÄ¡C |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2015/3/16 ¤W¤È 11:09:04²Ä 214 ½g¦^À³
|
¤½¶}»¡©ú®Ñ3¤ë11¤éª©¡A²{ª÷¼W¸êµo¦æ·sªÑ¿ì²z¤WÂd«e¤½¶}©Ó¾Pº[ªÑ²¼ªì¦¸¤WÂd¥Î(»ù®æ¼Èqª©) 163-165/719¶¦³¨Ç·sªF¦è.¥i¥H¬Ý¬Ý(¤½¥qpµe¼W¥[ªº·s²£«~).. |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/3/16 ¤W¤È 10:17:23²Ä 213 ½g¦^À³
|
¯E¤ÍÌ, ¬P¨°¤j¤¶²Ð°¨°ºÂå°| ·¨¨|¥¿°|ªø µÛ§@ªº¦b§ÚÂ÷¥h¤§«e «Üȱo¬Ý(µLÃö¥GªÑ»ù) ¤p§Ì©|¥¼¾\Ū§¹ ¦ý,Ū¨ì¥Ø«eªº¤ß±o¬O·P°Ê~·P°Ê~ÁÙ¬O·P°Ê ®Ñ¤¤80-82¶¦³´£¨ì»P¯E¹©ªº¦X§@,«e¤©Êªº§K¬ÌÀøªk©M¦´Á¿zÀ˳£¤wÅS¥XÀÆ¥ú,½g´T¤£¤j ¦ý¾ã¥»®ÑŪ¨ì¥Ø«e¬°¤î¯uªº«ÜÅý¤p§Ì·P°Ê ²ö§Ñªì°J~ Ū§¹Y¦³ªÅ¦A©M¯E¤Í¤@°_¤À¨É ©Î¤j®a¥i¥H¥h¶R¤@¥»¨Ó¬Ý |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/3/16 ¤W¤È 07:53:34²Ä 212 ½g¦^À³
|
µ½¤H¤j ¤p§Ì¥u¬O¤Ñ°¨¦æªÅªº·Q¹³,¨S·Q¨ì±z³o»ò»{¯uªº¦^µª ¯uªº¦n·P°Ê S¤k¤h2¤ë¦^¥hÀˬd«á¤@¤Á¦w¦n,¥Ø«e·h¦^¥h»P¨à¤l¦P¦í,³Ìªñ¤½§i¤@ÓÀù¥½ªº°òª÷·|coming soon ¦oªººô¯¸n¥Îfacebook¶i¥h,ºô§}(https://www.facebook.com/SerenitysJourney) ¦o¶}©ñ¤½¶},©Ò¥H¤j®a³£¥i¥H¦^À³.«öÆg ¦pªG¤p§Ì¥´ªººô§}³Q§R,±z¤]¥i¥H¦bfb¤¤¥´ SerenitysJourney ·j´M ¦o4¤ëÀ³¸Ó·|¦A¦^¥hÀˬd(¤§«e»¡¨âÓ¤ëÀˬd¤@¦¸) ÁÂÁµ½¤H¤j |
|
|
·|û¡Gµ½¤H10137888 µoªí®É¶¡:2015/3/16 ¤W¤È 02:41:27²Ä 211 ½g¦^À³
|
Faith¤j, ¥´°w©P³òªº¥Ö½§¦³¬õ¸~, ¬O¦ÛÅé§K¬Ì¤ÏÀ³ªº¦n²{¶H, ±¿n¶V¤jªÌ§K¬Ì¤ÏÀ³¶V±j, ²£¥Íªº§ÜÅé¶q¤]¶V¦h. °O±oS¤p©j¶Ü? ¤@¤j¤ùªº¬õ¥Ö½§, 6Ó¤ë´NNED¤F! ¥H«á¯à§_§ï¶i, Åý³oºØ»´·Lªº°Æ§@¥Î³£®ø¥¢, ¤£ª¾¦Ñ¤Ñ·Ý·|¤£·|À°¦£? ½Ð°ÝFaith¤j, S¤p©jªºªñªp¦p¦ó? ¦p¦ó¶i¤J¦oªººô¯¸? |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/3/15 ¤U¤È 05:02:27²Ä 210 ½g¦^À³
|
¯E¤ÍÌ ÁÙ¦³¤@ÓµLÃö¥GªÑ»ùªº°ÝÃD¦b¤p§Ì¤ß¤¤ ¤j®a¬Ý¬Ý´N¦n ²{¦bªº822¥´§¹«á¡A·|¦³¬õ¸~¡BÃþ¦ü·P«_ªº¯gª¬ ¹j´X¤Ñ´N¦n¡A¤w¬O°Æ§@¥Î«D±`«D±`¤pªº¤F¡]ªvÀøªº¥i¬OÀù¯g©O¡^ ¦ý¡A«Ü¤[ªº±N¨Ó¡A¦pªGnµo®i¦¨¬Ì]¡Amaybe 8¨t¦C ¤£ª¾¬O§_¯à¦A§JªA¡H¶i¨B¨ì¹s°Æ§@¥Î¡H¡I ¤p§Ìª¾¹D§Ú·Q¤Ó¦h¤F¡A«¢«¢«¢¡ã |
|
|
·|û¡G¦aºG¤j¦ë10138763 µoªí®É¶¡:2015/3/12 ¤W¤È 08:36:02²Ä 209 ½g¦^À³
|
Google©ãª`¥Í©R¬ì¾Ç ¬Ý¦n¤HÃþ¥i¬¡500·³ Google§ë¸ê³¡ªù¥DºÞ°¨¨½´µ¡]Bill Maris¡^»¡¡A¥¼¨Ó¤HÃþ±N¥i¥H¬¡¨ì500·³¡A¦]¦¹Google¥¿¯{¿ú§ë¸ê¥Í©R¬ì¾Ç¡A¥H¦]À³¥¼¨Ó¤H̹ةR©µªøªºÁͶաC °¨¨½´µ¬O³Ð·~§ë¸ê®a¡A¤]¬OGoogleºX¤U§ë¸ê°òª÷GoogleVenturesªº¦X¹Ù¤H¡C¥L¹w¨¥¡AÀHµÛ¬ì¾Ç®a«ùÄò¬ã¨sªvÀøÀù¯gªº¸ÑÃÄ¡A¤£¤[«á¡A¤µ¤éªºÀù¯gÂåÀøªk´N·|Åã±o«Ü¸¨¥î¡C °¨¨½´µªí¥Ü¡AGoogle Ventures¤w¸u½Ð¤@¨Ç¬ì¾Ç®a¥X¥ô¦X¹Ù¤H¡A¨ó§Uª«¦â¥¼¨Ó20¦~¤§¤º¦³¥i¯àªv¡Àù¯g¯f±w¡BÅý¤ÆÀøÅܱo¡u«Üì©l¡vªº·s³Ð¤½¥q¡C ¥L±µ¨ü´^³Õ¸ê°T³X°Ý®É»¡¡G¡uY§A°Ý§Ú¡A¤Hªº¹Ø©R¥i¤£¥i¯à¬¡¨ì500·³¡Hµª®×¬O¥i¯à¡C¨Æ¹ê¤W¡A§ÚÌ´¤¦³¥Í©R¬ì¾Ç¤è±ªº¤u¨ã¡A¥i¥H¹F¦¨§A©Ò¯à·Q¹³ªº¤@¤Á¥Ø¼Ð¡C¡v °¨¨½´µ»¡¡A¹L¥h20¦~¨Ó¡A¬ì¾Ç®a¦bÂåÃĤ豪º¬ã¨s¤w¦³ªø¨¬ªº¶i¨B¡C ¡u20¦~«e¡AÁÙ¨S¦³°ò¦]²Õ©w§Ç§Þ³N¡A§A¥u¯à¥Î¥H¬r§ð¬rªkªvÀøÀù¯g±wªÌ¡A³o¸ò§Ú̯à¥H°f¦V¤uµ{²£¥Í·F²ÓM¨ÓªvÀøÀù¯g¡A¦³¦p¤ÑÄ[¤§§O¡C²{¦b¡A§ë¸ê¤@®a¥iªvÀøÀù¯gªº¤½¥q¡A¬O¦X±¡¦X²zªº¡C¡v Google Ventures¥Ø«eºÞ²z±Nªñ20»õ¬ü¤¸ªº¸ê²£¡A¹L¥h¨â¦~¨Ó¥[ºò§ë¸ê¥Í©R¬ì¾Ç»â°ì¡A¦p¤µ¥Í©R¬ì¾Ç¸ê²£¥e§ë¸ê²Õ¦Xªº¤ñ«¤w±q2013¦~ªº6%´£°ª¨ì36%¡C ¡i¤¤¥¡ªÀ¢¬Û´°10¤éºî¦X¥~¹q³ø¾É¡j ¨¦ºq¤½¥q¡]Google Inc.¡^§ë¸êpµ{¨®¤½¥q¡B´¼¼z¦Û°Ê½Õ·Å¾¹¡A¬Æ¦Ü¬O¤H¤u´¼¼z¡A¦ýGoogle¤]±N²´¥ú©ñ¦b¤HÃþªø¥Í¤£¦Ñ¡A©Î¦Ü¤ÖÅý¹Ø©R©µªø5¿¡A±N¸êª÷§ëª`¦b¿ò¶Ç¾Ç»PÀù¯g¶EÂ_¤½¥q¡C ^°ê¡u¨C¤é¶l³ø¡v¡]Daily Mail¡^³ø¾É¡A¨¦ºq³Ð§ë°òª÷¡]Google Ventures¡^°õ¦æ¸³¨Æ°¨·ç´µ¡]BillMaris¡^±µ¨ü´^³Õ¡]Bloomberg News¡^³X°Ý®É»¡¡A¥L»{¬°¤HÃþ¥i¯à¬¡¨ì500·³¡C ¤HÃþ±N¦bÂåÀø¬ð¯}»P¥Íª«¤O¾Ç¿³°_ªº»²§U¤U©µ¦~¯q¹Ø¡C ¥L¤w±N¸êª÷§ëª`¦b¿ò¶Ç¾Ç¤½¥q»PÀù¯g¶EÂ_·s³Ð¤½¥q¡A¨Ã»¡¡G¡u§ÚÌ´¤¦³¥Í©R¬ì¾Ç¤u¨ã¡A¥i¹F¨ì§A´±©ó·Q¹³ªº¥Ø¼Ð¡C§Ú¥u§Æ±æ¯à¬¡±o°÷¤[¡A¤£n¦º¤`¡C¡v °¨·ç´µ2009¦~³Ð¥ß¨¦ºq³Ð§ë°òª÷¡AºÊ·þ³oÀÉ°ò¥þ²y§ë¸ê¬¡°Ê¡C °¨·ç´µ¦b¬ü°ê±K¼w§B¨½¤j¾Ç¡]Middlebury College¡^§ðŪ¯«¸g¬ì¾Ç¡A¨Ã¦b§ù§J¤j¾Ç¡]Duke University¡^±q¨Æ¯«¸g¥Íª«¾Ç¬ã¨s¡C ¦b¨ä¥L¤è±¡A¥L¤w«Øij¼ÚY¹êÅç«Ç¡]Aurolab¡^¬°¥Õ¤º»Ù¥¢©ú¬ãµo©Ú¤ô©Ê¤þ²m»ÄÃè¤ù¡]hydrophobicacrylic lens¡^¡A¨Ã¨ó§Uµo®i¨¦ºqªºCalicopµe¡C Calico¬O¨¦ºq»PÄ«ªG¡]Apple¡^2013¦~³Ð¥ßªº¬ãµo¤½¥q¡A¥Øªº¦bªvÀø¦Ñ¤Æ¬ÛÃö¯e¯f¡C ¨¦ºq¦@¦P³Ð¿ì¤H¨Ø¦N¡]Larry Page¡^»¡¡A³o¶µpµe±N°¼«©ó¡u°·±d¡B©¯ºÖ»Pªø¹Ø¡v¡CCalico¥h¦~9¤ë»PªÛ¥[ôÃÄ«~ÀsÀY¤½¥qAbbVie¦X§@¡A¶}³]¯«¸g¨t²Î°h¤Æ¯g»PÀù¯g¬ã¨s¤¤¤ß¡C ³o¨Ç¤½¥q±j½Õ¦ÛµM©µªø¹Ø©R¡A¤£¹LÁÙ¦³¤@Ó¹ÎÅé¬Û«H¾÷¾¹±N¬OÅý¤H¬¡¨ì¶W¹L120·³ªºÃöÁä¡C¾Ú°O¸ü¡A120·³¬O¡u¤HÃþ¹Ø©Rªº¯u¥¿µ´¹ï·¥¡v¡C ¨¦ºq¤uµ{Á`ºÊ¡B¤]¬O°¨·ç´µªº¦P¨Æ®w¯ýÃQº¸¡]RayKurzweil¡^¤§«eªí¥Ü¡A¦b30¦h¦~¤º¡A¤HÃþ±N¥i§â©Ò¦³°O¾Ð¤º®e¤W¶Ç¨ì¹q¸£¡AÅܦ¨¼Æ¦ìªø¥Í¤£¦º¡A³oºØ²{¶HºÙ¬°©_ÂI¡]singularity¡^¡C ®w¯ýÃQº¸¥h¦~¦b¯Ã¬ùªº¥þ²y¥¼¨Ó2045°ê»Ú·|ij¡]Global Futures 2045 International Congress¡^ÁnºÙ¡A¤HÃþ¨Å骺¥Íª«³¡¦ì±N³Q¾÷±ñ¹s¥ó¨ú¥N¡A³o³Ì§Ö¥i¦b2100¦~¹ê²{¡C |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/3/11 ¤U¤È 12:11:37²Ä 208 ½g¦^À³
|
¬ü°êªº Stellar ¥Í§Þ¤½¥q(OTCQB: SBOTF) (TSX VENTURE: KLH)µy¦µo¥¬·s»D¡A²Ä¤@´Ú¥HKLH¬°°ò¦ªº§K¬ÌªvÀø»s¾¯Àò±oFDA¬ð¯}©ÊªvÀøªº»{ÃÒ¡A¥Î©óªvÀøEGFRvIII-positive glioblastoma¡]¤@ºØ°ò¦]EGFRÅܲ§«¬EGFR v3¶§©Êªº´c©Ê¸£½F¦h§Î©Ê½¦½è¥À²ÓM½Fglioblastoma multiforme¡G¬ù¦û³oºØ¸£Àùªº30%¡^¡A¥Ø«e¥ÑCelldex¡]NASDAQ:CLDX¡^¤½¥q¦b¥þ²y200Ó°ê®a¦¬®×342¦ì¸g¶EÂ_«á±µ¨ü¼sªx©Ê¥þ¤Á°£¡]Gross total Resection¡^ªº±wªÌ¶i¦æÀH¾÷Âùª¼Phase IIIÁ{§É¸ÕÅç¡A¥N¸¹ACT IV¡C¬Ý¬Ýrindopepimut+GM-CSFªº°t¤è¬O§_Àu©ó²{¦æ¼Ð·ÇÀøªktemozolomide+KLH¡CKLH¬Orindopepimutªººc¦¨¤¸¯À¤§¤@¡C¥Dn«ü¼Ðª½±µ³]©w¬°overall survival¡A¦¸n«ü¼Ð¤~¬OPFS¡C¡]http://www.stellarbiotechnologies.com/media/press-releases/detail/314/first-fda-breakthrough-therapy-designation-for ¡^ ¡u¦h§Î©Ê½¦½è¥À²ÓM½F(glioblastoma multiforme)¬O¤j¸£³Ì±`¨£ªº´c©Ê¸~½F¡A¤]¬O¤£§é¤£¦©ªº¸£Àù¡A¦p¶È¨Ï¥Î¤â³NªvÀø¡A¤¤´Á¦s¬¡¶È¦³3-4Ó¤ë¡F¥[¤W¤â³N«á©ñ®gªvÀø¡A¥i©µªø¦Ü10Ó¤ë¡F¥[¤â³N«á©ñÀø¤ÎBCNU¡A¥i±N¤¤´Á¦s¬¡¦A©µªø¤@ÂI¦Ü¤@¦~¡A¦ý¬O¤¦~¦s¬¡²v¤@¯ë¤´¬°¹s¡C¥Ñ©óÀø®Ä¹ê¦b«Ü®t¡A«K¦³³\¦h¾ÇªÌ¹Á¸Õ¦UÃþ«D¶Ç²Îªº·sÀøªk¡C¡K¡K¡v¡]ºK¿ý¦Ûhttp://wwwu.tsgh.ndmctsgh.edu.tw/rtd/internet/Cancer_2_11.htm ¡^§Úªº¤j¾Ç³Ð°|®Õªø´N¬O¿©±w³oºØµ´¯g¦ÓÃã¥@¡C PennÃļt¥ç°w¹ï³oÓ¸£Àù¬ãµoCAR-T§K¬ÌÀøªk¡A¤w§¹¦¨Á{§É¤@´Á¡C¡]http://www.crownbio.com/car-t-immunotherapy-revs-glioblastoma/ ¡^ Celldex¤½¥qÁÙ¦³¥t¤@Ó¬ãµo¤¤²£«~¥Î©ó¤T³±©Ê¨ÅÀù¡A2013¦~12¤ë±Ò°ÊÁ{§É¤T´Á¡A¥N¸¹METRIC¡A¨Ï¥ÎGlembatumumab vedotin (CDX-011)¨Ó°w¹ï¤@ºØÁÞ³J¥ÕNMB¡]GPNMB¡^ªº³Q°Ê§K¬ÌÀøªk¡A¨ä²Õ¦¨¬Oµ²¦X°w¹ïGPNMBªº§ÜÅéCR011»P¤@Ó±j¤O¤Æ¾ÇÃĪ«monomethyl auristatin E (MMAE)¦¨¬°§ÜÅéÃĪ«½Æ¦Xª«¡]ADC¡^¡C¦b¥¦ªº¤G´Á¸ÕÅ礤¡A¤T³±¨ÅÀù¥BGPNMB°ª«×¶§©Êªº±wªÌ¡AOS¡G¹êÅç²Õ¡G¹ï·Ó²Õ¡×10.0¡G5.2 months¡C¡]http://www.celldex.com/pipeline/cdx-011.php ¡^ «á°O¡G 1.Stellar¤½¥q¥ç¨ÑÀ³¯E¹©OBI-822©Ò»ÝªºKLH¡C¤U¤@Ó§t¦³KLH¦Ó¨ú±oFDA¬ð¯}©ÊªvÀø»{ÃÒªº§K¬Ì»s¾¯¡A§Æ±æ¬OOBI-822¡C 2.¨Ì¾Ú³o¦¸ªk»¡·|¤¤¶ÀÁ`©Ò´£¨ÑªºÂ²³ø¡A¸£Àù¤¤ÁÞ§Üìªí²{²vGH¡G35¢M¡ASSEA-3¡G53¢M¡ASSEA-4¡G71¢M¡A©Ò¥HGlobo H¨t¦Cªº²£«~À³¸Ó³£¦³®Ä¡C¥u¬O¥«³õ¼ç¤O¸û¤p¡A¯Ç¤J³o¶µ¾AÀ³ÃÒªº³W¹º®£©È¬O«Ü¤[¥H«áªº¨Æ¡C 3.§Æ±æOBI-822ªvÀø¤T³±¨ÅÀùªºÀø®Ä¡A¬O¶}ª¼«áªº«GÂI¤§¤@¡C ¥H¤W°T®§¨Ñ§@°Ñ¦Ò¡A¦³»~½Ð«ü¥¿¡C |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/1/26 ¤U¤È 02:54:21²Ä 207 ½g¦^À³
|
¸ò«e´X¦¸¤@¼Ë¡A¤¤¬ã°|ÁÞ´¹¤ù¦b³o¦¸ªº¸V¬y·P¬Ì±¡¤¤¡u¦A¦¸¡v§Ö³tŲ©w¯f¬r®è Âà¸ü¦ÛÄ«ªG¤é³ø¡G2015/01/26 ¡u¤¤¬ã°|¥HÁÞ´¹¤ù´ú¸V¬y·P¯f¬r¡@2¤p®É·d©w¡v ¡u¤¤¥¡¬ã¨s°|¤µÁ|¦æ·s¿³¶Ç¬V©Ê¯e¯f°ê»Ú¬ã°Q·|¡A¦h¦W°ê¤º¡B¥~·P¬V¯g±M®a¨ì³õ¥æ¬y©¼¦¹¾Ç³N¬ã¨s¡A¥xÆW¥Ø«eªº¸V¬y·P¬Ì±¡¤]¦¨¬°µJÂI¡A¸Ó°|°|ªø¯Î±Ò´f¤]µoªíÁÞ´¹¤ù¹B¥Î©óÀË´ú¸V¬y·P¯f¬rªºªì¨B¦¨ªG¡A쥻½T»{H5N2¯f¬rÄݧC¯fì©Ê©Î¯fì©Ê¡A¶Ç²ÎÀËÅç¦Ü¤Ö±oªá6¤p®É¤~±o¨ìµ²ªG¡AÁÞ´¹¤ù¶È2¤p®É§Y¥i·d©w¡C ¯Î±Ò´fªºÁÞ´¹¤ù¬ã¨s²`¨ü°ê»ÚªÖ©w¡A°w¹ï¨äì²z¡A¤¤¬ã°|°ò¦]Åé¬ã¨s¤¤¤ß°Æ¬ã¨sû§d©v¯q¸ÑÄÀ¡A¸Ó´¹¤ù¤W¸ü¦³µL¼Æµ²ºc¤£¦PªºÁÞ¤À¤l¡A¥Ñ©ó¯f¬rn·P¬V±J¥D²ÓM¡A³£±o¥ý±q·P¬V±J¥DªºÁÞ¤À¤l°_¨B¡A©Ò¥H¥un§â¯f¬r©ñ¦b´¹¤ù¤W¡A¦AÆ[¹î¯f¬r»PÁÞ¤À¤lµ²¦Xªº±¡§Î¡A§Y¥i§PÂ_³o¬Oþ¤@ºØ¯f¬r¡C §d©v¯q»¡¡A¦b³oªi¸V¬y·P¬Ì±¡¤¤¡AH5N2¯f¬r¦û«n¨¤¦â¡A¨ä¤À¬°°ª¡B§C¯fì©Ê ¨â¤jÃþ¡AY¯à§Ö³tÀËÅç¨äÄÝ©óþ¤@Ãþ¡A¹ï©ó±±¨î¬Ì±¡ÂX´²·|¦³À°§U¡FÁÞ´¹¤ù¬ã¨s¹Î¶¤¦¹«e±q¹A©e·|¨ú±o7®è¨ú¼Ë¦Û¾iÂû³õªº¯f¬r®è¡A¨Ã¹B¥ÎÁÞ´¹¤ùÀËÅç¡Aµ²ªG¦b2¤p®É¤º§Y¥i¤ÀªR¥X¨äÄÝ°ª¡B§C¯fì©Ê¡A¦Ó¶Ç²ÎÀËÅç³Ì§Ö¤]±o6¤p®É¡AY¤S¦³¨ä¥L¦]¯À¤zÂZ¡A¨Ò¦pÀËÅç§Þ³N¤£°÷¯Â¼ôµ¥¡A¬Æ¦Ün3¤Ñ«á¤~±o¨ìµ²ªG¡C ¹ï©óÁÞ´¹¤ùÀËÅç¸V¬y·P¯f¬r¡A§d©v¯qªí¥Ü¡A¥Ø«e¶ÈÄݪì¨B¦¨ªG¡A¥¼¨ÓÁٻݦ¬¶°§ó¦h¯f¬r®è¤~¯à½T»{ÀËÅç·Ç½T«×¡F¥L¤]»¡¡A¤é«áY¯à«ùÄòÂX¥R¡B¾ã²zÁÞ´¹¤ù¤W¦UºØ¯f¬r»PÁÞ¤À¤lµ²¦Xªº«¬ºA¡A¸Ó´¹¤ù¥i±æ¦¨¬°¡u¯f¬r¦Ê¬ì¥þ®Ñ¡v¡A¦³§UÁ{§ÉÂå®v¯à¥Î³Ì§Ö®Ä²vŲ©w¯f¬rºØÃþ¡B¨³³t¹ï¯g¤UÃÄ¡C ¦¹¥~¡A³õ¥~¤]¦³¤@¬q¤p´¡¦±¡A°ê¤º¸V¬y·P¥¿¬y¦æ¡A¬ã°Q·|·Ç³ÆªºÀ\ÂI¡A¶È¦³½Þ¡B³½¡B½µæµ¥¥D¹¡A¤]¥¿¦n§¹¥þ¨S¦³¸VÃþ¦×«~¡A¸Ó°|¤u§@¤Hû»¡¡Aˤ£¬O©È¤H¦Y¸V¦×¡A¥u¬O¦]·sÂA¸V¦×³Ìªñ¸ûÃø¨ú±o¡A©Ò¥H¥¼·Ç³Æ¡C¡]ªô«T¦N¡þ¥x¥_³ø¾É¡^¡v |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/1/13 ¤W¤È 08:59:21²Ä 206 ½g¦^À³
|
¤¤¬ã°|¶}µo¡uÀù¯g®·¤â¡v µo½Z®É¶¡¡G2015/01/12 10:23 ¡]http://www.cna.com.tw/news/firstnews/201501120076-1.aspx ¡^ ¡]¤¤¥¡ªÀ°OªÌ³\¯´ºû¥x¥_12¤é¹q¡^¤¤¬ã°|¸ó°ê¬ã¨s¹Î¶¤§Q¥Î©`¦Ì§Þ³N¡A¶}µo´`Àô¸~½F²ÓMµÑ¨ú¨t²Î¡A¯à±q¦å²G¼Ë«~¤¤µÑ¨úÀù²ÓM¡AºÊ´ú¼Æ¶qÅܤƩM¯S©Ê¡A¦³§U¯f±¡¯f±¡°lÂÜ¡Bµû¦ô¹w«á±¡§Î¡C ¤¤¥¡¬ã¨s°|°|¤Æ¾Ç¬ã¨s©Ò°Æ¬ã¨sû¤×¼SµØ¡B¬ü°ê¥[¦{¤j¾Ç¬¥§üÁF¤À®Õ¤À¤lº[ÃIJz¾Ç¨t±Ð±Â´¿¾Ëºa¡B¤é¥»²z¤Æ¾Ç¬ã¨s©Ò²Õ¦¨ªº¬ã¨s¹Î¶¤¡A¬ãµo´`Àô¸~½F²ÓMµÑ¨ú¨t²Î¡A¥i¥Î©ó«áÄò²ÓM°ö¾i»P°ò¦]¬ðÅܤÀªR¡A¬ã¨s¦¨ªG¥Zµn¦b°ê»Ú´Á¥Z¡u¬ü°ê¤Æ¾Ç·|©`¦Ì(ACS Nano)¡v¡C ¬ã¨s¹Î¶¤ªí¥Ü¡AÂå¥Í¶EÂ_Àù¯g®É¡A°£¤F¨Ì¾a²z¾ÇÀˬd»P¼v¹³¾ÇÀˬd¡AÁٻݲÓM¾Ç©Î¯f²z¾ÇÀˬdªºÀ°§U¡A¨Ó°§C»~¶E²v¡F¦Ó¶Ç²Î¤W±Ä¨ú¬ï¨ë¡B¤Á¤ù»P¤â³Nµ¥«I¤J©Ê¤è¦¡¨ú±o²ÓM©Î²Õ´¼Ë«~¡A·|¹ï±wªÌ¨Åé±a¨Ó¸û¤jt¾á¡A¥B±Ä¼ËÀW²v¤]¨ü¨î¡C ¬°ÁקK¶Ç²Î«I¤J©Ê±Ä¼Ëªº¯ÊÂI¡A¬ã¨s¹Î¶¤ªí¥Ü¡A¥i³z¹L«D«I¤J©ÊªºÀËÅç¤è¦¡¡A¨Ó¤ÀªR¦å²G¤¤ªº´`Àô¸~½F²ÓM¡A³z¹LºÊ±±´`Àô¸~½F²ÓMªº¼Æ¶qÅܤƤΨä°ò¦]¯S©Ê¡Aµû¦ô¹w«á±¡§Î¡B¤Ï¬MÀø®Ä¡B°lÂܯf±¡»P¹w´ú´_µo·ÀI¡C ¬ã¨s¹Î¶¤§Q¥Î¼öÅTÀ³©Ê©`¦ÌÅ]°ÀÖ´¹¤ù¡A¶}µo´`Àô¸~½F²ÓMµÑ¨ú¨t²Î¡A³z¹L¼öÅTÀ³¯S©Ê¡A§ÜÅé»P¸~½F²ÓMªº±µÄ²µ{«×·|³s±a¤j´T§ïÅÜ¡A¥iÂǦ¹¤Á´«°ª/§C·Å±±¨îÅ]°ÀÖ®·®»©MÄÀ©ñ´`Àô¸~½F²ÓM¡A¦P®É¾ã¦X·Å±±¨t²Î¡B·L¬y¹D§Þ³Nµ¥¡A«Øºc´`Àô¸~½F²ÓMµÑ¨ú¨t²Î¡C ¬ã¨s¹Î¶¤ªí¥Ü¡A¸gµÑ¨ú«áªº¸~½F²ÓM¦s¬¡²v°ª¨Ã«O¦³§¹¾ã©Ê¡A¯à¥Î©ó¤§«áªº²ÓM°ö¾i»P°ò¦]¬ðÅܤÀªR¡F¦bÀù¯gªvÀø¹Lµ{¤¤¡A¸~½F²ÓM·|¤@ª½ÀH¥Í²zÀô¹Ò¦ÓÅܤơA³z¹LµÑ¨ú¨t²Î¯à´x´¤¸~½F²ÓMªº¥Í²zª¬ºA¡A¨ó§U´x±±«D¤p²ÓMªÍÀù±wªÌ¯fµ{¶i®i¤ÎªvÀøÃĪ«ªº¿ï¾Ü¡C ³oÓ·s»D¸ò¥ý«e¶K¹Lªº³o¤@«h¡A¤£ª¾¹D¬O¤£¬O¦P¤@¥ó¨Æ¡H¤W¤@«h½Í¤å³¹¥Zµn¡A¤U±³o¤@«h½Í§ÞÂà¡C¤£¹L³£¬O»EµJ¦b¦å²G¼Ë¥»¤¤¤Q¤Àµ}¤Öªº¸~½F²ÓM(circulating tumor cells, CTC)¡C ¡uÀù²ÓM®·¤â¡v¦¨¥\§ÞÂà 2014-11-14 ¡]http://www.genomics.sinica.edu.tw/index.php/tw/news/lastest-news/438-2014-11-14-03-46-45¡^ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/1/9 ¤U¤È 01:13:02²Ä 205 ½g¦^À³
|
OBI822§Z±_Àù§C°Æ§@¥Î»P°ª@¨ü©Ê»á¦³Ävª§¤O Lynparza (olaparib)§Z±_ÀùÃÄ ÄY«¤j°Æ§@¥Îĵ§i: http://www.drugs.com/lynparza.html 1 Lynparza may cause serious side effects that can lead to death,ÄY«°Æ§@¥Î¥i¯à¾ÉP¦º¤` including:¥]¬ABone marrow problems called Myelodysplastic Syndrome (MDS) °©Åèµo¨|¤£¨}¯gÔ¸s or Acute Myeloid Leukemia (AML)«æ©Ê°©Åè©Ê¥Õ¦å¯f 2 Symptoms of low blood cell counts are common during treatment, but can be a sign of serious bone marrow problems, including MDS or AML. MDS°©Åèµo¨|¤£¨}¯gÔ¸s»P AML«æ©Ê°©Åè©Ê¥Õ¦å¯f Symptoms may include: ¯gª¬¦p¤U weakness , weight loss , fever, frequent infections ,blood in urine or stool(¦å§¿ ¦å«K) shortness of breath ©I§lµu«P, feeling very tired bruising or bleeding more easily ®e©ö·ï¦å ¥X¦å Your healthcare provider will do blood tests to check your blood cell counts: before you start treatment ªvÀø«e¶·´ú¦å²y¼Æ 3 Lung problems (pneumonitis)ªÍª¢ . Tell your healthcare provider if you have any new or worsening symptoms of lung problems, including shortness of breath, fever, cough, or wheezing. Your healthcare provider may do a chest x-ray if you have any of these symptoms. ¦³¯gª¬¶··Ó¯Ý³¡X¥ú |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/1/9 ¤W¤È 11:57:48²Ä 204 ½g¦^À³
|
¦U¦ì¤j¤j ª¾¤vª¾©¼ ¦Ê¾Ô¦Ê³Ó The FDA¡¦s approval is based on Phase II data in which the drug charted a 34% objective response rate for an average of 7.9 months. Treatment with olaparib also led to progression-free survival (PFS) of 11.2 months versus 4.3 months on placebo. Lynparza (olaparib); AstraZeneca; For the treatment of previously treated BRCA mutated advanced ovarian cancer, Approved December 2014 (fda 2014 ) Olaparib Àø®Ä: 1 Olaparib «ÈÆ[¤ÏÀ³²v34%¡]ORR¡^¤¤¦ì½w¸Ñ«ùÄò®É¶¡¬°7.9Ó¤ë¡C»P¦w¼¢¾¯¬Û¤ñ¡Aolaparib µL¯e¯f¶i®i¥Í¦s´ÁPFS¡G11.2Ó¤ë vs 4.3Ó¤ë¡A¤G´ÁÁ{§É¬ã¨s¥H¦Ü¤Ö3¦¸¤ÆÀø¥¢±ÑªºBRAC°ò¦]¬ðÅܱߴÁ§Z±_Àù±wªÌ137¤H¬°¹ï¶H, 2 ¤µ¦~µy¦ªü´µ§Q±d¹ïolaparib±H¤©«p±æ¡A»{¬°¸ÓÃĪº¦~¾P°âÃB±N¬ð¯}20»õ¬ü¤¸¦]¦¹©Úµ´½÷·ç1140»õ¬ü¤¸¨ÖÁÊ 3 OBI-822 §Z±_Àù¥Ø«e¶i«×(¨Ì¨Ìªñ´Á¤WÂd»¡©ú®Ñ) ¦Û102 ¦~10 ¤ë»P°¨¶¥Âå°|¦X§@OBI-822 §Z±_ÀùÁ{§É¤G´Á¡A³z¹L¦¹Á{§É¤G´Á¦¬¶°¤§¨ã°Ñ¦Ò»ùȪº¼Æ¾Ú¡A¥xÆW¯E¹©ÀÀ©óµu´Á¶¡¦V¥_¬ü¡B¼Ú¬w¤ÎªF¨È¦a°Ï¤§·sÃÄ¥DºÞ¾÷Ãö¥Ó½Ð¶i¦æÁ{§É¤T´Á¸ÕÅç¡A¥H¥[³t¤½¥q²£«~©ó§Z±_Àùªº¬ãµo³t«×¡C¬ã§Pµu´Á·|¥[³t±À¥X¤T´ÁÁ{§É¸ÕÅç(¤G´ÁÀ³¦³¬ì¾Ç¤WÁ{§Éªºµo²{) 4OBI-822 §Z±_ÀùÄvª§Àu¶Õ:(¨Ìªñ´Á¤WÂd»¡©ú®Ñ) ¥Ø«e¥þ²y©|¥¼®Öã¥ô¦ó¤@Ó§Z±_Àù¥D°Ê©ÊÀù¯g§K¬ÌÀøªk(Àù¯gªvÀø©Ê¬Ì])¡A¦]¦¹OBI-822 ¦b¥«³õ¤WµL¬ÛÃþ¦ü¤§²£«~¡A¤Z¬O Globo H§Üì§e¶§©Êªº±wªÌ³£¥i±µ¨üOBI-822 ªvÀø¡A¤j¬ù¥e¤F§Z±_Àù±Ú¸sªº50%~90%¥H¤W¡COlaparib ¾A¥Î¹ï¶HBRAC°ò¦]¬ðÅܱߴÁ§Z±_Àù±wªÌ,¤j¤jÁY¥«³õ³W¼Ò 5 ¥¼¨ÓOBI-822 §Z±_Àù PFS »P «ÈÆ[¤ÏÀ³²vORR ·|¤£·|¤ñ Olaparib Àu²§ ¤j®a«ø¥Ø¥H«Ý ^¤åì¤å¡GAstraZeneca grabs a surprise early approval for its $2B cancer contender ¥H¤W²L¨£ ´£¨Ñ¦U¦ì¤j¤j°Ñ¦Ò ¦p¦³¿ù½Ð´£¥X§ó¥¿«Øij |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2015/1/9 ¤W¤È 11:40:24²Ä 203 ½g¦^À³
|
JM¤j¾ã²z¤½¶}»¡©ú®Ñ¡B¤Þ¸g¾ÚÂIªº³t«×»P¥\¤O¥X²³ ±aÀY¤jô¦b¡m¤ÑÀs¤K³¡¡nùؾÉP¤F¦¿´òªº¯É¶Ã¡A ¦ý»P¯Eô³Ì«á±N¤@²Î¦¿´ò¡A¬G¨Æµ²§½¦ü¥G¤£¤Ó²Å¦X ®e¤p§Ì¦¬¦^±aÀY¤jô¤@Ãã¡A§ï¥Î¤j®v¡C |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/1/9 ¤W¤È 11:18:11²Ä 202 ½g¦^À³
|
Cliff¤j «D±`«D±`«D±`.....·PÁÂ+1 ¤p§Ì²`²`¤@Áù°` |
|
|
·|û¡GJM10139061 µoªí®É¶¡:2015/1/9 ¤W¤È 11:16:00²Ä 201 ½g¦^À³
|
¸ô¤H¶Ã¤J, ·i§g¤@¯º^^ http://baike.baidu.com/view/992550.htm ±aÀY¤jô ±aÀY¤jô¬Oª÷±e§@«~¡m¤ÑÀs¤K³¡¡n¤¤ªº¤@Ó¤Hª«¨¥÷¡A´¿±a»â´¼¥ú©M©|¡B»¯¿ú®]µ¥¤H¥ñÀ»«´¤¦ªZ¤h¦Ó»~±þ¿½»·¤s¡]¿½®p¥Í¤÷¡^¤Ò°ü¤Î±Ú¤H¡A¦]¦¹¿½®p¥ß§Ó¬d¥X¦¹¤H¨¥÷¡A¥²±þ¤§¥H³ø¤÷¥À¤j¤³¡C¤@¶}©l±d±Ó°²»¡¬qÅAªº¤÷¿Ë¬q¥¿²E¬O¡§±aÀY¤jô¡¨¡A¨Ã¾ÉP¿½®p»~±þªü¦¶¡C³Ì²×¦b¤ÖªL¦x¯u¬Û¤j¥Õ¡Aì¨Ó±aÀY¤jôªº¯u¹ê¨¥÷¡A³ºµM¬O¤ÖªL¤è¤V¥È·O¤j®v¡C |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2015/1/9 ¤W¤È 11:04:27²Ä 200 ½g¦^À³
|
Cliff¤j¡A ±z²W³Õªº¾ÇÃÑ¡B¿¦±Kªº«äºû¡BµL¨pªº¤À¨É¡A °£¤F²q·Q¤j¤§«e´¿»¡¹L¡A¦b¯E¹©ªO¤W±z¬O±Ð±Â¡A±a»â§Ú̳o¤@¸s¾Ç¥Í¤@¿sÁÞ¬ì¾Çªº¶ø±K¥~¡A®e¤p§Ì¦b¦¹¥i¥H´LºÙ±z¬°¯E¹©ª©ªº±aÀY¤jô¡I(§ë¸ê·ÀIÁÙ¬On¦Û¤vt³d) ¯E¹©ª©¤W¬yÄýªÌ²³¡A©Î³\¤´¦³·¥¤Ö¼Æ¹³±z¤@¼Ë¾Ö¦³²W³Õªº¾ÇÃÑ¡B¿¦±Kªº«äºûªº§ë¸êªÌ¦bª©¤W¥uÆ[¤£»y¡A¦ýÄ@§â¦Û¤vªº±M·~¤Î¥Î¥\©Ò±o¸ò¤j®a¤À¨ÉªÌ¡ACliff¤j±zµL¤H¥X¨ä¥k¡AÅý¤p§Ì¦b¦¹P¤W³Ì¤jªº·q·N¡A³o¤]¬O¤p§Ìªñ¨â¦~¨Ó§ë¸ê¯E¹©¡A°£¤Fª÷¿ú¦¬¤J¤§¥~¡A³Ì¤jªº¦¬Ã¬¡A·íµM¤]¬Û·í·PÁ¨䥦¼ö¤ßªº¡A¥Î¥\ªº¡BµL¨p¤À¨Éªº¦U¦ì¤j¤j¡I |
|
|
·|û¡GJM10139061 µoªí®É¶¡:2015/1/9 ¤W¤È 10:55:51²Ä 199 ½g¦^À³
|
103/12/26ª©¥»¦@402pages, 104/01/06ª©¥»¦@440pages, Diff.=38pages 103/12/26ª©¥»¦@¨â¥÷·|p®v®Ö¾\³ø§i®Ñ, 102/4/10(p246-270, 25pages), and 103/03/26(p271-313,43pages) 104/01/06ª©¥»¦@¤T¥÷·|p®v®Ö¾\³ø§i®Ñ, °£¥H¤W¨â¥÷, ·s¼W103/11/14(p246-283,38pages) ©Ò¥H¥»¦¸"²{ª÷¼W¸ê¤½¶}»¡©ú®Ñ½Z¥»"update¥Dn¬° 1.·s¼W103/11/14·|p®v®Ö¾\³ø§i®Ñ(38pages) 2.¤½¶}»¡©ú®Ñ¤¤¬ÛÃö°]·|³øªí¤§update(²Îp®É¶¡Åܧó) |
|
|
·|û¡G±Û«a10139522 µoªí®É¶¡:2015/1/9 ¤W¤È 10:23:03²Ä 198 ½g¦^À³
|
Cliff¤j¡A±zµL¨pªº¥Î¤ß°^Äm¥»ª©¡A¯«¤H¯Åªº«äºû¡A±R«ôªº¤ß¥Ñ°J¤É°_¡A·P®¦¦A·P®¦¡I |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/1/9 ¤W¤È 09:53:59²Ä 197 ½g¦^À³
|
Nice JM¤j¡I S.F¤j¡A±z¨¥«¤F¡C ®e¤p§Ì´À±z×¥¿¤@¤U¡A¯u¥¿¡u¦Ê¦~Ãø±o¤@¨£¡B»õ¤¤¿ï¤@¡vªº¡A¦b¾Ç¬É¬O¯Î°|ªø¡F¦b·~¬É´N¬O¯E¹©¡A¥H§ë¸ê¨¤«×¦Ó¨¥¡A¥u¦³¥¦¬Oȱo¤j®a¥h»EµJªº¡A¨ä¾lªº¨Æ±¡²Î²Î³£¬O¹L²´¶³·Ï¡C «e¤Ñ°|ªø¦]À³¤p§Ìªº¨DÃÒ¡A»¡MSKCCªº²Ä¤@´Á¸ÕÅçµ²ªG´N¤w¸g«Ü¥¿±¡A¤]¦A¦¸´£¨ì¤F¥HGH¨t¦C¤TÓÁÞ§Üì¦b¨ÅÀù±wªÌªºªí²{²v¥i°ª¹F¡u98¢H¡v¡A¡u©Ò¥H¤£¥²¨Æ¥ý°µcompanion test¡K¡K¡v¡K¡K¡u¦ý¦bªÍÀùªº³¡¤À´N¨S¦³¨º»ò°ª¡A¯à¨Æ¥ýÅç¤@¤U¬O¤ñ¸û¦n¡K¡K¡v ¦^·Q¤@¤U¡A¤¤¬ã°|ÁÞ´¹¤ù¬O¦b2008¦~6»P7¤ë¥Ó½Ð¬ü°ê±M§Q¡F¤ÀªR¨ÅÀù²Õ´¤¤ªºGH¡BSSEA-3§t¶q³Ì¦h½g´Tªº¨º½g¡uwww.pnas.org/cgi/doi/10.1073/pnas.0804979105 ¡v¤]¦b2008¦~8¤ë´N¥Z¸ü¡FGH-DT/C34¬O¦b2009¦~8¤ë¥Ó½Ð±M§Q¡F¦Ó822ªº²Ä¤G/¤T´Á¸ÕÅç«h¿ð¦Ü2010¦~¤U¥b¦~¤~¶}©l¡A©Ò¥H«Ü¥i¯à¤½¥q¤è±·í®É´N¤w¸g¬ã§P¦¨¥\¾÷·|«Ü¤j¡A¥u¬O½Õ¾ã¤F¾¯¶q¡A¨S¦³ªþ¥[¥ýÅçGHªº°Ê§@¡A¦p¦¹¡AÃþ¦üTheratope¦bÁÞ§Üìªí²{²v°¾§C¤Î¸ÕÅç¤ÀÃþ¤W¤£¨ÎªºÅU¼{¡AÀ³¸Ó¬O¤£¥²¾á¤ß¡C¦pªG¦A§â²Ä¤G/¤T´Á¸ÕÅç³sµÛ¤@°_pµe¡F¤T´Á¸ÕÅç¹Lµ{¤¤´c¤Æ¤H¼Æ«Ü¤Ö¡A¥O¤½¥qÀY¤j¡]ªÑªF·|´²·|«áÅ¥¨ìªº¡^¡F«á¨Ó±i¸³¹ï´CÅé´£¨ì¤WÂd«e¤£¥²´Á¤¤¤ÀªR¡K¡Kµ¥¡A¦A¥[¤WMrs Serenityªº®×¨Ò¡B£«¬Â¤jªº¤À¨Éµ¥µ¥¡FÀ³¸Ó¶i¤@¨B»¡¡A¹ï´²¤á¦Ó¨¥¡A±q±µÄ²¶}©l¡A¨C¦h¥X¤@¶µ·s¶i®i®É¡A¤ß¸Ìªº·Pı³v¦¸·|¬O¡u¥i¯à¦³®Ä¡K¡KÀ³¸Ó·|¦³®Ä¡K¡K¦n¹³¯uªº¦³®Ä¡K¡KÁÙ¯uªº«Ü¦³®Ä¡K¡K¡v¡A¦ý¦b¤½¥qªº·Pı«o¥i¯à¬O¡u²Å¦X¹w´Á¡K¡K²Å¦X¹w´Á¡K¡K²Å¦X¹w´Á¡K¡K¡v¡A¦b·sÃÄ°ª·ÀIªº¬ãµo¹Lµ{¤¤¡A¥L̤w¸g¾¨¥i¯à¦a§â·ÀI°¨ì¤@Ó¬Û¹ï¦a§C·ÀIªº±¡ªp¤U¡A°µ¬Û·í¦³§â´¤ªº¨Æ¡A¦p¦¹§Y¨Ï³B©ó¿³Âd¡A§Y¨Ï¤´³BÁ«·l¡A¬Û¹ï·ÀI¤w¸g¤p«Ü¦h¡A¥u¬O¤½¥q§@·§C½Õ¡A¿ï¾ÜÅý®É¶¡¥h°µ³Ì«áªº»¡©ú¡C ¥H¤W¿Ä¦XÓ¤H§PÂ_¡A¤£¬°«P¾P¡A¥u°µ¤ÀªR°Q½×»P°Ñ¦Ò¡A³Ì²×µ²½×°ß¸Ñª¼µ²ªG¬O¤¡C Companion diagnostic test¡G 2014/12/19 FDA®ÖãLynparzaÃÄÃҥΩóªvÀø¥½´Á§Z±_Àùªº¦P®É¡A¤]ªþ±a®Öã¤Fªº¤@¶µªvÀø«eªº¦ñÀH©Ê¶EÂ_ÀËÅçBRACAnalysis CDx¡A¥Î¨Ó¥ýÀËÅç±wªÌ¬O§_¨ã¦³¯Ê³´ªºBRCA°ò¦]¡A¥H¨M©w¬O§_¾A¥ÎLynparzaªvÀø¡C ¦b¦¹¤§«eBRACAnalysis CDx¥u¬O¤@¶µ¥u¯à¥Î©ó³æ¤@¹êÅç«Çùتº¬ã¨s©Ê½èÀËÅç¤u¨ã¡A²{¦b¤w³Q®Ö㬰¤@ºØLDT¡]laboratory developed test ¡^¡A¥i¼sªx¥Î©óªvÀø«eªºÀËÅç¡A¦Ó¥B¤]¬O²Ä¤@Ó³QFDA®Ö㪺¦ñÀH©Ê¶EÂ_ÀËÅç¡C ¡u¡K¡Kthe BRACAnalysis CDx is the FDA¡¦s first approval of an LDT under a premarket approval application and is the first approval of an LDT companion diagnostic.¡v §Æ±æ¤U¤@Ó®Ö㪺¬OOBI-868¡C ì¤å½Ð¬Ý¡G ¡uFDA approves Lynparza to treat advanced ovarian cancer¡vDecember 19, 2014 ¡]http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427554.htm¡^ |
|
|
·|û¡GJM10139061 µoªí®É¶¡:2015/1/9 ¤W¤È 08:55:30²Ä 196 ½g¦^À³
|
p216 ·Ç«h¤Î¸ÑÄÀ p225 ¤»¡B«n·|p¶µ¥Ø¤§»¡©ú p235,236 ¨CªÑÁ«·l ¥Ø«e¬Ý¨ìªº¦h¬°°]·|¼Æ¦rªºupdate(²Îp®É¶¡Åܧó) |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/1/9 ¤W¤È 08:11:09²Ä 195 ½g¦^À³
|
·s¸ê®Æ 2015/1/6¤½¥q¤S¤W¶Ç¤F¤@¥÷¡u104/1/6»ù®æ¼È©wª©-¦Û¦æ¸É¥¿¡vªº²{ª÷¼W¸ê¤½¶}»¡©ú®Ñ½Z¥»¡AÀɮפj¤p¤ñ103/12/26ªºª©¥»¤j¤F¤@¨Ç¡Aþ¦ì¤j¤j¦ò¤ß¥h¬Ý¬Ý¦h¤F/§ï¤F¬Æ»ò¤º®e¡H |
|
|
·|û¡G¦³FUªº¤H10136189 µoªí®É¶¡:2015/1/8 ¤U¤È 06:04:03²Ä 194 ½g¦^À³
|
¯uªº«Ü·PÁÂCliff ¤j ÁÂÁ±zªºÀ°¦£,Åý§Ú¥i²z¸Ñ¬ÛÃö¸ê®Æ.¯uªºÀ°§U«Ü¦h |
|
|
·|û¡GS.F10138950 µoªí®É¶¡:2015/1/8 ¤W¤È 02:51:13²Ä 193 ½g¦^À³
|
Cliff ¤j¤j ±z¯uªº¹ê¦b¬O¤Ó¯«¡B¤Ó¶Ç©_¤F¡C ¦Ê¦~Ãø±o¤@¨£¡B»õ¤¤¿ï¤@¡C |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/1/7 ¤U¤È 11:06:40²Ä 192 ½g¦^À³
|
¦³FU¤j¡G ¤£¬O¤T³±Àù IIA ¤À´Á T2 ¸~½F2-5¤½¤À Nx ²O¤Úµ²«I¥Ç¥¼ª¾ À³¸Ó©|¥¼Âಾ¡A©Ò¥H¨SM p«ü¯f²z¶EÂ_ medullary features¡GÀù²ÓM«¬ºA¡GÅ説²ÓM ¡]http://www.tbca-npo.org.tw/upload/%7BCA1A34F3-E182-4E8A-81E4-30F331068609%7D_20110603-%E5%80%8B%E4%BA%BA%E5%8C%96%E7%9A%84%E6%B2%BB%E7%99%82%E6%BA%96%E5%89%87%E8%88%87%E7%99%82%E7%A8%8B%E5%BB%BA%E8%AD%B0.pdf ¡^ §ó¸Ô²Óªº¬Ý³o¸Ì¡G http://www.lshosp.com.tw/Grand%20round/PDF/981111.pdf ¡]ª`·NSlide 29/30/35/38¡^ ¥ÎIHC4ªººâ¦¡ºâ¥X´_µo·ÀIµû¦ô«ü¼ÆÁÙÆZ°ªªº¡C ER = 20 PR = 0 Her2 = 1 Ki67 = 90¡]Ki-67²ÓM¼W´Þ«ü¼Ð¡A¥Î¨ÓÀË´ú²ÓMªº¼W´Þ²v¡A¤ñ¨Ò¶V°ªªí¥ÜÀù²ÓM¥Íªø¤Àµõ³t«×¶V§Ö¡^ IHC4 = 191.294 ¡]>+30 ÄÝ°ª·ÀI¡^ »¡©ú¡G http://www.sanofi.com.tw/l/tw/zh/layout.jsp?cnt=013FB5B2-3B58-4D9B-95D1-BBE2FCB7EF1E pºâ¤½¦¡¡G¡]³oÓ¦n¥Î¡^ https://www1.cgmh.org.tw/intr/intr5/c6210/breast%20cancer%20prognosis.html ¶È¨Ñ°Ñ¦Ò¡A¥H¥DªvÂå®vªº¶EÂ_¡B¸ÑÄÀ»P³B¸m¬°¥D¡C |
|
|
·|û¡G¦³FUªº¤H10136189 µoªí®É¶¡:2015/1/7 ¤U¤È 10:04:47²Ä 191 ½g¦^À³
|
¦b½Ð°Ý¦U¦ì¤j¤j¤@Ó°ÝÃD Y¦b¯f¾úªí¤W§e²{¥X¥H¤U´XÓ¤º®e,³o¨Ç¤º®e«üªº¬O¤T³±©ÊÀù¶Ü?? PERMANENT DIAGNOSIS: BREAST, RIGHT, EXCISION -------INVASIVE CARCINOMA WITH MEDULLARY FEATURES PATHOLOGICAL STAGE: IIA (pT2 Nx) ER: (+), 20%, W PR: (-) HER-2/neu: (1+) Ki-67: (UP TO 90%) ½Ðª¾¹Dªº¤j¤jÀ°¦£¸Ñµª~~«D±`·PÁ |
|
|
·|û¡G¦³FUªº¤H10136189 µoªí®É¶¡:2015/1/7 ¤U¤È 09:22:24²Ä 190 ½g¦^À³
|
·PÁÂ¥xÁÞ¤jªºÀ°¦£~~~ ¯uªº«ÜÁÂÁ±z |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/1/7 ¤U¤È 05:27:20²Ä 189 ½g¦^À³
|
¯E¤ÍÌ 888«²{¦¿´ò¤F «¢«¢«¢ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/1/6 ¤U¤È 11:29:17²Ä 188 ½g¦^À³
|
FU¤j ¨ÅÀù¯f²z³ø§i²©ö«ü¤Þ (An Introductory Guide to Breast Cancer Pathology Report) ¹Å¸qªø©° https://www1.cgmh.org.tw/intr/intr5/c6210/breast%20cancer%20pathology%20report.html |
|
|
·|û¡G¦³FUªº¤H10136189 µoªí®É¶¡:2015/1/6 ¤U¤È 09:40:23²Ä 187 ½g¦^À³
|
ɥΤ@¤U±ø¤jªº¤º®e¸ß°Ý¦³Ãö©ó¨ÅÀùªº¬ÛÃö°ÝÃD ±ø¤j: ¦U¦ì¤j¤j: ¨ÅÀùÃþ«¬¥i¤À¬°: 1 ºÞµÄA«¬¡]ER/PR¶§©Ê¦ÓHER2¬°³±©Ê¡^(¶Pº¸»X¶§©Ê), 2 ºÞµÄB«¬ (HER2¶§©Ê ER/PR³±©Ê), 3 ¤T³±©Ê(ER/PR¡BHER2¬Ò¬°³±©Ê) ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K ·Q½Ð°Ý¦U¦ì¤j¤j,¦b¨Å©Ð¤Á¤ù¤ÆÅç³ø§i¤W·|¦³¥ô¦ó¬ÛÃö©ó¨ÅÀùÃþ«¬ªº¥ô¦ó¸ê®Æ¶Ü?? ¦]¬°§Ú¦b¤ÆÅç³ø§i¤WµLªk¬Ý¨ì¬ÛÃö©ó¤Wz 1.2.3µ¥¬ÛÃö¦r²´~~]] ³Â½Ð¦U¦ì¤j¤j§iª¾¦p¦ó§P©w¤è¦¡. ·PÁ |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2015/1/5 ¤U¤È 08:50:19²Ä 186 ½g¦^À³
|
Cliff ¤j ³o¤]¤Óºëªö¤F ·PÁ±zµL¨pªº¤À¨É ±zªº¸Ñ»¡ ª½«ü°ÝÃDªº®Ö¤ß ©Î¥iÅý¤j®a©ê±o§ó¨ã«H¤ß ¹ï822ªºÃĮľ÷²z ¤p§Ì¦pÀò¦ÜÄ_ ÁÂÁ±z ! ¤]·PÁÂ¥xÁÞ¤j ´£¨Ñ³¯¹a¬z±Ð±Â«ü¾Éªº³Õ¤h½×¤å ³o©MCliff ¤jªº¸ê®Æ ©Î¬°822¤@´ÁÁ{§É±wªÌªº¦s¬¡ª¬ªp ´£¨Ñ¨âÓ¥i¯àªº¾÷¨î¦õÃÒ ¤£¹L¥xÁÞ¤j ¥i§_½Ð±z´£¨Ñ¤¤¬ã°|¨ÅÀù¬Ì]¤@´ÁÁ{§É¸ê®Æ³ø¾Éªººô§} ¤p§Ì§ä¤F³\¤[ ¤´ºÃ´b³s³s ³oÓ¸g¤@´Á¤HÅéÁ{§É ´N³ø¾É§PÂ_ À³¬O¦³«Ü´ÎÀø®Äªº¬Ì] ¦ý¨ì©³¬OþÓª©¥»? ¬°¦ó¨S©µÄò? Åý822±Ä¥ÎMemorial Sloan-Kettering Cancer Center ©Ò¬ãµoªº¬Ì] Ä~ÄòÁ{§É¤G ¤T´Á ÁÙ¬O³oÓ¬Ì]´N¬O822 ¬O°OªÌ¥ý¥Í»~»{¤F ¥u¤£¹L GH ¬O¥Î¤¤¬ã°|ªº§Þ³N¨Ó¦X¦¨ ´N»¡¦¨¬O¤¤¬ã°|¨ÅÀù¬Ì]? ¤p§Ì²Â©å ¹ï©ó±z²¤¨ã¸õÅD©Ê«ä¦Òµ²½×ªº¤å³¹ ±`»Ý¬ãŪ¦A¤T ©Î¤~¯à²¤¦³»â·| ·PÁ±z ! ¦b³oӪѻù½pÀq´Á¶¡ «ê´£¨Ñ§Ṳ́@Óר¾i©Ê §V¤O»{ª¾ªº¾÷·| §Úª¾¹D ¤p§Ì¹ï©ó822¤@¨ÇÃIJz¤Wªº²q´ú»¡ªk ©Î³\·|Åý¬Y¨Ç¤j¤j»~»{¬°¤p§Ì¤S¦b»¡822ªº¤£¬O ´£¥XºÃ°Ý ¨Ã«D¬ÝÃa822ªº«e´º (©Î³\¨Ì²{¦bªº±¡ªp ¦ó¶·¬ÝÃa) ¦Ó¬OnÂç²MºÃÂI Åý¦Û¤v©ê±o§ó¦w¤ß ·í£~£~¤jµo¤å»¡ °¨°º±N¤G´ÁÁ{§Éªº»¡©ú·|±À¿ð Y¦¹¶Ç¨¥¬°¯u ¤½¥q¦ü¥G¤£Ä@¦b¤WÂd°Ñ¦Ò»ù¥¼©w®×¤§«e ÅýªÑ»ù¦³¤Ó¤jªºªi°Ê ? ²q´ú¤§¨¥ ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a ! |
|
|
·|û¡G¹Ç§AÅó±ø±ø10135894 µoªí®É¶¡:2015/1/5 ¤U¤È 02:37:52²Ä 185 ½g¦^À³
|
»¯ºaªN¡]³Ç¥X¶E©Ò°|ªø¡B¬ü°êÀù¯g§K¬ÌªvÀø¾Ç·|Âå®v¡^»¡: Àù¯g»P§K¬Ì¨t²Î ¡@¡@Àù²ÓM»P§K¬Ì¨t²Î¤§¶¡ªº¼Ä§Úª§¾Ôµ²ªG¦³¥i¯àÀù²ÓM³QÄè·À¡A©Î¬OÀù²ÓM²æ°k¡]tumor escape¡^¡A¦¨¥\¦a°k¹L§K¬Ì¨t²Îªº°l±þ¡C¥¿±`±¡ªp¤U¡A¤HÅ骺§K¬Ì¨t²ÎºÊ±±¨Ã²M°£Àù²ÓM¡A¤Ï¤§¡A§K¬Ì¥\¯à³à¥¢ªº¤H«h®e©ö¤ÞµoÀù¯g¡C³Ìªñ¤@¶µ¿D¬wªºÂå¾Ç¬ã¨s°w¹ï905¦W±µ¨ü¤ßŦ©ÎªÍŦ²¾´Ó¤â³N«á¡A¨Ï¥Î§K¬Ì§í¨î¾¯¡]¤]´N¬O§Ü±Æ¥¸ÃÄ¡A§í¨î¨Åé§K¬Ì¥\¯à¡A§K°£¹ï²¾´Ó¾¹©xªº±Æ¥¸¡^«á¹ïÀù¯gµo¥Í²vªº²Îp¡A°lÂܵo²{¨ä¤¤¦³102¦W¯f±w¿©±w¤FÀù¯g¡A¾÷²v¬O¥¿±`¤Hªº7¿¤§¦h¡C¥t¥~¤@¶µ¦b¤é¥»ªº¬ã¨s«h°w¹ï3625¦W°·±dªº¤H11¦~ªº°lÂܲÎpµo²{¡A¦å²G¤¤²O¤Ú²y§]¾½¥\¯à¸û±jªº¤H¸û¤£©ö¿©±wÀù¯g¡C Àù¯gªº§K¬ÌÀøªk 1893¦~¡A¬ü°ê¯Ã¬ùªºWilliam ColeyÂå®v¦b¤@¦WµLªk¶}¤M¥Bµ´±æªºÀù¯g¯f±w¨¤Wª`®g´î¬rµL¶Ç¬V¤Oªº²Óµß²G¡A§Æ±æÂǵۿEµo¯f¤Hªº¦ÛÅé§K¬Ì¤ÏÀ³¨Ó±±¨îÀù¯g¡Cª`®g«á¯f¤HªGµM¦p¹w´Á¯ë¥þ¨Å¸§N©Mµo¿N¡A´X¤Ñ«á©_Âݵo¥Í¤F¡A¯f¤H¨¤Wªº¸~½F³vº¥®ø¥¢¡A¤TÓ¤ë«á³ºµM§¹¥þªv¡¡I¤§«áColeyÂå®v¨Ï¥Î³o¨Ç²Óµß¡u¬Ì]¡vªvÀø¤F±Nªñ1000¦WÀù¯g¯f¤H¡A¨ä¤¤¦³500¦W¥H¤W¸~½F´X¥G§¹¥þ®ø¥¢¡CµM¦Ó¥LªºªvÀø«o¤£¬°·í®É¤@¨Ç¥D¬yÂå®v©Ò»{¦P¡A¬Æ¦Ü¦]¬°§Q¯qÃö«Y¡]·í®É©ñ®g½uªvÀø¤Î»ö¾¹è¦b±À¼s¡^¦Ó©è¨î¥L§åµû¥L¡A³s¬ü°êÀù¯g¾Ç·|¤]¥D±iColeyªº²Óµß¡u¬Ì]¡vµL®Ä¡A¬ü°êFDA¤]¤£©Ó»{¥¦¦Xªk¡A¨Ï±o¥Lªº¡u¬Ì]¡vÀHµÛ¥Lªº¹L¥@¦Ó³vº¥³Q¤H¿ò§Ñ¡C¤µ¤é¦]µÛÀù¯g§K¬Ì¾Çªº¬ã¨s¦¨ªGÂ׺ӡAº¥º¥¨ú¥N¤F¶Ç²Îªº©ñ®g½u¤Î¤Æ¾ÇªvÀø¡A¦¨¬°Àù¯gªvÀøªº·s¥D¬y¡A«á¤H¤]¶}©l¤F¸Ñ·í¦~³o¬q¯µ¨¯¡A¥H¤ÎColeyÂå®v¦bÀù¯gªvÀø¤Wªº³Ð·s»P°õµÛ¡A¨Ã°lºÙWilliam ColeyÂå®v¬°§K¬ÌÀøªk¤§¤÷¡I https://www.facebook.com/notes/178913408791153/ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/1/5 ¤W¤È 09:44:20²Ä 184 ½g¦^À³
|
¦U¦ì¤j¤j ©êºp ¬ã¨s¥Í¬O ·¨®a©y ¦U¦ì¤j¤j¥i°Ñ¦Ò¦¹½g½×¤å 2013 ®ü¤j ·¨®a©y ¥Íª«¬ì§Þ¬ã¨s©Ò «ü¾É±Ð±Â ¨H®a¹ç¡B§õ¥ò¨} To determine if Globo H is a therapeutic target for pancreatic ductal adenocarcinoma ·j´M¦r: ±´°QGlobo H §@¬°¯ØŦ¸¢ÀùªvÀø¼Ðªº |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/1/5 ¤W¤È 09:30:31²Ä 183 ½g¦^À³
|
¦U¦ì¤j¤j ¥i°Ñ¦Ò¦¹½g½×¤å ¦]¬°¯Ø¸¢Àù¬O833¬ãµo¨t¦C¤§¤@ To determine if Globo H is a therapeutic target for pancreatic ductal adenocarcinoma ±´°QGlobo H§@¬°¯ØŦ¸¢ÀùªvÀø¼Ðªº 2013 ®ü¤j ¨H®a¹ç¡B§õ¥ò¨} ¥»½×¤åµ²ªG»¡©ú¡AGlobo H ¥i¹B¥Î¦b°µ¬°¯ØŦÀù¼Ð°O¡A¨Ã¥Bªí²{Globo H ªº¯ØŦÀù²ÓM¦³ªí²{¯ØŦÀù¸~½F·F²ÓMªº¯S©Ê¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/1/5 ¤W¤È 12:02:03²Ä 182 ½g¦^À³
|
¤p®æ¤j ¦êÁp³o¨â¦~·j¶°¨ìªº¸ê°T¸g¹LÅÞ¿è±À²z ²{¶HÆ[¹î ¥[¤W¤ÑÃÈ®y¤Ñ¥Íªº¤@ÂIª½Ä±¤O»P¬}¹î¤O§Ú¤ß¤¤¤w¦³µª®× |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/1/4 ¤U¤È 11:49:01²Ä 181 ½g¦^À³
|
ÁÞ§Üì¦]¬°§K¬Ìì©Ê¡]immunogenicity¡^®z¡A¤j¦h¥u»¤µo«DT²ÓM¨Ì¿à«¬ªºIgM¡A¤£©ö²£¥ÍT²ÓM¨Ì¿à«¬ªºIgG¡C ¥´¤F822¤§«á¡A¦b«e±ªº´X¾¯¸~½FÁY¤p¸û§Ö¡A«á±ªº´X¾¯ªºÁYÀù®ÄªG´Nº¥Åܱo¤£©úÅã¡F²Ä¤@´Á¦s¬¡ªºªº±wªÌ¡A¬Æ»òì¦]Åý¥LÌÄ~Äòºû«ù¤£´c¤Æ¡H ±q¤@¨Ç¥Î©óMelanomaªº¬ã¨s¤åÄm¡A§ä¨ì¤F¤@¨Ç¦³ÃöÁÞ§Üì¦b¤HÅé©Ò»¤µoªº§ÜÅ骺¤F¸Ñ¡G¡uPreclinical studies of carbohydrate mimetic peptide vaccines for breast cancer and melanoma , Vaccine 25 (2007) 3022-3031¡v¡F¡]http://www.sciencedirect.com/science/article/pii/S0264410X07000394 ¡^¡A ¡uCirculating carbohydrate-reactive IgM antibodies are proposed as a mechanism of immune surveillance of the innate immune system . Such antibodies might be designated as natural antibodies because of their ubiquitous occurrence with no basis for assignment of immunogenic induction. The fact that survival rates of cancer patients are correlated with low avidity and low titer carbohydrate-reactive antibodies argues that having more robust IgG responses may not be of absolute necessity.¡]µù¡^¡v ³o¬qªº·N«ä»¡¨ì¡A¡]ÁöµMÁÞ§Ü쥼¯à²£¥Í«Ü¦h¨ã¦³°O¾Ð©ÊªºIgG¡^¡A¤£¹L´`Àô¤¤ªº§ÜÁÞÃþªºIgM³Q±ÀÂ_¬O§K¬ÌºÊµø¨t²Îªº¾÷Âà¡A¦¨¬°¥ý¤Ñ©Ê§K¬Ìªº¤@û¡A±À´ú¤é«áY¦³·s²£¥Íªº§Üì¡]Àù²ÓM¡^¡A±o¥H¦A±N¥¦Äè·À¡C ¡]µù¡^©Ò³sµ²ªº¥t¤@½g¤å³¹¬O¡uIgM Anti-Ganglioside Antibodies Induced by Melanoma Cell Vaccine Correlate with Survival of Melanoma Patients¡FJournal of Investigative Dermatology (1999) 112, 205¡V209¡F¡]http://www.nature.com/jid/journal/v112/n2/full/5600410a.html ¡^¡v ±q¶Â¦â¯À²ÓM½Fªº¤HÅé¬Ì]¸ÕÅç¦^·¹¤À²Õ§@¤ÀªR¡A¡]¤À¦¨¦s¬¡5¦~¥H¤W¡B¦s¬¡2-5¦~¡B¦s¬¡<1¦~¤Î¹ï·Ó²Õ¦@¥|²Õ¡^¡AÀˬd¨ä¦U²Õ±wªÌ¦b²Ä0¶g»P²Ä¥|¶gªºIgM¬Û¹ï¿@«×ÅܤơAµo²{¦s¬¡5¦~¥H¤Wªº¨º¤@²Õ¡A¨ä²Ä¥|¶gªºIgM¿@«×³Ì°ª¡A¨ã¦³²Îp±oÅãµÛ·N¸q¡C ¬O§_¦s¬¡±o¶V¤[ªº±wªÌ¡A¨äÅ餺·í®É³Q»¤µo¥X¨Óªº°ª¿@«×IgM¬OÃöÁä¡H ¬Ý¹ÏFig.1¡G¡uhttp://www.nature.com/jid/journal/v112/n2/fig_tab/5600410f1.html?url=/jid/journal/v112/n2/full/5600410a.html#close¡v¡A ¬ÝTable 1.²ÎppÈ¡G¡uhttp://www.nature.com/jid/journal/v112/n2/fig_tab/5600410t1.html?url=/jid/journal/v112/n2/full/5600410a.html#figure-title ¡v¡C ÁöµM822¹ïÀ³ªº§Üì¬OGH¡F³o¨Ç¶Â¦â¯À²ÓM½F¬Ì]¹ïÀ³ªº§Üì¬OGM2/GM3/GD2/GD3¡A¤£¹L¬Ò¬°¤£©ö²£¥ÍIgGªºÁÞ§Üì¡A¥i¯à¦³±µªñªº¯S©Ê¥i·í°Ñ¦Ò¡C¸Ô²ÓªºGHªº§ÜÅé¤À¥¬·íµMÁÙ¬O¨Ó¦Û¸Ñª¼¬°¬O¡C Ó¤H±À·Q¡A§@¬°¹w¨¾©Êªº¬Ì]¡A·íµMn¥H¯à¤j¶q²£¥ÍªºIgGªº®ÄªG³Ì¦n¡F¦Ó´NªvÀø©Ê²£«~¦Ó¨¥¡A822©Ò²£¥ÍªºIgM¨ÌµM¥i¥H¹F¨ìÄè·ÀÀù²ÓMªº®ÄªG¡]±q822²Ä¤@´Áªºµ²ªG¥iª¾¡^¡A¤W±²Ä¤@½g¤å³¹¡]Vaccine¡A2007¡^ªºIntroductionùجƦܴ£¨ì¡A±qGD2¡BGM2»PLewis Yªº¬ã¨sÅã¥Ü¡A³o¨ÇIgM©Ò³y¦¨ªº¸ÉÅé¨Ì¿à«¬ªºÀù²ÓM¬r±þ§@¥Î¡]complement-dependent cytotoxicity¡FCDC¡^¡A¨Ã¤£¨È©ó²ÓM¨Ì¿à«¬¬r±þ§@¥Î¡]antibody dependent cellular cytotoxicity¡FADCC¡^¡C ¡uAntibodies that recognize GSLs such as the gangliosides GD2, GM2 and the Lewis Y (LeY) antigen are demonstrated to mediate complement-dependent cytotoxicity (CDC) and have been suggested to be more cytotoxic to tumor cells than antibodies that recognize protein antigens or TACAs-linked to protein antigens that kill tumor cells by antibody dependent cellular cytotoxicity (ADCC).¡v ¥H¤W³£¬O±À½×¡A¦Ñ¸Ü¤@¥y¡A¶È¨Ñ°Ñ¦Ò¡C |
|
|
·|û¡G¤p®æ10136562 µoªí®É¶¡:2015/1/4 ¤U¤È 10:57:34²Ä 180 ½g¦^À³
|
¥xÁÞ¤j:¨C¤@¦¸¬Ý¤F±zªº¤å³¹,¥u¦³´Ü¨Ø¤Î·PÁ±zªº¥Î¤ß. ³o¤@´Á(941)¤µ©P¥Zp154³ø¾Éªk°È³¡³¡ªøù¼ü³·Ãҹ꿩±w¨ÅÀù²Ä¤G´Á,¤w±µ¨ü¤â³N¨Ã¶i¦æ¤ÆÀø¤¤. ·sÀøªk¬ð¯} ¨ÅÀù¥i·íºC©Ê¯fÂå........ §@¬°¯E¹©ªºªø´ÁªÑªF,¤]À³ÀH®ÉÀH¦aª`·N·sÀøªk©Ò±a¨ÓªºÄvª§ ·íµM§ó§Æ±æOBI-822ªºÁ{§Éª¬ªp¯à¤Î¦®³¨ìÃĵý,À°§U§ó¦h±oÀùªº¤H |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2015/1/4 ¤U¤È 10:13:32²Ä 179 ½g¦^À³
|
¦U¦ì¤j¤j: 822 833 ¤@¨Ç½×ÂI¦A±j½Õ»P¸É¥R §Æ±æÅý¦U¦ì¤j¤j¯à´x´¤822®Ö¤ßÄvª§¤O 1 ¥@¬É¤W¥ô¦ó¤@ÓÃĪ«¬ãµo¥un¯à§ä¨ìÀù·F²ÓM¨Ã¥BÄè·À¤§Àù¯g´N¦³ªv·Uªº¥i¯à ,©¯¹Bªº¥xÆW§ä¨ì¤F, (822 833³£§ä¨ì3ÓÁÞ ¤À¤l¼Ð¹v,¦bÀù²ÓM»P·F²ÓM³£¦³ªí²{) 2 ¨ÅÀù822¤£¬O»P¶PÀù¥(¥]¬AÂù¼Ð¹v)³B©óÄvª§ºA¶Õ,¦]¬°822¾A¥Î¯f±w»·¶W¥XHer2¶§©Ê¶PÀù¥20%¾A¥Î¯f±wªº3¿¥H¤W, ¥un¥¼¨Ó¸Ñª¼®ÉPFS¤ñ¶Pº¸»X¶§©Ê»P¤T³±©Ê¨ÅÀù³Ì¦nªºÃħóÀu²§«K¯à§ð¦û¨ÅÀù³Ì¤j¥«³õ¤ñ²v,¦p¯à¤ñ¶PÀù¥Âù¼Ð¹vÃÄPFS18.5 Ó¤ë§óÀu²§¤]¯à¦A§ð¦ûHer2¶§©Ê20%¥«³õ 3 ¤¤¬ã°|2002¦~¹ê¬I¨ÅÀù¤@´ÁÁ{§É¦³®Ä©Ê¹F¤K¤Q¢H¡A§Y¤Q¦ì¨ü´ú¨ÅÀù±wªÌ¬I¥´¸Ó¬Ì]«á¡A¥i¦³®Ä±þ¦ºÀù²ÓM¡A¥B°lÂܤ¦~«á¡A ¨ÅÀù´_µo¤H¼Æ¥u¦³¨â¦ì¡C¤¤¬ã°|¬ã¨s¹Î¶¤¶i¦æ¨ÅÀù¬Ì]¬ã¨s¡A¤G¡³¡³¡³¦~¶i¤J°Êª«¸ÕÅ綥¬q¡A¨ÅÀù²ÓMÄè·À²v°ª¹F¤E¤Q¢H¥H¤W¡F ¤G¡³¡³¤G¦~¶i¤J²Ä¤@´Á¤HÅéÁ{§É¸ÕÅç¡A¥H¤Q¦Ü¤Q¤G¦ì¨ÅÀù¥|´Á¯f±w¬°¼Ë¥»¡A®ø·ÀÀù²ÓM²v¤]¹F¨ì¤K¤Q¢H¡A¨ÃÃÒ¹ê¨ÅÀù¬Ì]ªº¦w ¥þ©Ê¨S¦³°ÝÃD¡C·j´M¦r: ¨ÅÀù¸ÑÃÄ3¦~«á¤W¥« 4 Globo-H à¤ÆCeramide¬OÀù²ÓMªº¦Û§Ú¨¾¿m¨t²Î¡A¥i¥HÅýÀù²ÓM¸ú¹L¨Åé§K¬Ì²ÓMªº§ðÀ»,¦Ó¥´¤JªºOBI-822¤SºÙ¬°¤Ï¨¾ ¿m¨t²Î¡A·íÀù²ÓM©ñ¥XGlobo-H Ceramide ®É IGG IGM·|¹³§l¹Ð¾¹¤@¼Ë§â¥¦§l¨«Åý¦¹¨t²ÎµLªk¹B§@¡A§K¬Ì²ÓM´N¥i¥H»´ ÃPªºÄè·ÀÀù²ÓM¡C 5¦b¸~½Fè§Î¦¨®É¡A¤j¤p¦b1-2 mm¡AÀù²ÓM¥u»Ý§l¦¬©P¾DÀô¹Òªº¾i¥÷§Y¥i¦s¬¡¡F¤@¥¹¤j¤p¶W¹L3mm(0.3¤½¤À)¡A´N¥²¶·¾a·s¥Í¦åºÞ¨Ó¨ÑÀ³¾i¥÷¡C 6«P¶i¦åºÞ·s¥ÍªºGlobo-H Ceramide ¤Î¨ä¤À¤l¾÷¨î¤§±´°Q ³Õ¤h½×¤å µ{´º«Û °ê¨¾Âå¾Ç°| 2014 Promotion of Angiogenesis by Globo-H Ceramide and Its Molecular Mechanism ¦U¦ì¤j¤j¥i°Ñ¦Ò¨ä½×z ¥»½g½×¤åºKn«á±µ²½×«ü¥X:GH Cer«P¶i¦åºÞ·s¥Íªº¬¡©Ê¥H¤Î¥ý«e¹êÅç«Ç©Òµoªíªº¹êÅçµ²ªG¡AGHCer¹ïT¡AB²ÓMªº§K¬Ì§í¨î¬¡©Ê¥H¤Î¦b¨ÅÀù·F²ÓM¤¤¥i¥Hµo²{Globo-Hªºªí²{¡Cºî¦X¥H¤W¤TÂI¡A¥iª¾·sµo²{Globo-H¦b§@¬°Àù¯g§K¬ÌÀøªk²£¥Í±M¤@¥B¦³¤¤©M®ÄªGªº§ÜÅé©Î¬O°w¹ïGlobo-Hªº¬Ì]¡A¬O¤@Ó¨}¦nªºªvÀø¼Ðªº¡C§Ú̪º¹êÅçµ²ªG¶i¤@¨B±j¤Æ¤F¥Ø«e¥¿¦b¶i¦æªºÁ{§É¤G/¤T´Á°w¹ï¨ÅÀùªºGlobo-H ¬Ì]¾Ç²z¤WªºÄÄz 6 822 @¨ü©Ê¦w¥þ©Ê·¥¨Î, ÁÞ¤À¤l¦X¦¨§Þ³N¯E¹©¦³±MÄݱÂÅv ,§O®a¤½¥qµL¦X¦¨§Þ³N¦p¦ó¯à°µ¥XÁÞ¤À¤lÃĪ«, D§b¤j: ÁÂÁ§Aªº§ó¥¿,833¬O6Ӥ맹¦¨10°w,¤õºô¬Û·í±K¶°,µ¥¤@´Áµ²ªG³ø§iµoªí¦A¦æ±À½× ¥H¤W¸ê°T¶È´£¨Ñ°Ñ¦Ò ½Ð¹LÂo¤ÀªR»P¸ÑŪ |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2015/1/4 ¤U¤È 09:16:12²Ä 178 ½g¦^À³
|
¦Ñ¹«¤j ±zªº³o½g¤å³¹ Åý¤p§Ì¨ü¯q¨}¦h ÁÂÁ±z! ¹ï©ó ¡§"¶Ç²Î¤Æ¾ÇªvÀø¤@¯ëªº·§©À¬On¤j©ó20%¥H¤W¡A¤~¤ñ¸û·|¦³¾÷·|¦¨¥\¤W¥«¡AµM¦Ó¼Ð¹vÃĪ«¸~½F¤ÏÀ³²v¥i¯à¥un¦³3%ªº¤ÏÀ³²v´N¥i¯à¦¨¥\¤W¥«" ³o¼Ë¬O¤£¬O¯à¸Ñµª¤@´ÁÁ{§É·í¤¤¤¦ìSD±wªÌ«ùÄò¦s¬¡¨ì²{¦b?¡¨ ³oÓ°ÝÃD¶W¥G¤p§Ìªºµ{«× ¹ê¦bµLªk´£¥X¥ô¦ó¹³¼Ëªº¬Ýªk ¤p§Ì©Î¥u¯à³o¼Ë²q ½Ð¤j®a«ü¥¿ ¶Ç²Î¤Æ¾ÇªvÀø©Î³\¬O¥Î©ó¤@½uªvÀø »Ýn°ª¤ÏÀ³²v ¥H°§C¸~½Ft²ü ¦ý¤í¯Ê«ùÄò¤ÏÀ³²v ²øÂå®vªº¥t½g¤å³¹´¿´£¤Î ( http://www.tma.tw/ltk/100540703.pdf ) ¡§¡K ²{¤µ¦³³\¦h¼Ð¹vÃĪ«¶i¦æ¬ãµo¡A³o¨Ç¼Ð¹vÃĪ«¦h¥b¬OÄÝ©ó²ÓMéwÃþÃĪ« (cytostatic drugs)¡A ³oÃþÃĪ«¥i¥HÅý¸~½F°±¤î¥Íªø¤@¬q®É¶¡¡A¦ý³q±`µLªkÁY¤p¸~½FÅé¿n¡¨ ADCÃĪ« ¤]³\´N¬O°ò©ó³oºØ·Qªk¤Uªº²£ª« 822¥»¨¥i¥Hª®±þ¨ãGH¨t¦C§Ü쪺Àù²ÓM ¦ý±wªÌªº²ÓM¼Æ¦Ê¤À¤ñ ©Î¨M©w¤F¸Ó±wªÌ¥i¹F CR ¡NPR ¡NSD ¬Æ©Î´c¤Æ 822©Î¨ã¦³±þ¼Ä ¥H¤Î¥i¥HÅý¸~½F°±¤î¥Íªø¤@¬q®É¶¡ªºÂù«®ÄªG ¦ý°±¤î¥Íªø¤@¬q®É¶¡ªºÁ{¬É±ø¥ó¬O¤°»ò ? ³o¬q®É¶¡ªºªø©Îµu ¬O¨ú¨M¦óºØ«ÈÆ[±ø¥ó©MÅ餺Àô¹Ò ? ³o¨Ç822¤@´ÁÁ{§É5¦ìSD±wªÌ ¥i¥H¦b³ø§i¤§«áÄ~Äò¦s¬¡6 ~ 8 ¦~¥H¤W ¬O³o¨Ç±wªÌ¶i¤J¸ÕÅç®ÉÁöÄÝSD ¦ý¨ä¸~½Ft²ü©Î³\¤£°ª(¤]´N¬OPR ¦ý«Ü±µªñCRªºµ{«×) ©Î¤~¦³¥i¯à? ¥ç©Î±wªÌª¬ªp¸û§¡È¦n ¥H¤Î¶Pº¸»XÀøªkªº§U¯q? (For all patients, the median interval between breast cancer diagnosis and diagnosis of metastatic disease was 141 weeks (range 0¡V1,386 weeks); the median interval from diagnosis of metastatic disease to entry into this study was 96 weeks (range 11¡V446 weeks).(©úÅãÀu©ó²ÎpÈ) During the trial, 22 patients were on hormone therapy, either tamoxifen, anastrazole, or megestrol acetate.) (ºI¦Û822¤@´Á³ø§i http://www.ncbi.nlm.nih.gov/pmc/articles/PMC30643/ ) ©Îµ¥¸Ñª¼ªº¬ã¨s ²Îp ¤~¯à¬Ý±o¤ñ¸û²M·¡§a?! ¯ÂÄݲq´ú ½Ð¤j®a¬Ý¬Ý´N¦n ÁÂÁ¤j®a! |
|
|
·|û¡G¯ä¦Ñ¹«10139175 µoªí®É¶¡:2015/1/4 ¤W¤È 11:23:03²Ä 177 ½g¦^À³
|
²q·Q¤j ºaÁ`²ø¨ä¿pÂå®v¦³½g¤å³¹"¼Ð¹vÃĪ« (targeted agent)Á{§É¸ÕÅç³]p¤¶²Ð" ´£¨ì¼Ð¹vÃĪ«ªº¸~½F¤ÏÀ³²v»·»·§C©ó¶Ç²Î¤ÆÀøÃĪ« ¨Ò¦p¶PÀù¥18%ºâ«Ü°ªªº(¨Ö¥Î¤ÆÀøÃĤ~·|¹F¨ì69.3%),Àù«ä°±¥u¦³5.3% "¶Ç²Î¤Æ¾ÇªvÀø¤@¯ëªº·§©À¬On¤j©ó20%¥H¤W¡A¤~¤ñ¸û·|¦³¾÷·|¦¨¥\¤W¥«¡AµM¦Ó¼Ð¹vÃĪ«¸~½F¤ÏÀ³²v¥i¯à¥un¦³3%ªº¤ÏÀ³²v´N¥i¯à¦¨¥\¤W¥«" ³o¼Ë¬O¤£¬O¯à¸Ñµª¤@´ÁÁ{§É·í¤¤¤¦ìSD±wªÌ«ùÄò¦s¬¡¨ì²{¦b? |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/1/3 ¤U¤È 05:22:42²Ä 176 ½g¦^À³
|
¸gÀÙ³¡§Þ³N³B³J¥Õ½èÃÄ«~¶}µo¥|¦~pµe http://117.56.91.94/KMPublic/download.aspx?documentId=212821&fileName=1.%E8%9B%8B%E7%99%BD%E8%B3%AA%E8%97%A5%E5%93%81%E9%96%8B%E7%99%BC%E5%9B%9B%E5%B9%B4%E8%A8%88%E7%95%AB%EF%BC%88103%E5%B9%B44%E6%9C%88%E5%9F%B7%E8%A1%8C%E6%83%85%E5%BD%A2%EF%BC%89.html&ver=1 ¥þ¤HÃþ§ÜGlobo H ³æ®è§ÜÅé¶}µo¶i«×¡G2014¦~4¤ë°õ¦æ¶i«× ¸gÀÙ³¡§Þ³N³B³J¥Õ½èÃÄ«~¶}µo¥|¦~pµe(2014/05/07¬ö¿ý)¡A¾ãÓpµe¹w©w°õ¦æ¨ì2014/12/31 ³ü¡B°ò¥»¸ê®Æ¡G ¦~«×¤u§@ºKn¡G3.¥þ¤HÃþ§ÜGlobo H ³æ®è§ÜÅé¶}µo¡C¡]1,2,4²¤¡^ ¦~«×¥Ø¼Ð¡G3.¥þ¤HÃþ§ÜGlobo H ³æ®è§ÜÅé¶}µo¡C¡]1,2,4²¤¡^ ¶L¡B°õ¦æ±¡§Î¡G ¹w©w¤u§@ºKn¡G¡]¶ÈºK¿ý¬ÛÃö³¡¥÷¡^ ¡E¶i¦æ¤H·½¤Æ§ÜGlobo H³æ®è§ÜÅéõX®Æ³Ì¨Î»sµ{¶}µo ¡E®Ú¾Ú§ÜGlobo H»P§ÜCD3 Âù¯S²§©Ê§ÜÅ骺³J¥Õ¤ÀªR»P²ÓMÁäµ²¤ÀªR½Õ¾ãlinkerªºªøµu¡A¥]¬A§ÜGlobo Hªºintradomain linker¡B§ÜCD3ªºintradomain linker©Mkappa domain©M§ÜCD3 domain¤§¶¡ªºlinker¡C ¾ãÅé°õ¦æ±¡§Î»¡©ú¡G¡]¶ÈºK¿ý¬ÛÃö³¡¥÷¡^ ¡E¤H·½¤Æ§ÜGlobo H·Ç§ÜÅé¸gGlycan Arrayªº¤ÀªR¡AÃҹꦹ·Ç§ÜÅé¹ïÁÞ§ÜìGlobo Hªº±M¤@©Ê¿ë»{¯à¤O¡C ¡E¤w§¹¦¨«Ø¸m¤£¦Pºc«¬¤§§ÜGlobo H»P§ÜCD3Âù¯S²§©Ê§ÜÅé¡A¶i¦Ó½Õ¾ãºc«¬¥]¬ALinkerªø«×¡A¨Ã¦b§ÜÅéºc«¬introdomain¤§¤¤¸m¤JÂù²¸Áä¡A¥ç¤ÀªRºc«¬¤§§ïÅܬO§_¯à¼W¥[²£¶q»P¼W¶i§ÜÅéµ²¦X¯à¤O¡C ·íµM¡A¬ãµo¶i«×¬O¨ì¤F³o¼Ë¤@Ó¶i«×¡A¯E¹©±Ä¯Ç»P§_¡A¦³¨S¦³¥ÍÅÜ¡A¤½¥q»¡¤F¤~ºâ¼Æ¡A½Ð¦Û¦æµûÂ_¡C |
|
|
·|û¡Gµ½¤H10137888 µoªí®É¶¡:2015/1/2 ¤W¤È 01:28:27²Ä 175 ½g¦^À³
|
Cliff¤j©MJM¤j, ¤G¤Hªº´¼¼z³£¶W¤H, ¥O¤H·q¨ØÆg¹Ä!!! 99±iªº¦~«×½æÀ£¤w¸gµ²§ô. ¤WÂd«e·|¦³¸`µ|©M®M§Qªº½æÀ£¶Ü? ¤£ºÞ¦³¨S¦³½æÀ£, ·sªº¤@¦~, ¯E¹©ªº»ùȤS¦V¤W´£¤É, ·|¤ÏÀ³À³¦³ªº»ùÈ. ¯¬ºÖ¯E¤ÍÌ ¥¦w³ß¼Ö ÀH¤ß¦p·N °]·½¼s¶i |
|
|
·|û¡G£~£~10134649 µoªí®É¶¡:2015/1/1 ¤U¤È 03:07:38²Ä 174 ½g¦^À³
|
¡i¦h¾AÀ³¯g¤ñ¦h²£«~½u¦n¡j¡A¤@»yÂI¥X¤½¥qªº³¥¤ß©M¨Mµ¦¤è¦V¡C¹L´X¦~§Ú̧Y±N¬Ý¨ì¤½¥q²£«~¤S¦h¦³¦³®Ä¡AÀ½¶i¥@¬É¤@¬y¤jÃļt¡C¨ì²{¦b2015¦~¤´¤£¥²´Á¤¤¤ÀªR´N¬O¤¸¥¹³Ì¨ÎªºÂ§ª«¡C¤§«e½æ¥úªº³Ð§ë©Î¤j©@Y¦b¥b¦~¤º¨S¦³¦^¸É±N·|¥¢¥h¾÷·|¡C¹A¾ä¦~«e«á§Z±_Àùphase2ªº¦¨ªG¥i¯à·|±a¨Ó¤@ªi¦æ±¡¡A±µµÛ3¤ë23¤é±¾µP´NÀRÀRµ¥µÛ±µ¿æ¦Ó¦Üªº¤@ÓÓ¦n®ø®§¡C |
|
|
·|û¡GD§b10139065 µoªí®É¶¡:2015/1/1 ¤U¤È 12:40:11²Ä 173 ½g¦^À³
|
¥xÁÞ¤j¡G833¦b6Ӥ맹¦¨10°w¦ü¥G©Mªü¬Â¤j´y¯À822¨â¦ì¯f±wè¬I¥´¸~½FÁY¤p«Ü§Ö¦³ÃöÁp¡A±K¶°¦b¥b¦~¬I¥´¤×¨ä¦b«e2Ó¤ë±Ò°Ê¦Û¨§K¬Ì§ÜÅé¶q³Ì¤j®É®ÄªG³Ì¦n¡C¥t¥~888ì¾AÀ³¯g¬OªÍÀù¡A³o¦¸833¦b¤@´Á¥Ó½Ð¤FªÍÀù¸ÕÅçÀ³¸Ó´N¬O·QÃÒ©ú833¦Û¨§K¬Ì±Ò°Êªº®e©ö«×©M¶q¤W¯à°÷¶W¶V822¡A¬Æ¦Ü±µªñ888ªº¤ô·Ç¡F¥Nªí822¸ÕÅç¥Ø«eÀ³¸Ó«Ü¦n¤j¤j¼W¥[¤½¥q«H¤ßÅý쥻´NÄݳÆLªº888Åܱo¨S¨º»ò¢¤Á¡A¥[¤W¤WÂdÄw¸ê¤S¤ñ¤§«e¦h¤F20´X»õ¡A¦P®É¶i¦æ¦h¾AÀ³¯g¦ü¥G¤ñ¦h²£«~½u·|¬O§ó¦nªº¿ï¾Ü¡I¥H¤W¯ÂÄݲq´ú¡A§ë¸ê½Ð¦Û¦æ§PÂ_¡C |
|
|
·|û¡GJM10139061 µoªí®É¶¡:2015/1/1 ¤W¤È 11:39:39²Ä 172 ½g¦^À³
|
«¢!«¢!«¢!³o¤U¥þÀ´¤F,¤j®a¤]¤£¥Î¶Ë¸£µ¬¤T¤Ñ¤F!! ·sªº¤@¦~,¯u¥¿¶}¤ß^^ |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/1/1 ¤W¤È 11:28:01²Ä 171 ½g¦^À³
|
Yeah¡I JM¤j¤j¡A±z¤]¤Ó±j¤F§a¡H ¤p§Ì´ê¤F¦Ü¤Ö¤Ó¤p®É¡A«o³Q±z¤£¨ì¤Q¤¤ÀÄÁ´N¦Û°Ê¸Ñª¼¡K¡K¤£¥²µ¥¨ì¤T¤é¡K¡K ¡]¥i¨£±z²´·ú¦³ÂI±×±×ªº³á¡H¡K.¶}ª±¯ºªº¡I¡^ First in Class¡FBest in Class ·í±z¤£¸g·N¦a¤f¥X¡u³o¯u¬O°÷µL²á¤F¡I¡v¨º´N¬O¤F¡A ¦]¬°µL²á©Ò¥H³Õ¼Ö¡A ³Õ§g¯ºÀéÄê¡A¶Q¤â½Ð°ªÁ|¡C ¥oÂZ¤§³B¡A¤p§Ì¤@Áù°`¡I ¤¸¥¹§Ö¼Ö¡I |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2015/1/1 ¤W¤È 11:10:37²Ä 170 ½g¦^À³
|
Cliff¤j ±z¯uªº¤ÓÀu¡B¤ÓÆg¤F Åý¤p§ÌÆg¨Ø ¯E¤Í¦³±z»P¥xÁÞ¨â¦ì ¯uªº¬O§Ú̪ºÄ_!§Ú̪ººÖ®ð¡I Æg°Õ |
|
|
·|û¡GJM10139061 µoªí®É¶¡:2015/1/1 ¤W¤È 11:07:37²Ä 169 ½g¦^À³
|
·s¦~§Ö¼Ö¡I Cliff¤jªºV¦r®æ: ¯E¹©¬Ì]³Ð·s¬ãµo¡A·~¬Éº³Ð¦P·~³Ì¨Î ®¼¦³·N«ä!! ¯E¢Ý¢Ý¢Ý¢Ý¢Ý¢Ý¢Ý¡A¢Ý¢Ý¢Ý¢Ý¢Ý¢Ý¢Ý¨Î ¢Ý¹©¢Ý¢Ý¢Ý¢Ý¢Ý¢Ý¡A¢Ý¢Ý¢Ý¢Ý¢Ý¢Ý³Ì¢Ý ¢Ý¢Ý¬Ì¢Ý¢Ý¢Ý¢Ý¢Ý¡A¢Ý¢Ý¢Ý¢Ý¢Ý·~¢Ý¢Ý ¢Ý¢Ý¢Ý]¢Ý¢Ý¢Ý¢Ý¡A¢Ý¢Ý¢Ý¢Ý¦P¢Ý¢Ý¢Ý ¢Ý¢Ý¢Ý¢Ý³Ð¢Ý¢Ý¢Ý¡A¢Ý¢Ý¢Ý³Ð¢Ý¢Ý¢Ý¢Ý ¢Ý¢Ý¢Ý¢Ý¢Ý·s¢Ý¢Ý¡A¢Ý¢Ýº¢Ý¢Ý¢Ý¢Ý¢Ý ¢Ý¢Ý¢Ý¢Ý¢Ý¢Ý¬ã¢Ý¡A¢Ý¬É¢Ý¢Ý¢Ý¢Ý¢Ý¢Ý ¢Ý¢Ý¢Ý¢Ý¢Ý¢Ý¢Ýµo¡A·~¢Ý¢Ý¢Ý¢Ý¢Ý¢Ý¢Ý ¥u¤£ª¾¥H¤U¨â¥y¦ó·N¡H ¤T¤é¸Ñª¼®É ²Ä¤@¤é |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2015/1/1 ¤W¤È 10:53:35²Ä 168 ½g¦^À³
|
·s¦~·s«´§½¡A·L¨¥¤T¨â¥y¡F ¯¬§gÀò§Q¹d¡A¤Ì¹B¬Q©]¥h¡F ³Õ§g¯ºÀéÄê¡A¶Q¤â½Ð°ªÁ|¡C ÃѪ̤ůº§Ú¡A¤£ÃѲö©Ç§Ì¡F ¤T¤é¸Ñª¼®É¡A¤ßªá¦@¨Ã¸¦¡C ¥Õ·ö³y¥y¡A¤å¦r¹CÀ¸¡G ¬Ý¬Ý´N¦n¡A½Ð¤Å¦b·N¡C ¯EµM®ð¶Õ¶¯»\µØ®L¡A¤dÀÉ«°Ê¥Í§Þ¤×¨Î Á|¹©¥|±æ¦ó³B©ñ¤U¡A¶Ã§ë©ê¿ù©Ç½Ö³Ì½M Àù¤Ì¬Ì¯e¶Ë¤ß·´®a¡Aº¸¸·§Ú¶B³y·~ÄF°² ÅÖÅÖ¹à]¤Q¸ü¦³¥[¡A°Æ§@¥Î§C¦P¾«Åå³Y ¤@Áç»sÁ޳гyµL»ù¡A¼z²´¦A³Ð¦×¬r¼í¶® ´¹¤ùÀË´ú¹ñ·sµÞªÞ¡A¦t¤ºº¨£¥å¥jÀ±¨Î ³ÕºÓ®Iº¦@¿²¬ã¹Å¡AÃĬÉÁͶÕÁÞ°ò±Á¥Ò ¦ÊÂà¤d¦^»W¶Õ«Ýµo¡A·~¤¤À¼º¯E¹©°ß¥L ²Ä¤@¤é |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2014/12/31 ¤U¤È 11:49:38²Ä 167 ½g¦^À³
|
¥xÁÞ¤j ÆgÆgÆg Åý§Ṳ́@°_¤ß·Q¨Æ¦¨ ¤@°_¯è¦V¹Ú·Qªº©¼©¤ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2014/12/31 ¤U¤È 11:30:26²Ä 166 ½g¦^À³
|
¯è¦V¹Ú·Qªº©¼©¤ ¿O¥ú¤U±Mª`ªº±´¯ÁÁÞ¤À¤l¥@¬É ,¦p¹Ú¦p¤Û ¯«©_ªº¾÷¨î,¤d¦Ê¸Uªº²Õ¦X,´Á¬ß¤Þ»â¥ÍÂå¬ÉªºÅå©_ ²¢¬üªºªG¹ê¨Ó¦Û¦n©_ªº¤ßÆF»P¥Ã«íªº¦uÔ, ¦h¤Ö¥ú³±ªº¬G¨Æ §Y±N¶°µ²ÄÝ©ó¥xÆWªºÁÞÄ¥¶¤ ,¯è¦V¹Ú·Qªº©¼©¤ ¯è¦V¤Ó¥¬v,¯è¦V¤j¦è¬v,¯è¦V¦L«×¬v ,¯è¦V§§ÄR®ü¬v ¯è¦V¥_®ü,¯è¦V¦a¤¤®ü,¯è¦V·Rµ^®ü,¯è¦V½«µM¤j®ü ¯è¦V¹Ú·Qªº©¼©¤........ ¥h¦~±q¦U¦ì¤j¤j¾Ç¨ì«Ü¦h,½Ð®e³\§Ú¦A¶K¤@¦¸¯è¦V¹Ú·Qªº©¼©¤---ÄÝ©ó§ÚÓ¤Hªº´Á¬ß»P«H¤ß, ¨Ã¥H¦¹¸Ö¯¬ºÖ¯E¤Í2015¤ß·Q¨Æ¦¨ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2014/12/31 ¤U¤È 11:19:06²Ä 165 ½g¦^À³
|
¤p©_¤j: ©ñ°²¦n¦n¥ð®§¤@¤U,¥R¹q«á¦b¥Xµo,ÁÂÁ§A´£¨Ñ»¡©ú,§Ú·|¦A§V¤O¥hÁA¸Ñ¹Ïªí¦p¦ó¹º¥X µ½¤H¤j:§A´£¨ìÓ´Á¬I¥´¶¡¹j,§Ú¤jP¤ÀªR¦p¤U 822¤@´Á: ²Ä1, 2, 3, 7, and 19¶g («e¤T¶g±K¶°¦w¥´¨C¶g¤@°w,¤@Ó¤ë«á¦A¥´¤@°w¤Î3Ó¤ë«á¥´³Ì«á¤@°w)(¬I¥´±´¯Á´Á) 822¤G/¤T´Á: ²Ä1, 2, 3, 5, 9,13,17,25,and 37¶g(«e¤T¶g±K¶°¦w¥´¨C¶g¤@°w ¹j¨â¶g¦A¥´¤@°w,±µµÛ¨C¤ë¥´¤@°w³s¥´3Ó¤ë, ³Ì«á¹j2Ӥ르¤@°w¤Î¹j3Ӥ르¤@°w)¥»¦¸Á{§É¦ü¥G¦³¦b¤ÀªR¹j2Ó¤ë¸É¥´¤@°w(25¶g)¤Î¹j3Ó¤ë¸É¥´¤@°w(37¶g)ªº±¡ªp,¥H«KÁA¸Ñ¥¼¨Ó³Ì¨Î¬I¥´¤è¦¡(¬I¥´¬ã¨s´Á) 9Ӥ맹¦¨9°w ,»P¤@´Á¤ñ¸û¦h4°w 833¤@´Á: ²Ä1, 2, 3, 4, 6, 8,12,16, 20, and 24¶g ,«e4¶g±K¶°¦w¥´¨C¶g¤@°w,¹j¨â¶g¦A¥´2°w,«á¥|Ӥ붡¹j¤@Ӥ르¤@°w p4°w ,8Ӥ맹¦¨10°w (³Ì¨Î¬I¥´©w®×´Á) OBI-822/821¦b¬ü°ê°µªºÂಾ©Ê¨ÅÀù²Ä¤@´Á¤HÅéÁ{§É¸ÕÅ窺¸ê®Æ¨ÌÁ`¦s¬¡´ÁOS²Îp 10¦~6¤H 9¦~7¤H 8¦~2¤H 7¦~2¤H 6¦~2¤H 5¦~1¤H 3¦~3¤H 2¦~2¤H 1¦~2¤H (5¦~¥H¤W20¤H) ¥H¤U¬O¨ÌÁ`¦s¬¡´ÁOS/3 «á±q¤p¨ì¤j±Æ¦C 4 4 8 8 12 12 12 20 24 24 28 28 32 32 36 36 36 36 36 36 36 40 4 0 40 40 40 40 ( ¨ú¤¤¦ì¼Æ¬ù¦b²Ä13 14 ) ¨Ì¶PÀù¥Âù¼Ð¹v OS/PFS=3.05 56.5/18.5 =3.05 ±À¦ôOBI-822/821Âಾ©Ê¨ÅÀù²Ä¤@´ÁÁ{§É PFS: ¬ù 32 Ó¤ë ¥H¤W¨Ã«Dºë½T²Å¦X²Îpªº±À¦ô ¯ÂÄݦn©_¤ß¤§±´¯Á ¶È¨Ñ°Ñ¦Ò ¤£n·í¯u |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2014/12/31 ¤U¤È 11:03:53²Ä 164 ½g¦^À³
|
·PÁªü¬Â¤j ¦Ó¥BÁöµM¬OÂùª¼¡A¦ý®Ú¾ÚÁ{§É°lÂܳø§i¤£Ãø²q¥Xþ¨Ç¯f±w¥´¨ì822 ÁöµM¨S¦³¥þ³£NED,¦ýY¯à±N´c©Ê¸~½F¨}©Ê±±¨î¦í¡A¨Ã¦s¬¡¨º»ò¤[ ¤]°÷¼F®`¤F ©I¥s¥xÁÞ¤j©ÎCliff¤j ¨â¦ìªº¸Ö¥y¶W±jªº¡A§Öªï±µ2015¤F¡A¤£§«½Ð¨â¦ì¦A¨Óº¥´ªo¸Ö «¢«¢«¢ Y¦£¸LµÛ¡A´N§O²z·|¤p§ÌªºµL²zn¨D¤F ¯¬ºÖ¯E¹©¡B¼í¶®¡B¯E¤Í¡BÀù¯g¯f±w ¤ß·Q¨Æ¦¨ |
|
|
·|û¡G¤ý£«¬Â10136621 µoªí®É¶¡:2014/12/31 ¤U¤È 08:20:44²Ä 163 ½g¦^À³
|
¦U¦ì¤j¤j:¬JµM¥´1.2°w´N¶}©l²£¥Í§@¥Î,¨º°¨°º§Z±_Àù¤G´Á¦¬®×¤@¦~¦h¥B¥þ³¡³£¥´ÃÄ,¤½¥q©w´Á¶}·|,Àø®Ä¦n¤£¦n¤½¥qÀ³¸Ó«D±`¤F¸Ñ. |
|
|
·|û¡G¤ý£«¬Â10136621 µoªí®É¶¡:2014/12/31 ¤U¤È 07:15:02²Ä 162 ½g¦^À³
|
¯E¹©¸³¨Æªø±i©À·O»{¬°¡AÀù¯g°ò¦]½ÆÂø¤S®e©öP©R¡A»Ýn¤£Â_¦³·sÃÄ¡A¬O³Ì¾A¦X¥xÆW·sÃļt¸ó¨¬ªº»â°ì¡C ¡@¡@¥Lªí¥Ü¡A¤HÅé¾¹©x¦³60¦hºØ¡A¨ä¤¤¦³95¢H¥H¤W³£·|¦³Àù¯g¯f¦]µo¥Í¡A¦Ó¨C¤@ºØ¾¹©x³£¦³3-4ºØªºÀù¯g°ò¦]¡A°w¹ï¨C¤@ÓÀù¯g°ò¦]¡A´N¦³¶W¹L10Ó¥H¤Wªº·sÃÄ¡A¶}µo¼t°Ó¦³¦U¦Ûµo´§ªºªÅ¶¡¡C |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2014/12/31 ¤W¤È 09:31:11²Ä 161 ½g¦^À³
|
²q·Q¤j¡A ¤p§Ì¬Q±ß¸£³U¤£²M·¡ «ö°e¥X¥h«á¤~µo²{§Ë¿ù±zªº·N«ä¤F ³o5ÓSDªº±wªÌ·¥¦³¥i¯à¤]¬O¦s¬¡«Ü¤[ªº16¦ì±wªÌ¤§¤¤ªº5Ó ½T¹ê¥O¤H·P¨ì¤£¥i«äij ´Á±æ¯E¹©¦b¦¬¶°§ó¦h¼Æ¾Ú«á¸Ñ¶}³oÓÁ¼ ³yºÖ²³¦hªº±wªÌ ÁÂÁ±zªº»¡©ú¡I |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2014/12/31 ¤W¤È 08:56:07²Ä 160 ½g¦^À³
|
¤p©_¤j ¹ï¤£°_ ¤p§Ì¨S¦³ªí¹F²M·¡ Åý±z»~·|¤F §Ú·Qn»¡ªº¬O ¦b10¦~°lÂÜ´Á¶¡ ¤´µM¦s¬¡ªº16¤H¤¤ ©Î¥]¬A15¦ì¥¼´c¤Æªº¸ÕÅçªÌ ¦ý³o¨ä¤¤À³¤]¥]§t5Ó¥¼´c¤ÆªºSD±wªÌ ³o5 Ó©¯¹Bªº¤H ¦ó¥H¦bÅ餺¤´¦³¸~½Fªº±¡ªp¤U Áٯ༵¹Lº©º©ªº8(?)¦~ ³o¬O§ÚÌ©Ò¦n©_ªº ¨ì©³¬OÅ餺¦óºØ¾÷¨î¨ÏµM ÁÙ¬O822©Î¶Pº¸»X(©Î¨ä¥L)Àøªk©ÒP? »¡¨ì¶Pº¸»XÀøªk Åý§Ú·Q°_¤@¦ìªB¤Í¤Ó¤Óªº¸g¾ú °²¦p±z¬O¤k©Ê¤j¤j ©Î¤j¤jªº·A¤Ò¤HÌ ¤d¸U§Oªø´Á(©Î°®¯Ü§O¨Ï¥Î)ªA¥Î¤k©Ê¶Pº¸»X ³o¥i¯à¬O¾ÉP¨ÅÀù«Ü¦MÀIªº¦]¤l ¥H¤W²L¨£ ¶È¨Ñ°Ñ¦Ò ÁÂÁÂ! |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2014/12/31 ¤W¤È 07:19:03²Ä 159 ½g¦^À³
|
¦¦w¡A¯E¤ÍÌ ¤µ¤Ñ¬O12¤ë31¤é¤F ·PÁ¯E¤Í̦b³o¤@¦~ªº¬Û¤¬«jÀy¡B¤À¨É¦h¤è¸ê°T ¯E¹©¦b2014¦~¦¬®×§¹¦¨¡B¥Ó½Ð¤WÂd¡B¨S¦³±j¢¸Ñª¼©Î¶i¦æ´Á¤¤¤ÀªR.833±Ò°Ê²Ä¤@´Á ¨Ã¥B¤½¶}©Ó¾P»ùq¦b310¥ª¥k. º}«Gªº¤@¦~ ®i±æ2015¦~¡A¤]·|¬O¬Û·íºë±mªº¤@¦~ ¦A¦¸·PÁ¯E¤ÍÌ¡AÅý§Ṳ́@°_Ä~Äò¬°¥xÆWªºÅº¶Æ¥[ªo ¤]n·PÁ²Ӥߪºª©¥D ¯E¹©¥[ªo |
|
|
·|û¡Gµ½¤H10137888 µoªí®É¶¡:2014/12/31 ¤W¤È 06:09:47²Ä 158 ½g¦^À³
|
·PÁ£«¬Â¤jªº¸ê°T©M¦U¦ì¤j¤jªººëÅP¤ÀªR. 822¤@´Á: ²Ä1, 2, 3, 7, and 19¶g 822¤G/¤T´Á: ²Ä1, 2, 3, 5, 9, 13, 17, 25, and 37¶g 833¤@´Á: ²Ä1, 2, 3, 4, 6, 8,12,16, 20, and 24¶g "¤T.²Ä¤@°w¥´§¹24¤p®É¥ª¥k, ¤âÁu¶}©l¬õ¸~, ¥´²Ä¤@°w¨ì²Ä¤G°w®É¥i¥H¬Ý¥X¸~½F¶}©lÁY¤p, ²£¥ÍÅܤÆ, «e´X°wÁY¤p³t«×§Ö, ¶V¨ì«á±³t«×¶VºC, ¥´§¹Àøµ{¥b¦~¦hÄ~Äò°lÂÜ, ¸~½F¨S¦³´c¤ÆÅܤj©ÎÅܤp«Üéw." ±Àºâ³o¤G¦ì°Ñ¥[¸ÕÅ窺®É¶¡¬ù2013¦~8¤ë¥ª¥k. ¸~½FÁY¤pªº³t«×©M¥´°wªº¶g´Á¦³Ãö. ¥H«e±i¸³¨ü³Xªº¤@¬q½Í¸Ü: "¯Î±Ò´f©Ò¶}µoªº§Ü¨ÅÀùªºªvÀø©Ê¬Ì]¡A³z¹L¹ïÁÞ¤À¤l·sÃĪº¬ã¨s¡A µo²{¡u¨ÅÀù¡v¦³20¨ì30ºØ¤£¦Pªº¤ÀÃþ¡A³o¨Ç¤ÀÃþ¤¤¡A¯f±wPÀùªº¹Lµ{¤£¦P¡A©Òªí²{ªº¯f¼x¤]¦U²§¡C" ¥²¶·¦AÀˬd¤ÆÅç³o¤G¦ìªº¸~½F, ¬O§_ÁÙ¦³Globo H¨t¦Cªº¯f¬r? ©Î¬OÁÙ¦³¨ä¥LºØÃþªº¯f¬r? ©Î¬O¤wÅܦ¨¨}©Ê¸~½F? ¦pªGÁÙ¦³Globo H¨t¦Cªº¯f¬r, 1.¥´ªº°w¼Æ¤£°÷? 2.¨C¤@°wªº¾¯¶q¤£°÷? 3.³o¤G¦ìªº§K¬Ì¤ÏÀ³, ²£¥Íªº§ÜÅé¶q¤£°÷¦h?(¨CÓ¯f±wªº§K¬Ì¤ÏÀ³¯à¶q¤£¦P?) ³o¨Çì¦], »Ýn¸Ñª¼«á, ±N¸ÕÅç²ÕªºÓ§O¸ê®Æ, §@²`¤Jªº¤ÀªR¬ã¨s, ¬Ý¯à§_§ä¥Xµª®×, §@¥H«áTFDA¤W¥«ªºªvÀø°Ñ¦Ò©ÎFDA¤T´ÁÁ{§É¸ÕÅ窺§ï¶i°Ñ¦Ò. ¦pªG¤w¸g¨S¦³Globo H¨t¦Cªº¯f¬r, ´N¥iÃÒ©ú822/821ªºÀø®Ä«D±`Àu²§, ´Ý¯dªº¸~½F¬O¨}©Êªº? ©Î¬O¨ä¥L¯f¬r?(»Ýn¥t´MªvÀø?) ¥H¤W¬OÓ¤H·M«ä¶Ã·Q. ·q¯¬¯E¤Í̦w±d´r§Ö ·s¦~¸U¨Æ¦p·N ¦~¦~Âצ¬¦³¾l ¤U±¬OºK¿ý¦Û¤WÂd«eªº¤½¶}»¡©ú®Ñ. ¨Ì¬ü°ê°ê®aÀù¯g¬ã¨s°|(National Cancer Institute)«ü¥X¡A¥½´Á¨ÅÀù¯f¤Hªº¦s¬¡²v°¾§C¡A¤¤¦ì¦s¬¡´Á¬°18~24Ó¤ë¡A5年¦s¬¡²v¤~15~18%¡C OBI-822 ¬O§_½T¹ê¨Ï¥½´Á¨ÅÀù¯f¤H©µ½w´_µo¤Î¼W¥[¦s¬¡²v¡A¤´»Ý«ÝÁ{§É¤G/¤T¸ÕÅçµ²ªG¤ÀªR§¹¦¨«á½T»{¡C ±qÁ{§É¤@´Á¸ÕÅç27¦ì¨ü¸ÕªÌµ²ªG¨Ó¬Ý¡A¦Û¥[¤JÁ{§É¸ÕÅç¶}©l¡A¦b¬ù2年Æ[¹î´Á¤¤¡A²Ä¤@Ãþ¬°¸g¨ä¥L¤è¦¡ªvÀø«á¤wµL¯e¯f¼x¥ü¯f¤H¦@15¤H¡A¦³10¤H¥¼´_µo¡F ²Ä¤GÃþ¦¬®×¹ï¶H¬°¤´¦³¯e¯f¼x¥ü¡B¦ýÄ~Äòªu¥Î²üº¸»XÀøªkªº¯f¤H¡A¦@12¤H¡A¦³5¤H¥¼´_µo(¸ê®Æ¨Ó·½¡GPNAS, 98¡A3270-3275¡A2001)¡C OBI-822 °£¤F¼Ðªº¯f¤H(target patient)¤ñ¤Wz¨â¶µÀøªk²[»\½d³ò¤j¥B¥]§t¤T³±©Ê¯f¤H¤§¥~¡A´X¶µ«ü¼Ð¤]¦P®ÉÅã¥Ü¡AOBI-822 ±N¨Ó¥ÎÃĤW±N¨ãÄvª§Àu¶Õ¡A ¥]¬A¯f¤H¨¤W¥u¦³¤p°Ï°ì¥Ö½§¤ÏÀ³»P¦ü¬y·P¯gª¬¥~¡A¨Ã¥¼µo²{²üº¸»XÀøªk©Ò±a¨Óªº¤@¯ë¤ÆÀøÀøªk°Æ§@¥Î¡A¤]µL§ÜÅéÃĪ«Herceptin ©Ò±a¨Óªº¤ß¬r©Ê»PÄY«¤ßŦ°Æ§@¥Î¡C ³Ì«nªº¬O¡AOBI-822 §@¥Î¾÷Âà»P¤Wz¨â¶µÀøªk§¹¥þ¤£¦P¡A¥¦¬O¥H¬Ì]¤è¦¡´£¤É¯f¤H²ÓM§K¬Ì¤ÎÅé²G§K¬Ì¹ï§ÜÀù²ÓM¡A°§C°Æ§@¥Î¡A§ïµ½¯f¤H¥Í¬¡«~½è¡C |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2014/12/30 ¤U¤È 11:56:12²Ä 157 ½g¦^À³
|
²q·Q¤j¡A ¤p§Ì¤W¤@½gµ¹±zªº¶K¤å ¸£³U¤£²M·¡¡AÅÞ¿è¿ù»~ ½Ð·í§@¤p§Ì¨S¼g ¤£¦n·N«ä |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2014/12/30 ¤U¤È 11:39:53²Ä 156 ½g¦^À³
|
²q·Q¤j¡A ¡y¦b¤@´ÁÁ{§É³ø§i°O¸üµÛ ¦³10¦ìNED¸ÕÅçªÌ ¤´«O«ùNED 5¦ìSD¸ÕÅçªÌ ¤´«O«ùSD ³o¯uªº«ÜÅý¤H¦Ê«ä¤£¸Ñ 10¦ìNED«O«ù¥¼´c¤Æ ©|¥i²z¸Ñ ¦ý5¦ìSDªÌ«o¤´¥iºû«ù¨º»òªøªº¦s¬¡®É¶¡¡z ¤½¶}»¡©ú®Ñ¸ÌªºÁ¿ªk¬O¡A¦b¨â¦~ªºÆ[¹î´Á¡K¡K ¨â¦~Æ[¹î´Á¡A12¦ìSD¤¤¦³5¦ìºû«ùSD¡Aªí¥Ü¦³7¦ì¤w¸g´c¤Æ¡K ¦]¦¹¤p§Ì±À·Q±z¥i¯à´Á¶¡¬Ý¿ù¤F¡C ¥xÁÞ¤j¡A 190¤H©Î191¤H(47.5%)¦bªí2ªº²ÎpÅã¥Ü±o«Ü²M·¡¡A´N¬O´¦¶}µª®×pºâPFS®É¡A¸ÕÅç²Õªº´c¤Æ¤H¼Æ¡A¡y¹Ï¤@¦b0.5©¹¥k²¾°Ê©¹¤U¹ï·Ó18.5Ó¤ë®É,¦s¬¡©|¥¼´c¤Æ¤H¼Æ¬ù¦b139¦Ü83¤H¤§¶¡ ,¦pªG¦s¬¡©|¥¼´c¤Æ¤H¼Æ§ì100¤H¡z¡A³o¡y¦s¬¡©|¥¼´c¤Æ¤H¼Æ¡z¨ä¹ê¥s°µn at risk¡A¤j·§ªº·N«ä¬O¡A¦b18.5Ó¤ë®É¡A°²³]§ì100¤H¡Aªí¥Ü´c¤Æ¼Æ¦r©Î³]¸ê®Æªº¼Æ¦r¤j©ó18.5Ӥ몺¤H¦³100Ó¤H¡A302¤H´N¦p²q·Q¤j©Ò»¡¡A¬O¤p©ó18.5Ӥ몺( ³]¸ê®Æ¤H¼Æ + ´c¤Æ¤H¼Æ ) ªºÁ`©M¡An at risk¬O¦bpºâ¦s¬¡¨ç¼Æ®É¥Îªº¡A¯u¥¿ªº§t·N§Ú¤]¤£¤Ó·|ªí¹F¡C Rabbit¤j´£¨Ñ¤F¤@ӫܴΪº¹Ï¡A³o¬O¤w§¹¦¨ªºOS¦s¬¡¨ç¼Æ¹Ï¡A¤§«eªº¸ê®Æ¹Ï2¡AÁöµM¥i¥H¥Î¨Ó¥Ó½ÐÃÄÃÒ¡A¦ý²¦³º¸ÕÅç²ÕÃĮĤӦn¡AÆ[¹î°lÂܮɶ¡¤£°÷¤[¡A¦]¦¹¦º¤`¤H¼Æ¤£°÷§â¦s¬¡¦±½u°¨ì0.5ªº¤ô¥½u¡A¸g¹L¤@¬q®É¶¡«á¡Aµe¥X§ó±µªñ¨Æ¹êªº¦s¬¡¨ç¼Æ¹Ï¡A·íµM¡A¹L¤F¤@¬q®É¶¡¤§«á§e²{¥Xªº¼Æ¾Ú¡A¹ï·Ó²Õªº¦±½u¹Ï¤]¦³¨ÇÅܤơA¹ï·Ó²ÕªºOS¤]¤£¤@¼Ë¤F¡A¦ý¹ï©ó¸ÕÅç²ÕÃÄ®ÄÀu©ó¹ï·Ó²Õ³oÓ²Îp¤ÀªR¡A¹Ï2»P³Ì·sª©ªº¹Ïªºµ²½×¬O¤@¼Ëªº¡C |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2014/12/30 ¤U¤È 07:59:25²Ä 155 ½g¦^À³
|
¥xÁÞ¤j ±zªº°ÝÃD²o¯A¤¤¦ìPFS ©ÎOS ªººâªk ¦b¤p©_¤j¸Ñµª«e «Øij±z¥ý¥h¬ã¨s¥¦ªººâªk ©Î³\³o¼Ë ±z¤~·|ª¾¹D¤p©_¤j¦b»¡¤°»ò °ò¥»¤W °²¦p«e±ªº³]¸ê®Æ¶V¦h §Y¨Ï¬O´c¤Æ¤H¼Æ¤Ö ¤]·|¤ñ¸û®e©ö¹F0.5 ¦]¬°¦s¬¡¾÷²v¶V¨Ó¶V¤p ¦±½u©¹¤U¼Yªº³t«×·|¥[§Ö ±z»¡ªº190¤H ©M302¤H ¨Ã¤£¬O´c¤Æ¤H¼Æ ¦Ó¬O( ³]¸ê®Æ¤H¼Æ + ´c¤Æ¤H¼Æ ) ªºÁ`©M ¤p§Ì¥´¦r«ÜºC µLªk»¡±o¸Ô²Ó «Ü©êºp |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2014/12/30 ¤U¤È 05:51:00²Ä 154 ½g¦^À³
|
Rabbit¤j §A´£¨Ñ³o±i¬O³Ì·sª©µL»~,«OÃÒ¼öÄËÄ˪º,ÁÂÁ§A,¦U¦ì¤j¤j¥i¥H¥J²Ó¬Ý¬Ý (¥H«e¨º¤@±iOSÁÙ¨S¦bºâ¥X¨Ó,¥uºâ¥XPFS) |
|
|
·|û¡G´µ¤p¤å10139040 µoªí®É¶¡:2014/12/30 ¤U¤È 05:18:58²Ä 153 ½g¦^À³
|
·PÁÂrabbit¤j¤j, http://www.perjeta.com/hcp/clinical/efficacy/overal ¤Ö¶K¤F¤@Ól ¥¿½TÀ³¸Ó¬O http://www.perjeta.com/hcp/clinical/efficacy/overall |
|
|
·|û¡Grabbit10136567 µoªí®É¶¡:2014/12/30 ¤U¤È 05:13:57²Ä 152 ½g¦^À³
|
Hi ¥xÁÞ¤j §Ú¤£ª¾¹D¦³¨S¦³¤H¤À¨É¹L³oÓ Perjeta + H + D ªº¸ê°T http://www.perjeta.com/hcp/clinical/efficacy/progression-free http://www.perjeta.com/hcp/clinical/efficacy/overal ¨Ñ°Ñ¦Ò |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2014/12/30 ¤U¤È 04:54:19²Ä 151 ½g¦^À³
|
¤p©_¤j: ¦A½Ð±Ð¤@¤U ¶P¯e§´Âù¼Ð¹vÃĪ«»¡©ú®Ñ ¹Ï¤@¬OµL¯e¯f´c¤Æ¦s¬¡´ÁªºK-M¦±½u¡A¦b¬Y¤@®É¶¡´¦¶}¬Ýµª®×¡A¦¹®É¸ÕÅç²Õ¹F47.5%ªº¤H´c¤Æ¡A¹ï·Ó²Õ¹F59.6%ªº¤H´c¤Æ¡A¸ÕÅç²Õ»P¹ï·Ó²Õªº¦±½u³£»P¾÷²v0.5ªº¤ô¥½u¦³¬Û¥æ http://www.ccgh.com.tw/CK/ck_MedMaintain2/download/iperj..pdf 402¤Hx47.5%=190¤H ¤]´N¬O¬ù¦³212¤H¦s¬¡©|¥¼´c¤Æ, ¥i¬O¹Ï¤@¦b0.5©¹¥k²¾°Ê©¹¤U¹ï·Ó18.5Ó¤ë®É,¦s¬¡©|¥¼´c¤Æ¤H¼Æ¬ù¦b139¦Ü83¤H¤§¶¡ ,¦pªG¦s¬¡©|¥¼´c¤Æ¤H¼Æ§ì100¤H¤]´N¬O¦³302¤H¤w¸g´c¤Æ , ¹F¨ì0.5®É ¬°¦ó¤@Ó190¤H´c¤Æ ¥t¤@Ó¬O302¤H´c¤Æ ¨âÃä¤H¼Æ®t¶Z¦p¦¹¤j |
|
|
·|û¡G¤ý£«¬Â10136621 µoªí®É¶¡:2014/12/30 ¤U¤È 03:44:48²Ä 150 ½g¦^À³
|
¤½¥q©w´Á¨ìÂå°|Å¥¨úÁ{§É²³ø,¹ï¯f±w±¡ªp¤ÎÃÄ®ÄÀ³¸ÓÁAY«ü´x. |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2014/12/30 ¤U¤È 03:40:39²Ä 149 ½g¦^À³
|
¸É¥R103.3.5ªk»¡·|²³ø¤U¸ü http://pchome.megatime.com.tw/post/sto5/mkt2/2 ¦³¿³½ìªº¯E¤Í¥i¥H¬Ý¤@¤U |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2014/12/30 ¤U¤È 03:22:36²Ä 148 ½g¦^À³
|
ÁÂÁÂCliff¤j ¤p©_¤jªººëªö¸ÑªR °²¦p ¡¨ÃĮĤj³¡¤À¨M©w©ó GH¨t¦C§Üì ²ÓM¼Æ¦Ê¤À¤ñªºÁp¶°¡¨ ³oÓ°²³]¦¨¥ß ¨ºÁ{§É¸ÕÅ窺µ²ªG ´N·|¦³¹B®ðªº¦¨¤À ¤×¨ä¤H¼Æ¤Ö®É °²Y¸ÕÅç²Õªº±wªÌ ¦h¼Æ¨ã¦³°ª²ÓM¼Æ¦Ê¤À¤ñ ÃĮĥi¯à´N·|Åã±o«Ü´Î °²Y¸ÕÅç²Õªº±wªÌ ¦h¼Æ¨ã¦³§C²ÓM¼Æ¦Ê¤À¤ñ ÃĮĥi¯à´N·|Åã±o´¶´¶ ¸Ñª¼®É¤¤¦ìPFS¤]³\«n ³Ì«nªº ©ÎÁÙ¬O¦b822¼Ð¹v©Êªº°ª§C§a? Cliff¤j¹ï°ÝÃD«ä¦Ò «Ü¦³¤Þ¾É©Ê Cliff¤j¹ïarteminªº¤j§@ µn¦b¡¨½Ð¤j®a¨Ó²q·Q"¯E¹©¤½¥q¦b¥¬¤°»ò (2014/10/10 ¤U¤È 08:38:31) ©Î¥iÀ°§Ú̸Ѵb---¬°¦ó¨ãGHÀù²ÓM³Q®ø·À«á ¥i¥Hºû«ù¤@¬q®É¶¡ªºÃ©w ¦P®ÉCliff¤j¤]«ü¥X ¡§ ¬O§_¦³¨ä¥LPÀù©Ê§C©óGH¨t¦CÁÞ§Ü쪺¸~½F¼Ð°O¦bÄ~Äò¼vÅTµÛ¦o̪º¯f±¡¡]MUC1¡H©Î¨ä¥L?¡^¡¨ Cliff¤jªº·N«ä©Î¬O Áö¦b®ø·ÀGH«á Àù²ÓM¤WÁÙ·|¦³¨ä¥L¼vÅT´c¤Æªº¦]¤l Ä~Äò·o³J ©Î¤£¥i¯àÄ~Äò«O«ù¦bSDª¬ºA? ¯E¹©¦b 2013 3/7 ªºªk»¡·|¸ê®ÆÅã¥Ü ¤@´ÁÁ{§É©|¦³16¦ìªº¸ÕÅçªÌ¦s¬¡(¨ä¤¤¦³¨â¦ìªº³]¸ê®Æ¬O 3+ ¤Î 5+ ¨ä¾l³£¦b8+¥H¤W) ¥B¦b¤@´ÁÁ{§É³ø§i°O¸üµÛ ¦³10¦ìNED¸ÕÅçªÌ ¤´«O«ùNED 5¦ìSD¸ÕÅçªÌ ¤´«O«ùSD ³o¯uªº«ÜÅý¤H¦Ê«ä¤£¸Ñ 10¦ìNED«O«ù¥¼´c¤Æ ©|¥i²z¸Ñ ¦ý5¦ìSDªÌ«o¤´¥iºû«ù¨º»òªøªº¦s¬¡®É¶¡ ¬O822ªº®ÄªG ÁÙ¬O¦³¨ä¥L¾÷¨î©ÎªvÀø¨ÏµM? ²q´úµLÃö¨Æ¹ê ½Ð¤j®a¬Ý¬Ý´N¦n ÁÂÁÂ! |
|
|
·|û¡G¯ä¦Ñ¹«10139175 µoªí®É¶¡:2014/12/30 ¤U¤È 01:58:32²Ä 147 ½g¦^À³
|
ÁÂÁ£«¬Â¤j 822ªº¹ï¤â¬O¶P¯e§´,PR¤ñ¨Ò°ª¹F74.6% ©Ò¥H³o¨â¦ì¥Î¨ì822ªº¯f±w¨S¦³¥X²{PR¤~n¾á¤ß §ÚÌnÃö¤ßªº¬O"¥´§¹Àøµ{¥b¦~¦hÄ~Äò°lÂܸ~½F¨S¦³´c¤ÆÅܤj©ÎÅܤp«Üéw" ³o¬O³Ì«nªºPFS~~~37¶g+¥b¦~¦h(¨ú30¶g)=67¶g 67¶g¤j¬ù¬O16.75Ó¤ë Â÷18.5Ӥ뤣»· ¦Ó¥BÀ³¸Ó¥i¥H«ùÄò¼W¥[~~~~~³o³¡¤Àn³Â·Ð£«¬Â¤jÀ°¤j®a°lÂܤF ÁÂÁ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2014/12/30 ¤U¤È 01:33:24²Ä 146 ½g¦^À³
|
¤p©_¤j: ÁÂÁ§Aªº¸Ñ´b,¸g¹L§Aªº¸Ñ»¡Ó¤H¤ñ¸û©ñ¤ß ÂŤѤj: ¨Ì¾ÚResponse Evaluation Criteria in Solid Tumors(RECIST),§A¤µ¤Ñ¤¤¤È¶K¤å¤ÀªR§¹¥þ¥¿½T,¨ØªA§Aªº¤ÀªR¥\¤O, §¹¥þ²Å¦X¤U±¹ïCR PR SD PD ªº¸ÑÄÀ Evaluation Criteria for Target Lesions 1 Complete Response, or CR ¡V Signifies that all target lesions have disappeared during the course of treatment. 2 Partial Response, or PR ¡V Signifies that decreases of at least 30% have been noted in the lesion that has the largest diameter, or LD. 3 Stable Disease, or SD ¡V Signifies that there has been no significant decrease or increase in the size of target lesions, based on the smallest sum LD. 4 Progressive Disease, or PD ¡V Signifies that there has been an increase of at least 20% in the sum of the LD of targeted lesions. |
|
|
·|û¡Grabbit10136567 µoªí®É¶¡:2014/12/30 ¤U¤È 12:59:24²Ä 145 ½g¦^À³
|
¤£·|¦AÅܤpªº¸~½F ¤Ï¹L¨Ó»¡ YµL¦AÅܤj ¨º´N©Î³\¬O¨}©Ê¸~½F©Ò¥HºÙ¬° SD ¤H¤@¥Í·í¤¤ ¾¹©x¸~½F¦]¬°¾¹©x¦¬ÁY¹B°Ê¾÷¨î ¥»¨Ó´N¦³µo¥Íªº¾÷²v SD ªº¯f±w±µ¤U¨Ó´N¾a¥L̦ۤvªº¥Í¬¡§@®§¨Óºû«ù¯f¼x¤F Y¦]¬°¦n¤F ¤S¶}©l¶Ã¦Y¶Ã³Ü¶Ãª± ¨º´N¥i±¤¤F |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2014/12/30 ¤U¤È 12:56:26²Ä 144 ½g¦^À³
|
ÁÂÁÂCliff¤j¡A ¤wÀˬd¤F¤¤¤åªº¿ù¦r¡A^¤å¦r³o»ò©úÅ㪺¿ù¦r³ºµM©¿²¤¤F¡I ¥xÁÞ¤j¡A ¦b±zªº¨Ò¤l¤¤ ¤@¡G¡yA¬O¹êÅç²Õ 190¤H B¬O¹ï·Ó²Õ95¤H A²Õ¦pªG´c¤Æ¤H¼Æ40¤H B²Õ´c¤Æ¤H¼Æ90¤H¡z¡A³o»òÄa®íªº´c¤Æ¤H¼Æ¤ñ¨Ò¡AªÖ©w·|¦³«Ü¤pªºpÈ¡A¤]´N¬O·¥ÅãµÛªº®t¯q ¤G¡G¡yA²Õ´c¤Æ¤H¼Æ¸ûB²Õ¤Ö PFS ¤ë¼Æ¤@©w·|¹F¨ì²z·Qª¬ªp¶Ü? ¦] PFS¬O¨ú¤¤¦ì¼Æ,©È¦³·¥ºÝÈ¥X²{ ,¦pªG©Ô¤jÆ[¹î®É¶¡¡AÅýA²Õ´c¤Æ¤H¼Æ¾A«×¼W¥[±Æ°£·¥ºÝÈ¥X²{,¦p¦¹¬O§_·|¦³§ó¦nªºPFS¤ë¼Æ?¡z ¤p§Ì¤§«e(¤Q¤@¤ë©³¤§«e)¹ï¦s¬¡¤ÀªRªº²Îp»{ÃѤ£²M¡A¤£¾å±o«ç»ò³B²z³]¸ê®Æ¡A¦]¦¹»~¾É¤j®a¤F¡A¯u¬O©êºp¡C¦b§¹¥þ¨S¦³³]¸ê®Æªº±¡ªp¤U¡APFS¬O¨ú¤¤¦ì¼Æ¨S¿ù¡A¦ý¥un¦³³]¸ê®Æ¡APFS´N¬O·í´c¤Æ¤H¼Æ¹F¨ì¥i¥Hµe¥X¦s¬¡¨ç¼Æ»P0.5¤ô¥½u¬Û¥æªº®ÉÔ¡A¤~·|¥X²{¦¹¹êÅ窺PFS¡A¤Ö¼Æªº·¥ºÝȹïFPS¤£¤Ó·|¦³¼vÅT¡C ½Ð¦A¥J²Ó¬Ýhttp://www.ccgh.com.tw/CK/ck_MedMaintain2/download/iperj..pdfùØÀYªº¨Ò¤l ¹Ï¤@¬OµL¯e¯f´c¤Æ¦s¬¡´ÁªºK-M¦±½u¡A¦b¬Y¤@®É¶¡´¦¶}¬Ýµª®×¡A¦¹®É¸ÕÅç²Õ¹F47.5%ªº¤H´c¤Æ¡A¹ï·Ó²Õ¹F59.6%ªº¤H´c¤Æ¡A¸ÕÅç²Õ»P¹ï·Ó²Õªº¦±½u³£»P¾÷²v0.5ªº¤ô¥½u¦³¬Û¥æ¡A³o®É¨â²ÕªºPFS³£¥i¥H(¨D)µe¥X¨Ó¡A¦pªG¦¤@Ó¤ë©Î±ß¤@Ӥ봦¶}¬Ýµª®×¡Aµe¥X¨Óªº¨âÓ¦±½u»P¹Ï¤@·|¦³ÂI¤£¦P¡A¦ýªø¬ÛÃþ¦ü¡A¦b²Îp¤W³£¥i¥H¹F¨ìÅãµÛ®t²§¡A¦pªG¯uªºnµ¥¨ì©Ò¦³¤H³£´c¤Æ¡A¤]¥i¥Hµe¥X¤@ӹϫ¬¡Aªø¬Û»P¹Ï¤@Ãþ¦ü¡A¦ý¦±½u¥i¥Hµe¨ì¾÷²v0ªº¤ô¥½u¡A¦ýFPSªºµ²ªGÁÙ¬O»P¹Ï¤@®t¤£¦h¡A¤£·|¦]¬°©Ô¤jÆ[¹î®É¶¡´N·|¦³§ó¦nªºPFS¤ë¼Æ¡A¦s¬¡¤ÀªRªº¸ÕÅ礣·|¦³¤H°µ¨ì¥þ³¡±wªÌ³£´c¤Æ¤~¤ÀªR¡A®t¤£¦h¥i¥H½T©w¸ÕÅ窺µ²ªG´N¥i¥H¸Ñª¼¤F¡C ¹Ï¤G¬OÁ`¦s¬¡´ÁªºK-M¦±½u¡A¤ÀªRµL¯e¯f´c¤Æ¦s¬¡´Áªº¼Æ¾Ú®É¡A¤]¤@¨Ö¤ÀªRÁ`¦s¬¡´Á¡A¦ýÆ[¹î®É¶¡¤£°÷¤[¡A¥u¦³165¦W±wªÌ¦º¤`¡A²Îp¤W¥¼¹FÅãµÛ¤ô·Ç¡A¤Sµ¥¤F¤@¦~¡A¸ÕÅç²Õ¦³28.1%¦º¤`¡A¹ï·Ó²Õ¦³37.9%¦º¤`¡A¦¹®Éªº¼Æ¾Ú¤w¹F²ÎpªºÅãµÛ¤ô·Ç¤F¡A¥i¥H¥Ó½ÐÃÄÃÒ¤F¡AÁöµM¸ÕÅç²Õ¥u¦³28.1%ªº¦º¤`¡A¸ÕÅç²Õªº¦±½uÁÙ¨S°¨ì0.5ªº¤ô¥½u(¹Ï¤G¥u¦b¤j¬ù0.6¤W¤U)¡A¦ý¥H«á¦A«ùÄò°lÂÜ¡A¸É¤W§¹¾ãªºOS¸ê®Æ´N¦æ¤F¡C ¦]¦¹¡A¡yA²Õ´c¤Æ¤H¼Æ¸ûB²Õ¤Ö PFS ¤ë¼Æ¤@©w·|¹F¨ì²z·Qª¬ªp¶Ü¡z¡A³o¬O½T©wªº¡C ¡y¦pªG©Ô¤jÆ[¹î®É¶¡¡AÅýA²Õ´c¤Æ¤H¼Æ¾A«×¼W¥[±Æ°£·¥ºÝÈ¥X²{,¦p¦¹¬O§_·|¦³§ó¦nªºPFS¤ë¼Æ?¡z¡A³o¥y¸Ü¤£¯à³o¼ËÁ¿¡A¦pªG´c¤Æ¤H¼Æ¤£¨¬¥Hµe¥X»P0.5¬Û¥æªº¤ô¥½u¡A©Ô¤jÆ[¹î®É¶¡¬O¬°¤Fµ¥«Ý¦±½u»P0.5¤ô¥½u¬Û¥æªº¼Æ¾Ú¥X¨Ó¡A¦pªG¦±½u¤w¸g¹L¤F0.5ªº¤ô¥½u¡A¤£ºÞ¦Aµ¥¦h¤[¡APFSªºµ²ªG³£¬O®t¤£¦hªº( ©ÎªÌn»¡¤@¼Ë¤]¥i¥H)¡C. ¥H¤W·N«ä´N¬O¡A´Nºâ²{¦b¥ß¨è´¦¶}¬Ý822¸ÕÅ窺¼Æ¾Ú¸ê®Æ¡A¨â²Õ¤]¥i¥H¹F¨ì²Îp¤WªºÅãµÛ®t²§¡A¹ï·Ó²ÕªºFPS¤w¸g½T©w¥i¥Hµe¥X¨Ó¤F¡A¸ÕÅç²Õªº´c¤Æ¤H¼ÆÁÙ¤£°÷¦h¡A¥i¯à¥u¯àµe¨ì¤ô¥½u0.7¥ª¥k¡A»Ýn¸ÕÅç²Õ¤j¬ù¤H¼Æªº35%~40%¡A¤]´N¬O¸ÕÅç²Õ¤j¬ù80~91¤H´c¤Æ¡A¤~¯à½T©w¸ÕÅç²ÕªºPFS¡A§_«h´£¦´¦¶}¡A¨â²Õ¦³²Îp¤WªºÅãµÛ®t²§¦ýÁÙ¨S¦³§¹¾ãªº¸ÕÅç²ÕPFS¡A¤]¤£ª¾¯à¤£¯à³o¼Ë¨Ó¥ý¥Ó½ÐÃÄÃÒ¡C²z½×¤WÀ³¸Ó¬OÁ`´c¤Æ¤H¼Æ¹F176¤H¥H¤W¡A´N¥i¥H¸Ñª¼¡A¤p§Ì¤£ª¾¹D«ç»ò¸ÑÄÀ¬°¦ó¬O176¤H¡AD§b¤j´£¨Ñªº¸ê®Æ¥i¥H¸ÑÄÀ¡C |
|
|
·|û¡GÂŤÑ10138178 µoªí®É¶¡:2014/12/30 ¤U¤È 12:41:20²Ä 143 ½g¦^À³
|
¯e¯f¶i®i ¡]PD, progressive disease¡^¹v¯f¨_³Ì¤j®|¤§©M¦Ü¤Ö¼W¥[≥20%¡A©Î¥X²{·s¯f¨_ ¯e¯féw(SD, stable disease)¹v¯f¨_³Ì¤j®|¤§©MÁY¤p¥¼¹FPR¡A©Î¼W¤j¥¼¹FPD ³¡¤À½w¸Ñ(PR, partial response)¹v¯f¨_³Ì¤j®|¤§©M´î¤Ö≥30%¡A¦Ü¤Öºû«ù4¶g §¹¥þ½w¸Ñ(CR, complete response)©Ò¦³¹v¯f¨_®ø¥¢¡AµL·s¯f¨_¥X²{¡A¥B¸~½F¼Ð»xª«¥¿±`¡A¦Ü¤Öºû«ù4¶g ¥H¤W±³o©w¸q¨Ó»¡ À³¸Ó¬OPR¤~¬O. ¥t¥~ ¸~½F«á¨ÓÁY¤pÅܺC °£¤F¥i¯à¬OµLGH§Üì¨t¦CªºÀù²ÓM¥~ §K¬Ì°O¾ÐºCºC§Ñ±¼¤]À³¦³Ãö«Y(Ó¤H²q´ú). |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2014/12/30 ¤U¤È 12:20:50²Ä 142 ½g¦^À³
|
¤p©_¤j¥i¯à«æµÛ¥´¦r¡A»~§âNED¥´¦¨IND¡A¤j®aÀ³¸Ó¬Ý±oÀ´¡A¦Û¤v§ï¹L¨Ó´N¥i¥H¤F¡C 822ªºªvÀø¸gÅç¦b¸Ñª¼«á¤]±N²£¥Í§ó¦h«Ý¸ÑªººÃ°Ý¡A¤]µ¥©ó´£¨Ñ¤F¥¼¨Ó«áÄòªº¬ã¨s¤è¦V¡A¤@ªùGlobo HÀù¯gªvÀø¾Ç´N±N³vº¥§Î¦¨¡C Phase I¤´¦s¬¡ªºÓ®×¥L̪º«áÄò¤£ª¾¦p¦ó¡A¨ä¤¤¦³¦h¤Ö¦ì¬ONED¡H¦³¦h¤Ö¦ì¬Oºû«ùSD¡H¡]SD¥i¥Hºû«ù¨º»ò¤[¶Ü¡H¡^¡A³o´X¦ìªº«áÄò°lÂܬO«Ü¬Ã¶Qªº·s¸ê®Æ¡A¤£ª¾¤½¥q¦³¨S¦³pµe©µÄò±´°Q¡H ¥xÆW³o¨â¦ì®×¨Ò¡A¥Ø«eºâ¬OSD¡A¦p¤p©_¤j©Ò¨¥¡A¬O§_¦³¨ä¥LPÀù©Ê§C©óGH¨t¦CÁÞ§Ü쪺¸~½F¼Ð°O¦bÄ~Äò¼vÅTµÛ¦o̪º¯f±¡¡]MUC1¡H©Î¨ä¥L?¡^,©ÎªÌGH¨t¦CÁÞ§Üì¼È³Q®ø·À¦Óºû«ùéw¡A¬O¼È®Éîh¥ñÁÙ¬O¥¿»W¶ÕÁßÆC¤U¤@ªiªº´c¤Æ¡H§â¥¦§ä¥X¨Ó¤~¯àÄ~Äòµû¦ô¦h¤[·|¦A±Ò°Ê´c¤Æ¡A¡]¸òArtemin¦³Ãö¡H¡^§_«h³o¨Ç±wªÌ°µ§¹¼Ð·ÇÀøµ{«á¡A¸~½F¥¼§¹¥þ®ø¥¢¡AÁÙ¬O¾áµÛ¤@Áû¤ß¡A¥u¬O¤@¸ô°lÂܤU¥h¡AÁ`¤£¥i¯à¤@ª½³£ºû«ùµÛSD§a¡H¸Ó¦h¤[n¦A¦^°|°l¥[¤@¾¯©Î¤@ÓÀøµ{¡H¦b¦b³£Åý³o®a¤½¥q¥¼¨Ó¤£·|¨S·~°È¥i°µ¡A³oªùGlobo HÀù¯gªvÀø¾Ç¤~¥¿n®i¶}¡C |
|
|
·|û¡G£~£~10134649 µoªí®É¶¡:2014/12/30 ¤W¤È 11:59:05²Ä 141 ½g¦^À³
|
¬O§_¦³¥i¯à:ì¥ÍÀùGH¤ñ²v¤ñ¸û¤Ö,ÂಾÀùGH¤ñ²v¤ñ¸û¦h¡C |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2014/12/30 ¤W¤È 11:29:03²Ä 140 ½g¦^À³
|
ªü¬Â¤j¡A ÁÂÁ±z¡I ¬Ý§¹ªü¬Â¤jªº¸Ô²Ó»¡©ú«á¡A¦³´XÂI·Qªk¡G ¤@¡G822¯uªº¥i¥H±þ¦ºªí±¦³GH¨t¦CªºÀù(·F)²ÓM¡A¦Ü©ó¯à±þ¦º¦h¤Ö¡A¬ÝÓ¤H¨¤WªºÀù(·F)²ÓM¤WªºGH¨t¦CÁÞ§Ü쪺ªí²{¤ñ¨Ò¡C ¤G¡G¡y¨Ò¤l1.¨ÅÀù5¤½¤À>3¤½¤À,¨xªÍ2¤½¤À>1¤½¤À.¨Ò¤l2.¨ÅÀù3¤½¤À>1.9¤½¤À,¨xªÍ3¤½¤À>1.5¤½¤À¡z 쥻ªº¨Å©Ð³¡¦ì¸~½FÁY¤pªºµ{«×¤p©óÂಾªº¨xªÍ¸~½FÁY¤pªºµ{«×¡A¨Å©Ð³¡¦ìÁY¤pªºµ{«×¤£¨ì50%¡A¨xªÍ¸~½FÁY¤pªºµ{«×¦³¹F¨ì50%¡A¥u¬O¤£ª¾³o¼Ëªº±¡ªpÀ³¸Ó§P©w¬°PR©ÎªÌSD¡C¨xªÍªºÀù(·F)²ÓM¬O¨Å©Ð³¡¦ìªºÀù(·F)²ÓMÂಾ¥X¥hªº¡A«Ü¦³¥i¯àÂಾªº¨xªÍ³¡¦ìªºGH¨t¦CÁÞ§Ü쪺²ÓM¼Æ¦Ê¤À¤ñ¬O»P¨Å©Ð³¡¦ìªº²ÓM¼Æ¦Ê¤À¤ñ«Ü±µªñ¡A¦ý¨Å©Ð³¡¦ì¦³¸û¦h¤ñ¨ÒªºÀù·F²ÓM¡A¨Å©Ð¸~½Fªº¥Í©R¤O±j©ó¨xªÍªº¸~½F¡A¦]¦¹¨Å©Ð¸~½FÁY¤pµ{§Ç¤p©ó¨xªÍªºÁY¤pµ{«×¡C¦Ü©óS¤p©j¬OÄÝ©ó¤Ö¼Æ·¥°ªªº²ÓM¼Æ¦Ê¤À¤ñ¡AÂಾ¨ìþÓ³¡¦ì822³£¥i¥H³q±þ¡A©Ò¥H´NIND¤F¡CIND¦bMBC¬O«Ü¤£®e©öªº¨Æ¡A°Ñ¦Òhttp://www.ccgh.com.tw/CK/ck_MedMaintain2/download/iperj..pdf ùØÀY¶P¯e§´+¶PÀù¥+µµ§ü¾J³Ì¦nªº²Õ¦XÃĤ]¥u¦³5.5%ªº¤ñ¨Ò¬O§¹¥þ¤ÏÀ³¡A§¹¥þ¤ÏÀ³»PINDÀ³¸Ó¬O«Ü±µªñªº©w¸q¡C ¤T¡G¡y«e´X°wÁY¤p³t«×§Ö¶V¨ì«á±³t«×¶VºC¡z¡A¡y¥´§¹Àøµ{¥b¦~¦hÄ~Äò°lÂܸ~½F¨S¦³´c¤ÆÅܤj©ÎÅܤp«Üéw¡z¡A¦ýS¤p©j¦b¬ù¥b¦~´N¤w¸gIND¡A¤§«á«ùÄòºû«ùIND¡A¦Ó³o¨â¦ì±wªÌ¨ì«á±´X°w¸~½F´N¤£©ö¦A«ùÄòÁY¤p¡A¦ý¸~½F«o¤]¯àºû«ùéw¤£Åܤj¡CS¤p©j»P³o¨â¦ì±wªÌ¯àºû«ùµL¯e¯f¶i®i¥Í¦sªºì¦]¤£¦P¡AS¤p©j¤w¸g¬O»ö¾¹Àˬd¤Uªº¹sÀù(·F)²ÓM¡An¦A¥X²{©úÅ㪺¸~½F·Ó±À²zÀ³¸Ó¬O«Ü¤[¥H«áªº¨Æ¤F¡A¦Ó³o¨â¦ì±wªÌÅãµM¦³822µLªk±þ¦ºªºÀù(·F)²ÓM¦s¬¡µÛ¡A¦ý«o¤]»P¨Åé©M¥¦@¦s¤F¦n´XÓ¤ë¡A¦ó®ÉÀù(·F)²ÓM·|¦A¬¡ÅD¤j¶q¤ÀµõÁc´Þ¤£ª¾¹D¡A¦ý¥¢¥hGH¨t¦CÁÞ§Ü쪺¸~½FÅãµM«Â¤O¨S¨º»ò±j¤j¤F¡A¨ì©³¥¢¥h¤FGH¨t¦CÁÞ§Ü쪺¸~½F¬°¦ó¼W¥ÍÁc´Þªº¯à¤O´î®z¡H¬O³z¹L¤°»ò¾÷Âà§@¥Î¾ÉP´î®z¡H¦ó®É·|¦A«×Âà±j¡H³o¯u¥O¤H¦n©_¡I µ²½×¡G¥un¦³GH¨t¦CÁÞ§Ü쪺Àù(·F)²ÓM¡A822»¤µo¥Xªº§ÜÅé¤ÏÀ³´NÄè·À¥¦¡A¤ñ¨Ò¶V°ª¡AÃĮĶV¦n¡A§Y¨Ï¨S¦³§¹¥þÄè·À¡A¯d¦sªºÀù(·F)²ÓM¤]¦b¥¢¥hGH¨t¦CÁÞ§Üì«á«Â¤O´î®z¡A±wªÌºû«ùSDªºª¬ºA¡Aª½¨ì¸~½F¤S§ä¨ì·sªºÂX±i»â¦aªº¤èªk¡C ¥H¤W¯ÂÄݱÀ·Q¡A»P¹ê»Úª¬ªp¥²¦³·¥¤j¥X¤J¡A¤HÅ餺¥ô¦óªº¾÷Âà§@¥Î¬Ò»Ý¤j¶qªº¹êÅç¼Æ¾Ú¤è¯à¦õÃÒ¡A½Ð¤j®a¬Ý¬Ý´N¦n¡C |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2014/12/30 ¤W¤È 10:14:39²Ä 139 ½g¦^À³
|
¥xÁÞ¤j ¯uªºC ÁÙ¬O±z²Ó¤ß ·PÁ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2014/12/30 ¤W¤È 09:37:46²Ä 138 ½g¦^À³
|
Faith¤j: 12¤ë8¤é©ñ¤W¯E¹©ºô¶´N¦³pipeline ,¥xÆW¯E¹©¥Í§Þ²¤¶,²Ä3¤ÀÄÁ¶}©l¦³888 ³æ§Ü,¥¼¨ÓÁÞ°ò³æ§Ü§¡¬Û¤Æ,³æ§Ü°Æ§@¥Î»PÀø®Ä·|´£¤É,¥xÆW¯E¹©¤@©w·|±Ä¥Î·s¤@¥N³æ§Ü ,888ÄÝ©ó³Q°Ê§K¬Ì,¤]¯à¾A¥Î16ºØÀù¯g,±N¨Ó¥i¥H³æ¥Î©Î»P§O®a©Î¦Û®a¤½¥q²£«~Áp¦X¥ÎÃÄ ³oºØ©P±K³W¹º,¥Rº¡¶¯¤ß§§§Ó |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2014/12/30 ¤W¤È 08:51:11²Ä 137 ½g¦^À³
|
ÁÂÁ £«¬Â¤j¸Ô²Óªº»¡©ú ¥Ñ³o¨â¨Ò ¤p§Ì¥u¦³¤@Ó·Qªk «e´ÁÁY¤pªº³t«×§Ö «á´ÁºC ¬O§_ªí¥Ü 822¯uªº²£¥Í±þ¼Ä®ÄªG «e´Á¦]¨ãGHµ¥§Ü쪺²ÓM¦h ©Ò¥HÁY¤p³t«×§Ö «á´Á¦]GHµ¥§Ü쪺²ÓM³Q¦Y±o©Ò³ÑµL´X ¥HP³t«×Åܽw ¦Ó¯àÄ~Äò«O«ù¤£´c¤Æ ¤j·§¬O¦]¨ãGHµ¥¸û¦³«I²¤©Êªº²ÓM³Q¦Y¥ú¤F ©Ò³y¦¨ªºµ²ªG? ³o¸ò¤p©_¤jªº±À·Q¦n¹³³á!? J«ä¶Ã·Qªº²q´ú ½Ð¤j®a¬Ý¬Ý´N¦n ÁÂÁÂ! |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2014/12/30 ¤W¤È 08:08:38²Ä 136 ½g¦^À³
|
ªü¬Â¤j ÁÂÁ±z Cliff¤j ¤½¶}»¡©ú®Ñ¤¤½T¹ê¦p±z©Ò´£ªº(§Ú¬O¹ï·Ó¤W¤è¶½XP.130©MP.139) ©Ò¥H±z»¡ªº«Ü¦³¹D²z ¦Ü©ó¤½¥qªººô¸ô¶± §Ú°O±o¥H«e¦b³oÓ²£«~¬ãµo-²£«~¶±¤¤½T¹ê¦³888,¦ý²{¦b¨S¦³¤F http://obipharma.com/index.aspx?lang=chi&fn=index#PIPELINE |
|
|
·|û¡G£~£~10134649 µoªí®É¶¡:2014/12/30 ¤W¤È 05:25:40²Ä 135 ½g¦^À³
|
´«ºâ¦¨Åé¿n: ¤@¦~¥bÁY¤p¤F ²Ä¤@¨Ò¨ÅÀù78.4%,¨xªÍ87.5%¡C ²Ä¤G¨Ò¨ÅÀù74.5%,¨xªÍ87.5%¡C |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2014/12/29 ¤U¤È 11:22:03²Ä 134 ½g¦^À³
|
http://tsjh301.blogspot.tw/2014/08/obipharma.html ³oºô¯¸8¤ëºI¹Ï. 888¨S¥X²{¹L¤F.¤j®a»´ÃPÂI.§O¤Óºò±i... |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2014/12/29 ¤U¤È 10:09:49²Ä 133 ½g¦^À³
|
2015¥Í§Þ®i¤]ÁÙ¦³ 5. OBI-888 (Àù¯g³Q°Ê¦¡§K¬ÌÀøªk³æ®è§ÜÅé) ƒÜ pµe¬ãµo¾AÀ³¯g: °ª«×ªí²{Globo HªºÀù¯g, ¬ù¦³8ºØ¥H¤WÀù¯g ƒÜ ²£«~¶i«× : Á{§É«e¶}µo (¥þ²y) |
|
|
·|û¡G°e³øªº10135990 µoªí®É¶¡:2014/12/29 ¤U¤È 10:07:00²Ä 132 ½g¦^À³
|
©xºô¤Wªº²£«~°T®§¦n¹³¤@ª½³£¨S§âOBI-888©ñ¤W¥h¹L.¬O§Ú°O¿ù¤F¶Ü?? OBI-833¤]ÁÙ·f°tOBI-832.¦n¹³³£¨S§ï¹L§a.. |
|
|
·|û¡GCliff10135274 µoªí®É¶¡:2014/12/29 ¤U¤È 09:58:35²Ä 131 ½g¦^À³
|
©xºô¤Wªº²£«~°T®§ªº½T¤wµLOBI-888ªºÄæ¦ì¡Aì¦]¤£¸Ô¡A·d¤£¦nDCB¨ºÃä¶i«×¤£¶¶¡F»¡¤£©w¥u¬O·Q§â888ªº³¡¤À°µ§ó·s¡A¤uµ{¥¼§¹¦¨¼È¯d¥Õ¡A¹L´X¤Ñ¦A¬Ý¬Ý¡C ¦Ó·sª©ªº¼W¸êpµe»¡©ú®Ñ¡A¬O°w¹ï¦¹¦¸¼W¸êªº¥Î³~°µ»¡©ú¡Ap.130©ú¥Õ»¡¦¹¦¸¼W¸êª÷ÃB¬O¥Î©ó822/833/858/868; ¥¼´£¨ì888¡C¦ý¦bp.123ªí®æ¡u¥Ø«e¬ãµo¤¤·sÃıM®×¡v¤´¦C¦³888¡C ©Î³\¥u¬O¦¹¦¸¼W¸êª÷ÃB¤£¥Î©ó888¬ãµo¡A¤£¨£±oªí¥Ü888¤w³QºM±¼¡CÁ`¤£·|¨S®Õ½Z¡A¤~®t´X¶´N«e«á¥Ù¬Þ§a¡H ¦Ü©ó¬O§_822Àø®Ä¸ÕÅç¤w¸g¤Ó¦n¡A©Ò¥H¤£¥²888¡H§Úı±oÁÙ¥¼¸Ñª¼¡A´N¥H¥¼½T©wªº822Àø®Ä«æµÛ¥h¨MÂ_888¥Í¦º¡A³o¾÷·|¤£¤j¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2014/12/29 ¤U¤È 09:33:35²Ä 130 ½g¦^À³
|
¦U¦ì¤j¤j ¤p©_¤j: ¦pªG¬ü°ê¬Y¤@®a¥Í§Þ¤½¥q ¶i¦æ¤@ÓÂùª¼³]pªºÃĪ«¤T´ÁÁ{§É¹êÅç 1 A¬O¹êÅç²Õ 190¤H B¬O¹ï·Ó²Õ95¤H ½Ð°ÝA²Õ¦pªG´c¤Æ¤H¼Æ40¤H B²Õ´c¤Æ¤H¼Æ90¤H Ó¤H»{¬°À³¹F·¥ÅãµÛ®t²§ 2 A²Õ´c¤Æ¤H¼Æ¸ûB²Õ¤Ö PFS ¤ë¼Æ¤@©w·|¹F¨ì²z·Qª¬ªp¶Ü? ¦] PFS¬O¨ú¤¤¦ì¼Æ,©È¦³·¥ºÝÈ¥X²{ ,¦pªG©Ô¤jÆ[¹î®É¶¡ ÅýA²Õ´c¤Æ¤H¼Æ¾A«×¼W¥[±Æ°£·¥ºÝÈ¥X²{,¦p¦¹¬O§_·|¦³§ó¦nªºPFS¤ë¼Æ? ¥H¤W½Ð±Ð ¹F·¥ÅãµÛ®t²§¬O§_´N·|¦³²z·QªºPFS¤ë¼Æ 3 Ó¤H»{¬°¦¬§¹®×À³¸Ó¥u¦³¸Ñª¼,´Nºâ¹F¨ì¹w©w´c¤Æ¤H¼Æ¤]¤£·|¦³´Á¤¤¤ÀªR 4 ¤]³\ºô¶¦b¦~«×§ó·s,¤£nªM¤}³D¼v,¦Û¤vÀ~¦Û¤v |
|
|
·|û¡G£~£~10134649 µoªí®É¶¡:2014/12/29 ¤U¤È 09:25:39²Ä 129 ½g¦^À³
|
·|¤£·|¬Oµo²{³Q°Ê¦¡¤£°÷¤O?¥D°Ê¦¡´N¹³¾÷ºj,³Q°Ê¦¡´N¹³¨Bºj,¼Ä¤H²³¦h,¨Bºj¤£ºÞ¥Î¡C§Ú·í®É¬O³o»ò·Q,¦A¥[¤W·í®É¤é¥»¤j¶ï»¡¡u¨È¬wªºÆFªøÃþÃø§ä¡v,§Ú·Q»¡,§A¤j¶ïÃø§ä,Ãø¹D¨ä¥L¤H¦n§ä?¨ä¥L¤H¥i¥H¶¶§Q¶i¤JIND,¬°¦ó§A«o¿ð¿ðµLªkIND?¨º®ÉÔÁÞXªÑ»ù168¤¸,¯EXªÑ»ù95¤¸,¥þ´«!¬O¤£¬O888¦¬°_¨Ó¤w¸g»¡©úÁÞX¦¹¸ô¤£³q¤F?¾÷ºj¥´¤F¤@¦~¥b¤~±q5cm¥´¨ì3.5cm,¨º¦pªG´«¦¨¨Bºj¨Ó¥´,¬O¤£¬O®ÄªG¦³? |
|
|
·|û¡GD§b10139065 µoªí®É¶¡:2014/12/29 ¤U¤È 08:59:04²Ä 128 ½g¦^À³
|
©ÎªÌ¤½¥q¦bµ¦²¤¤W±N¸ê·½¥ý¶°¤¤¥H¥D°Ê§K¬Ì¡B¦h¾AÀ³¯g¬°Àu¥ý¡AÁYµu¸ÕÅç®Éµ{¦p¦¹822/833¦¨¥\¾÷²v¤j¤S¥i±Ï§ó¦h¯f¤H¡C¥H¤W¬°²q´ú©Î³\ªk»¡®É¨º¦ì¤j¤j¥iÀ°¦£´£°Ý¡HÁÂÁ |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2014/12/29 ¤U¤È 08:51:54²Ä 127 ½g¦^À³
|
¦U¦ì¤j¤j¡A·Q©M¤j®a¦A¨Ó±´°Q888 ¦p¦P£~£¼£~£¼¤j©Ò¨¥¡A·íªì888³]pªº¥Øªº¡A´N¬O¬°¤F¸É¨¬¦³GH¡A«o¹ï¥¦¨S¤ÏÀ³ªº¯f±w¡A °²³]·íªì¤½¥q§ì³oÃþªº¯f±w¬ù20% ¦pªG¡B¥H¤U¯Â¦pªG ¦¹¦¸822ªº¼Æ¾Ú¦b12¤ë¤¤¥ª¥k¤w¸g¥X¨Ó¡]Ä´¦pµL¯e¯f¶i®i¤H¼Æ¤ñ¤½¥q¹w¦ôªº¤Ö ¡A¤½¥q¤w´x´¤¨ì¬ù10%¥H¤U¬Æ¦Ü§ó¤Ö¡^¡A¦Ó¥Bµo²{Y¤@ª½°l¥[°w¾¯¡B¶q¼W¥[´N¯à³ê¿ô§K¬Ì¨t²Î ¨º»ò¡AÁÙ¦³Á{§É888ªº¥²n¶Ü¡H 888¥i¬O³sÁ{§É³£ÁÙ¶}©l©O¡I®Ú¥»¨S¦³ÃĮĦnÃaªº¼Æ¾Ú ¨º»ò¡A¨ú®ø888¡A¥Nªí¤°»ò¡H ¤p§Ì»{¬°¬O¥ó¦n®ø®§§a ¥t¤@Ó¥i¯à ¤½¥q¹q¸£µ{¦¡ºÞ²z¤Hû¡A¤£¤p¤ß±N888¥þ§R¤F «¢«¢«¢¡A¤Ñ¤U¨ÆµL©_¤£¦³ ¤£¦pÅ¥¤½¥qªº»¡ªk§a ªü¬Â¤j ±z¯uªº«Üµ½¨}¡B¼ö¤ß ÁÙ¦n¬OÂùª¼.....¡]§Ú¨ä¹ê®º¤F§a§N¦½¡^ ¥H«án°O±o»¡¬OªB¤ÍªºªB¤Í |
|
|
·|û¡GD§b10139065 µoªí®É¶¡:2014/12/29 ¤U¤È 08:46:11²Ä 126 ½g¦^À³
|
£~£~¤j¡G822¹ï©óµLGlobo-Hªº±wªÌ¬OµL®Äªº¡A¨º888·|¦³®Ä¡H833ªº¾¯¶q¹Á¸Õ©Î³\¥i¥H´£¨Ñ¤@Ó¤è¦V¡IÁÂÁ |
|
|
·|û¡G£~£~10134649 µoªí®É¶¡:2014/12/29 ¤U¤È 08:24:15²Ä 125 ½g¦^À³
|
888¥i³yºÖµLªk¹ïÁÞ¬Ì]²£¥Í§ÜÅ骺¯f±w,822¦Ü¤Ö¹ï©óµLGlobo-Hªº±wªÌ¬OµL®Äªº¡C©Ò¥H822ÃĮĦA¦n³£¨S¦³²z¥ÑºM¤U888§a? |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2014/12/29 ¤U¤È 06:04:58²Ä 124 ½g¦^À³
|
888½T¹ê¹ý¤U¤F ¤p§Ì·Q ·|¤£·|¤wµo²{822ªºÀø®Ä¤Ó¦n.¯f±w¥]¬Aªº½d³ò¼s¤j ®Ú¥»¤£»Ýn888 ¥u¬On°l¥[´X°wªº°ÝÃD |
|
|
·|û¡G¤ý£«¬Â10136621 µoªí®É¶¡:2014/12/29 ¤U¤È 05:39:13²Ä 123 ½g¦^À³
|
¤p©_¤j:¥ô¦óÓ¸ê§Ú³£¤£·|¥´¤W,ÁÂÁÂ! |
|
|
·|û¡G¤p©_10138298 µoªí®É¶¡:2014/12/29 ¤U¤È 04:20:33²Ä 122 ½g¦^À³
|
ªü¬Â¤j¡A °£¤F´yz±wªÌA¡B±wªÌBªº¸~½FÅܤƥ~ ¨ä¥¦¦³¥ô¦ó¥i¯à¦³Ãö±wªÌӸꪺ¥ô¦ó¤å¦r ½Ð±z³£¤£n¦bª©¤W¥´¦r¡I |
|
|
·|û¡GFaith10138335 µoªí®É¶¡:2014/12/29 ¤U¤È 04:01:37²Ä 121 ½g¦^À³
|
·PÁªü¬Â¤j ´£¿ô±z ¤£n¦b¹q¸Ü¸Ì°Ý,¤£n¥Î²°T,line,fb...µ¥¹q¤l²£«~°Ý ³Ì¦n¿Ë¦Û°Ý ÁÂÁÂÅo |
|
|
|